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ABSTRACT 
Sepsis is the leading cause of death in ICU patients. Patients with sepsis may 
develop sepsis-related cardiac dysfunction. The presence of this cardiac 
dysfunction can increase the mortality rate from 40% to 70%. Diabetes is a chronic 
disease that manifests as an elevation in blood glucose. Patients with diabetes are 
more susceptible to, and at increasing risk of developing, infections and 
subsequently sepsis. 
Activation of the NF-ĸB pathway plays a crucial role in the pathophysiology of 
sepsis-associated cardiac dysfunction and diabetic cardiomyopathy. The effect of 
diabetes on outcomes in patients with sepsis is highly controversial and it is still 
unclear whether pre-existing T2DM augments the cardiac dysfunction associated 
with sepsis and whether activation of NF-ĸB drives the cardiac dysfunction in 
T2DM/sepsis patients. 
In this thesis, I have first developed two models of high fat diet (HFD)-induced 
diabetes and diabetic cardiomyopathy in mice. Then, I developed two models of 
sepsis associated cardiac dysfunction using lipopolysaccharide (LPS) or caecum-
ligation and puncture (CLP) in diabetic mice. I have demonstrated that mice with 
pre-existing T2DM exhibit a significantly greater cardiac (organ) dysfunction after 
challenge with either (low dose) LPS or mild CLP surgery. The exacerbated 
cardiac dysfunction was accompanied by an increase in NF-ĸB activation and 
reduction in Akt phosphorylation in the heart and an increase in the serum levels of 
proinflammatory cytokines. The increase in cardiac dysfunction, as well as the 




largely attenuated by treatment with a selective IĸB kinase inhibitor (IKK-16) or a 
DPP-4 inhibitor (linagliptin). 
Thus, excessive activation of NF-ĸB in animals with diabetes/sepsis drives the 
observed excessive cardiac dysfunction, and that inhibition of NF-ĸB may be a 
useful target to treat the excessive inflammation and sepsis associated cardiac 
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CHAPTER 1:  GENERAL INTRODUCTION 
1.1 Sepsis 
1.1.1 Historical background 
The medical term ‘sepsis’ is derived from the Greek word ‘σηψις’ which means 
“decomposition of animal or vegetable organic matter“ 1. The term sepsis was first 
introduced in the medical literature by Hippocrates (ca. 460-370 BC) in the 
Hippocratic corpus 1,2. Despite the fact that sepsis is a term related to modern 
intensive care medicine, the medical concept of sepsis is considered to be old.  
In 1862, Mr. Edwin Smith discovered the oldest known report of a case of sepsis 
secondary to wound infection in Luxor, Egypt, which is now called ‘The Edwin 
Smith Surgical Papyrus 3’. The existing scroll, which was written in 1,600 BC 4 is 
a copy of a previous one from around 3,000 BC 5. Five of the 48 cases described in 
the scroll have a reference of fever as a secondary complication of an existing 
wound 3. By that, and without knowing the concepts of inflammation and 
infection, the Egyptian physicians identified clear signs of what was then called  
‘systemic infection and local suppuration’ 6. 
Despite the lack of the microorganism theory, the ancient Greeks were able to 
observe three key phenomena caused by microorganisms; sepsis (infection), pepsis 
(fermentation), and infection which was explained by the humeral theory 6. During 
this period, Hippocrates contributed the expression ‘wound putrefaction’, which is 
now called septicaemia 7. Later Ibn Sina (AD 980–1037) observed that fever 




bacteria was linked to the decay of organic matter only in the 18th century by the 
French scientist Louis Pasteur (1822 – 1895) 8. 
The Hungarian obstetrician Ignaz Semmelweis (1818-1865) identified, for the first 
time, the mechanisms underlying the transmission of childbed fever (puerperal 
sepsis) 9. He also observed the importance of hygienic measures in reducing 
mortality of women during childbirth 7. 
Hugo Schottmüller laid the foundation of the modern definition of sepsis in 1914. 
He descried that the existence of infection is an essential part of the disease 7. 
Lewis Thomas then introduced a new theory which proposed that it is the host’s 
response that is responsible of the clinical responses observed in septic patients 10. 
The result of this theory was a large number of clinical and experimental studies, 
which have changed the focus from the research from the infectious agent to 
research relating to the host immune response 7. 
And finally this theory was transferred into practice after The ACCP/SCCM 
Consensus Conference Committee American College of Chest Physicians/Society 
of Critical Care Medicine had been held in 1991. In this conference, it was agreed 
to define sepsis as a systemic inflammation in the presence of infection 11. 
1.1.2 Definitions of sepsis and their evolution  
A consensus conference was held in 1991 in Chicago by the American College of 
Chest Physicians/ Society of Critical Care Medicine with the aim of  “agreeing on 
a set of definitions that could be applied to patient with sepsis and its sequalae” 11. 
As a result of this conference, several new definitions were proposed (Systematic 




Multiple organ Dysfunction Syndrome and Hypotension) (Table 1.1) but other 
terms were neglected 11.  
Table 1.1 Definitions of the ACCP/SCCM consensus conference 
This table shows the definitions provided by the ACCP/SCCM consensus 
conference in 1991. Table adopted from Bone et al. 1992 11. 
Term Concept 
Colonization Refers to the presence of microorganism in given site, but no harm to the host. 
Infection 
Presence of a given agent causing harm to the host (the 
presence of a host inflammatory response to the 
organism). 
Bacteraemia 
Presence of viable bacteria in the blood, which may be 
transient; by extension, viremia, fungemia and 




Characterized as non-specific body response to a series 
of conditions causing inflammation including 
infection, burns, acute pancreatitis, trauma and others. 
At least 2 of the following conditions are required to 
meet the definition of SIRS: 
• Temperature > 38.0 °C or < 36.0 °C 
• Heart rate > 90 Beat/min 
• Respiratory rate > 20 breath/min or PaCO2* < 
32 mmHg 
• White blood cell count > 12,000/mm3 or < 
4,000/mm3 or > 10% of immature bands 
Sepsis SIRS triggered by bacterial, viral, fungal or parasitic infection. 
Severe sepsis Sepsis associated with organ dysfunction, tissue hypoperfusion or arterial hypotension.  




Functional organ changes in a severely ill patient, so 
that homeostasis cannot be maintained without 
therapeutic intervention.  
* PaCO2: partial pressure of carbon dioxide. 
It was hoped that these definitions would enable the attending physician to detect 
the disease earlier and consequently enable early treatment for patients with sepsis, 
allow the use and development of potential standard protocols of research, and 




According to the above table, it is clear that sepsis is a reaction of the host to an 
infectious agent. However, a similar reaction can be seen in the absence of 
infection. So the term systemic inflammatory response syndrome (SIRS) was 
proposed to describe a systemic inflammatory response regardless of the cause 
(Figure1.1).  
 
Figure 1.1 Mutual relations through systemic inflammatory response 
syndrome (SIRS), sepsis, and infection. Figure modified from Bone et al. 1992 
11. 
In 2001, the SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions 
Conference was held in Washington D.C. with the aim of amending the first 
definitions after the introduction of new insights into the pathophysiology of sepsis 
12. The most important outcomes of the conference were the following: It was 
recommended not to alter the definitions of sepsis, the use of SIRS for the 
diagnosis of sepsis was regarded as being too unspecific and further more specific 




Table 1.2 Diagnostic criteria of sepsis 
The table provide the diagnostic criteria of sepsis that were provided during the 
second consensus conference in 2001. Table adopted from Levy et al. 2003 13. 
General variables  
 
Temperature > 38.3 °C or < 36.0 °C, 
Heart rate > 90 beat/min, 
Tachypnea (respiratory rate > 20 breath/min in adults), 
Altered mental status. 
Inflammatory response variables 
 
White blood count > 12,000 cell/µL, < 4,000 cell/µL, or with > 10% 
immature form, 
Plasma C-reactive protein > 2 standard deviations above the normal value 
Hemodynamic variables 
 
Systolic blood pressure < 90 mmHg or mean arterial pressure < 70 mmHg, 
Mixed venous oxygen saturation > 70%, 
Cardiac index > 3.5 L/min/m2. 
Organ dysfunction variables 
 
PaO2/FiO2* < 300, 
Urine output < 0.5 mL/kg/hr or creatinine increase > 0.5 mg/dL, 
International normalization ratio > 1.5 or active partial thrompoplastin time 
> 60 sec, 
Platelet count < 10,000 cell/µL, 
Plasma total bilirubin > 4 mg/dL. 
Tissue perfusion variables 
 Hyperlactatemia > 1 mmol/L, Decreased capillary refill or mottling.  
* PaO2/FiO2: The ratio of partial pressure arterial oxygen and fraction of inspired oxygen. 
Finally, in February 2016, The Third International Consensus Definitions for 
Sepsis and Septic Shock (Sepsis-3) was published by the Journal of the American 
Medical Association (JAMA). The European Society of Intensive Care Medicine 
and the Society of Intensive Care Medicine invited a group of 19 experts in sepsis 
epidemiology, pathobiology, and clinical trials with the aim of assessing the 
definitions of sepsis and septic shock and to update them if needed 14.  The panel 
felt that the definitions of sepsis is highly dependent on the presence of systemic 
inflammation and that the term severe sepsis is a redundant term, as septic shock 
develops from sepsis (without a phase of severe sepsis). The panel concluded that 




dysregulated host response to infection”, organ dysfunction represent 10 % or 
more of in-hospital mortality rate and is reflected in two or more points increase in 
the Sequential (Sepsis-related) Organ Failure Assessment (SOFA) score, and they 
defined patients with septic shock as subset of patients with sepsis which have 
intense metabolic, cellular, and circulatory abnormalities resulting in higher 
mortality rate 14.   
1.1.3 Diagnosis 
The diagnostic criteria for sepsis and septic shock were first introduced in 1991 
and last updated in 2016. According to the latest update by the International 
Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), septic patients have 
documented or suspected infection along with sudden change of SOFA score of 
more than one from the baseline 14.   
The task force recommends using of Quick Sofa (qSOFA) (Table 1.3) as bedside 
criteria for recognising non-ICU patients with sepsis who are likely to have a poor 
outcome. The qSOFA score combines blood pressure (systolic) of maximum 100 
mm Hg, changes in mental status, and respiratory rate of 22 breaths per minute or 
more.  The advantages of using qSOFA over SOFA (Table 1.4), even though less 
powerful, are the following: The qSOFA score can be done rapidly (and quickly 
repeated) and does not require any clinical chemistry data. This should help the 
attending clinician to make a rapid assessment of the degree of organ failure, and 
allow to start or change a treatment or enable the transfer of the patient to the ICU 





Table 1.3 qSOFA (Quick SOFA) Criteria 
The table provides qSOFA criteria with the reference values, this scoring system 
helps physicians doing quick assessment of organ dysfunction in order to change 
patients’ medication or refer to the ICU. Table adopted from Singer et al. 2016 14. 
Criteria Reference 
Respiratory Rate >= 22 beat/min 
Altered mentation --------- 
Systolic Blood Pressure <=100 mm Hg 
 
Table 1.4 SOFA Criteria. Table adopted from Singer et al. 2016 14. 
 SOFA Score 






























<1.2 1.2-1.9 2.0-3.4 3.5-4.9 >5.0 
* PaO2/FiO2: The ratio of partial pressure arterial oxygen and fraction of inspired 
oxygen, MAP: mean arterial pressure. 
To diagnose septic shock, the patient must present with an abnormal circulation 
reflected by the need for vasopressor support to keep the mean arterial pressure 
(MAP) above 65 mm Hg, and with a cellular/metabolic dysregulation resulting in 
elevated lactate serum levels (more than 2 mmol/L) in the absence of 
hypovolaemia. This metabolic disorders should be severe enough to cause an 





Figure 1.2 Operationalization of Clinical Criteria Identifying Patients with 
Sepsis and Septic Shock 
Baselines SOFA score usually considered to be zero, unless the patient already has 
chronic or acute change in SOFA (organ failure) before the onset of infection. 
qSOFA: Quick SOFA, MAP: Main arterial pressure. Figure modified from Singer 
et al. 2016 14. 
1.1.4 Epidemiology 
As the definition of sepsis has been changed recently, all available publications 
about the epidemiology of sepsis have focussed on cases previously defined as 
having severe sepsis or septic shock. 
Severe sepsis is considered to be the leading cause of death in non-coronary 
intensive care units (ICU) critically ill patients15 and the second most common 
cause of death in this population in high income countries16. A study conducted by 
Angus et al. studying the discharge records in 1995 from seven hospitals in the 
United States showed that the annual incidence of severe sepsis was 3.0 cases per 




cases per 1000 of population) 17. About 50% of cases with severe sepsis occur 
outside the ICU. Twenty-five percent of patients with severe sepsis die because of 
the disease during hospitalization and this percentage almost doubled in patients 
with septic shock 15.  
Either Gram-positive or Gram-negative bacteria can cause sepsis. However, the 
incidence of Gram-positive bacterial sepsis has been on the rise for many years, 
and it is now more common than gram-negative bacterial sepsis 15,16. The reason 
for this may be the increase in nosocomial infections and the increasing use of 
invasive procedures 15.  
The type of organism that causes sepsis has a dramatic impact on outcome 15. 
Gram-negative bacteria are thought to induce a stronger inflammatory response, 
are found more frequently in septic shock patients than in patients with sepsis or 
severe sepsis 18 and sepsis caused by Gram-negative bacteria is associated with a 
higher mortality rate than those cases caused by Gram-positive bacteria.  The most 
frequent organisms that cause sepsis are: Staphylococcus aureus (20.5%), 
Pseudomonas species (19.9%) and Enterobacteriacae (mainly E. coli, 16.0%)19. 
Sepsis can start from different sites of infection. The most common site of 
infection is the respiratory tract (pneumonia), which is also associated with the 
highest mortality, followed by the genitourinary tract, then abdominal cavity, skin, 
and implanted devices 15. 
The incidence of sepsis has increased recently in the United States. This may be 
explained due to the aging of the population, increasing burden of chronic health 




chemotherapy, and invasive procedures 15. However, the mortality rate has 
declined because of the improvements in supportive care for ICU patients 20. 
1.1.5 Treatment 
Like other acute illnesses and trauma, early identification and proper management 
of sepsis are associated with better outcome 21. The Surviving Sepsis Campaign 
(SSC) published the first comprehensive guideline for the management of sepsis in 
2004. This guideline was then reviewed in 2008 and 2012. In 2015, a committee of 
55 experts from 25 different international organizations was assembled and 
divided into 5 sections (haemodynamic, infection, adjunctive therapy, metabolic 
and ventilation) to provide an update of the 2012 SSC guideline for the 
management of sepsis and septic shock. In 2017, the SSC published its latest 
guideline that provides new recommendations about managing adult patients with 
sepsis and septic shock aiming to establish best clinical practice  (The detailed 
recommendations are at the end of this thesis in Appendix 1) 21.  
In summary, the committee considered sepsis and septic shock as medical 
emergency that needs immediate intervention. The recommended first step is fluid 
resuscitation with crystalloid solutions (e.g. normal saline) using at least 30ml/kg, 
i.v. Additional fluid can then be given depending on the haemodynamic status of 
the patient. Once sepsis or septic shock is suspected in a patient, microbiological 
cultures should be obtained (including blood cultures) before the start of antibiotic 
treatment. Then an empiric broad-spectrum antibiotic should be initiated as soon as 
possible (the choice of the antibiotic to be used and the dosing regimen are based 
on the patient’s conditions). However, antibiotic treatment for 7-10 days is enough 




and controlled as soon as possible. Vasopressor treatment (e.g. norepinephrine) is 
recommended in patients with septic shock to increase the mean arterial pressure to 
65 mmHg. However, the committee did not recommend the use of hydrocortisone 
in patients with septic shock, if fluid resuscitation and vasopressor therapy were 
enough to restore haemodynamic stability. Prophylactic strategies for preventing 
the development of either peptic ulcer (using proton pumps inhibitors or H2 
receptors antagonist) or deep vein thrombosis (using unfractionated of low 
molecular weight heparin) should be considered in high-risk patients.  
1.1.6 Pathophysiology 
As outlined in the definitions of sepsis, infection is a key element of the disease. 
Many infectious agents can cause sepsis including fungi, viruses or bacteria 22.  To 
be able to cause a disease, these pathogens need to pass through the mucosal 
barriers, spread, and replicate in other organs. They use virulence factors to protect 
themselves from the host defence 16. The first line of defence of the host is the 
innate immune system that recognises the pathogen early and activates the 





Figure 1.3 Principles in innate immune recognition by PRRs. 
During microbial infection or breakdown of tolerance, pathogen-specific 
molecules, aberrant localization of foreign or self-molecules, or abnormal 
molecular complexes are recognized by PRRs. This event triggers PRR-mediated 
signalling and induction of an innate immune response, which ultimately results in 
resolution of infection but also may cause inflammatory diseases or autoimmunity. 
Figure adopted from Mogensen 2009 24. 
The presence of microorganisms and pathogens is usually recognised by a group of 
receptors called Germline-encoded pattern recognition receptors (PRRs) 25. This 
happens by recognising a conserved entity within microbes. These entities are 
called Pathogen Associated Molecular Pattern (PAMPs). However, some of these 
receptors are also responsible of recognition of endogenous molecules which are 
released from damaged cells. In this case they are termed Damage Associated 
Molecular Pattern (DAMPs) 25.  
Even though the Toll-Like Receptor (TLR) family is the major and most 




identified 24,25. PRR families can be classified as transmembrane proteins such as 
Toll Like Receptors (TLRs) and C-type Lectin Receptors (CLRs), or cytoplasmic 
proteins like Nucleotide-binding Oligomerisation domain (NOD) and the Retinoic 
Acid Inducible Gene (RIG)-I-Like receptors (RLRs) 25. 
Upon recognition of PAMPs, TLRs or other classes of PRRs activate cascades of 
intracellular signalling that upregulate the gene transcription of antimicrobial 
proteins, chemokines, type 1 interferon (IFNs), pro-inflammatory cytokines and 





















Table 1.5 PRRs and their ligands 
This table provides the four families of PRRs and their subfamilies, location, 
ligands, and origin of the ligand. Table is adopted from Takeuchi and Akira 2010 
25. 
PRRs Localization Ligand Origin of the ligand 
TLR    
TLR1 Plasma 
membrane 
Triacyl lipoprotin Bacteria  
TLR2 Plasma 
membrane 
Lipoprotin Bacteria, viruses, 
parasite, self  
TLR3 Endolysosome dsRNA Virus 
TLR4 Plasma 
membrane 
LPS Bacteria, viruses, self 
TLR5 Plasma 
membrane 
Flagellin Bacteria  
TLR6 Plasma 
membrane 
Diacyl lipoprotin Bacteria, viruses 
TLR7(human 
TLR8) 
Endolysosome ssRNA Bacteria, viruses, self 
TLR9 Endolysosome CpG-DNA Bacteria, viruses, 
protozoa, self 






RLR    
RIG-1 Cytoplasm Short dsRNA RNA viruses, DNA 
virus 
MDAS Cytoplasm Long dsRNA RNA viruses 
LGP2 Cytoplasm Unknown RNA viruses 
NLR    
NOD1 Cytoplasm iE-DAP Bacteria  
NOD2 Cytoplasm MDP Bacteria  
















In the following sections, I shall focus on TLRs, as bacteria are their main ligands, 
and bacteria are the main cause underlying the systemic infections associated with 
sepsis.  
1.1.6.1 TLRs 
In humans, 10 TLRs have been identified thus far 24,25 and two more have been 
discovered solely in mice 25.  Each TLR is able to recognise different PAMPs and 
DAMPs 25.  TLRs are type 1 integral membrane receptors in which the N-terminal 
is the ligand binding and recognition domain (leucine-rich repeats); this is 
followed by a single trans membrane region and then the cytoplasmic C-terminal, 
which functions as the signalling domain 25,27. This domain is also called Toll IL-1 
receptor (TIR) domain, as it is homologues to the IL-1R family members 
signalling domains28. 
In the case of sepsis (and for this research project in particular), the most important 
TLRs are TLR 2 and TLR 4, which recognise peptidoglycan (Pep.G) primarily 
released from Gram-positive bacteria and lipopolysaccharide (LPS) released from 
Gram-negative bacteria. 
TLR2 can only recognise PAMPs after forming a hetero-dimer either with TLR1 
or TLR6. The activation of TLR2 with ligands other than viral components, results 
in non-type 1 IFNs pro-inflammatory cytokines production such as IFNγ. After 
binding to LPS and the myeloid differentiation factor 2 (MD2), TLR4 forms a 





Figure 1.4 Signalling pathways of TLR4 and TLR2. 
After being activated by LPS, TLRs activate the MyD88 dependant and 
independent pathways and lead to activation and translocate of NF-ĸB to the 
nucleus. Figure adapted from Takeuchi & Akira 2010 25. 
After binding of ligands to their respective TLRs and the subsequent formation of 
dimers, a change to their crystal structure occurs, which allows the recruitment of 
the the suitable Toll/IL-1R- domain-containing adaptor molecule to the TIR 
domain of the TLR 26. The following five TIR-domain-containing adaptors have 
been reported: MyD88, TRIF, TIRAP/Mal, TRAM and SARM 25. However, 
signalling of TLR is usually driven by two key pathways, which are either MyD88 
or TRIF-dependent.  
The MyD88-dependant signalling pathway 
With the exception of the TLR3-pathway, MyD88 is a major element in the 
signalling pathways of all other TLRs 25. For example, TLR2 and TLR4 need to be 




associated kinase (IRAK)-4, which in turn activates IRAK-1 and IRAK-2 by 
dissociating them from MyD88. The activated IRAKs then interact with TNF-
associated factor 6 (TRAF6). TRAF6, together with E2 ubiquitin-conjugating 
enzyme complex, catalyses the formation of a lysine 63 (K63)-linked polyubiquitin 
chain on TRAF6 itself and generates an unconjugated free polyubiquitin chain. 
This free K63 polyubiquitin chain then activates a complex of TGF-β-activated 
kinase 1 (TAK1), TAK1-binding protein 1 (TAB1), TAB2, and TAB3. TAK1, 
TAB1, TAB2, and TAB3 then phosphorylate IKK-β and MAPK kinase 6. Each 
one of these kinases then activates its effector: IKK-β for example, phosphorylates 
IĸBα and free NF-ĸB that is then translocates from the cytosol into the nucleus, 
binds to the respective promoter region and regulates gene transcription. MAPK 
Kinase 6 activates the transcription factor complex AP-1 resulting in the 
expression of pro-inflammatory cytokine genes (figure 1.4) 25. 
The TRIF-dependant signalling pathway 
To activate the TRIF pathway, TLR4 requires TRAM to activate TRIF25. 
Activation of this pathway results in activation of both NF-ΚB and IRF3 molecule 
29. TRIF recruits both RIP1 and TRAF6 for this activation in 2 different pathways. 
After that TRIF collectively with RIP1, TRADD, TRAF6, and Pellion-1 forms a 
multi-protein signalling complex. This signalling complex activates TAK1 that, in 
turn, phosphorylates and activates MAPK and activates NF-κB by causing IBα 
phosphorylation29. Activation and nuclear translocation of IRF3 occurs when TRIF 
recruits both IKKi (IKKε) and the non-canonical IKKs (TBK1) to phosphorylate 





1.1.7 Cardiovascular dysfunction associated with sepsis 
The cardiovascular dysfunction caused by bacteraemia was first described in 1951. 
Today, we know that most septic patients, and all septic shock patients develop 
sepsis-related cardiovascular dysfunction 30. Despite the clear involvement of the 
immune system 31, the exact cause and mechanism of this cardiovascular 
dysfunction are still unclear 30,31. 
In the past, and before the introduction of pulmonary artery catheters, it was 
thought that patients with septic shock went through two specific, consecutive 
phases of shock: a ‘warm shock’ or hyper-dynamic phase in which, despite of 
having hypotension, patients have warm extremities and a bounding pulse, and the 
‘cold shock’ or hypo-dynamic phase, in which patients have cold extremities and a 
weak pulse, which ultimately leads to death 32 33. However, after using the 
pulmonary artery catheter to obtain the accurate measurements of cardiac output 
(CO) and left ventricular (LV) filling pressure, the hypodynamic phase (cold 
shock) was revealed to be the result of hypovolaemia due to inadequate fluid 
resuscitation 33.  
1.1.7.1 Characteristics of sepsis related myocardial dysfunction 
Using both pulmonary artery catheter and radionuclide cineradiography to measure 
cardiac function in septic shock patients, Parker and colleagues found that among 
survivors of sepsis, the ejection fraction was decreased, while the left ventricular 
end diastolic volume was increased compared to healthy individuals. They also 
found that these changes were reversible within 10 days. Many recent studies show 




related myocardial dysfunction 30.  
1.1.7.2 Aetiology of sepsis related myocardial dysfunction 
A complete picture of the aetiology of sepsis related myocardial dysfunction is still 
needed. The aetiology is multifactorial and it is necessary to gain a better insight 
into the pathophysiology of this dysfunction in order to develop new drugs to treat 
septic patients 30. The following concepts have been introduced to the literature as 
potential mechanisms.  
1.1.7.2.1 Myocardial Ischemia and micro-vascular dysfunction 
The tissue hypoperfusion theory postulates that blood perfusion to cardiac cells is 
reduced in septic patients. Therefore, ischaemic injury of cardiac cells happens due 
to inadequate O2 delivery. However, Cunnion et al. disproved this theory by 
placing thermodilution coronary sinus catheters in 7 septic shock patients to 
measure both coronary blood flow and cardiac metabolism. They concluded that 
there were no difference in the coronary blood flow or lactate production between 
septic patients (with or without cardiac depression) and healthy volunteers 34.    
1.1.7.2.2 Myocardial Depressant factors  
Parrillo et al. introduced this theory in 1985 by exposing spontaneously beating rat 
cardiomyocytes to the serum of septic shock patients. A significant reduction in 
contractility was observed when serum from patients during the acute phase of 
sepsis was used, while serum from healthy controls or from the same patients 
during the non-acute phase (either before the shock or after recovery) had no such 




depressant substance’ is the cause of myocardial dysfunction associated with 
sepsis 35. Another study conducted in 1999 confirmed this finding. In this study the 
authors analysed the ultra-filtrate and found that there are significantly higher 
concentrations of C3a, IL-8, and IL-1β in septic patients compared to healthy 
controls 36. 
Shortly after that, Pathan et al. partially characterised the physicochemical 
properties of these substances. These substances are 10-25 KDa in size, 
proteinaceous, water-soluble and heat stable 37. Other potential myocardial 
depressant factors are nitric oxide (NO), prostanoids, and cytokines 30.  
Cytokines 
It was suggested that TNF-α is responsible for the cardiovascular changes 
(including the myocardial dysfunction) associated with septic shock 38. Indeed, 
TNF-α challenge in canines dose-dependently depresses LV function 39 and after 
Vincent and colleagues showed an improvement in ventricular function in patients 
with septic shock treated with murine anti-TNF antibody 40. However, treatment 
with murine monoclonal anti TNF-α was not able to improve survival 41. 
Interleukin 1 (IL-1) is produced by neutrophils, macrophages and monocytes in 
response to TNF-α 42. Because of their short half-lives, TNF-α and IL-1 are 
responsible only for the early cardiac depression 43 and the prolonged effect of 
cardiac depression is attributed to an excessive myocardial nitric oxide (NO) 
synthesis in response to TNF-α and IL-1 44. IL-6 is another important cytokine. In 
the serum of septic patients, IL-6 has higher concentration compared to TNF-α and 
it also has more prolonged elevation. These two criteria make it a good severity 




Nitric Oxide (NO) 
Nitric oxide synthase (NOS) generates NO from the oxidation of L-arginine to 
form L-citrulline. Three isoforms of NOS have been identified in myocardial cells: 
neuronal (nNOS), inducible (iNOS), and endothelial (eNOS) 46. Unlike iNOS, both 
nNOS and eNOS continuously generate small amounts of NO. iNOS, on the other 
hand, is expressed in response to inflammation and generates large quantities of 
NO 47. In 2010, Bougaki and colleagues suggested that activation of eNOS 
decreases inflammatory cytokines synthesis and prevents myocardial dysfunction 
in experimental (CAST) sepsis. Since then, however, it has been suggested that 
NO formation by eNOS contributes to the early myocardial dysfunction in sepsis 
48.  The increased expression of iNOS plays a key role in the late cardiac 
dysfunction associated with sepsis. Many different mechanisms have been 
proposed by which an enhanced formation of NO by iNOS contributes to the 
cardiac dysfunction in sepsis. These include changes in both preload and afterload, 
down-regulation of β-adrenergic receptors 49, a reduction of the response of cardiac 
myofilaments to Ca2+ 50 and a significant contribution to mitochondrial dysfunction 
51 secondary to an increase in mitochondrial permeability as a result of 
peroxynitrite production (from NO and superoxide anions) 52,53. 
1.1.7.2.3 Changes in calcium trafficking 
Under normal physiological conditions, extracellular calcium enters the 
cardiomyocytes via the L-type calcium channels. Once inside the cells, it induces 
the sarcoplasmic calcium release via the activation of the ryanodine receptors. 
Intracellular calcium also activates actin-myosin interaction after binging to 




phospholamban is phosphorylated and activated leading to calcium sequestering in 
the sarcoplasmic reticulum by the sarco-endoplasmic reticulum calcium-ATPase 
(SERCA) 54. Under sepsis condition both the calcium current to the 
cardiomyocytes and the density of L-type calcium channel are reduced 55,56. 
Phosphorylation of phospholamban is also impaired in sepsis resulting in impaired 
calcium sequestering in the endoplasmic reticulum (ER). Ryanodine receptors and 
myofilaments show reduced responsiveness and sensitivity to calcium during 
sepsis 57. 
1.1.7.2.4 Mitochondrial dysfunction 
Cardiomyocytes have a high content of mitochondria that are mainly responsible 
for energy generation by producing ATP from ADP via oxidative phosphorylation 
58. Mitochondrial dysfunction is (in addition to reduced blood supply) a potential 
cause of the multiple organs failure, and, hence, a factor influencing prognosis and 
outcome in patients with sepsis 59. The mitochondrial dysfunction associated with 
septic cardiomyopathy comprises a change in mitochondrial architecture (swelling, 
internal vesicles formation and abnormalities in cristae) 60, damage of 
mitochondrial DNA 61, elevation in mitochondrial permeability transition 62 and 
inhibition of the cytochrome C oxidase activity 63. The drivers of mitochondrial 
dysfunction in sepsis are multifactorial but include the excessive formation of NO 
and peroxynitrite, hormonal dysregulation and downregulation of mitochondrial 
protein gene transcription. Overproduction of NO and peroxynitrite cause 
mitochondrial protein damage, alter mitochondrial respiration and increase 
mitochondrial permeability 52,53,64. Patients with sepsis show altered thyroid 




function and increase mortality in ICU patients 66. Downregulation of 
mitochondrial protein gene transcription was observed in healthy volunteers who 
received bacterial endotoxin 67 and in critically ill patients 68. As a result of 
mitochondrial injury, ATP production is reduced and, if low ATP level persists, 
the pathways leading to cell apoptosis are activated. However, cell death is not the 
main driver of the cardiac dysfunction associated with sepsis 69. Cells may 
compensate the reduction in ATP generation by increasing glycolysis 70, but this 
alone is not sufficient to deliver the amounts of ATP generated by ‘fully 
functional’ mitochondria. Under such circumstances, cells adapt by reducing their 
metabolic activity and this may be a protective mechanism to prevent cell death 
similar to the hibernation state (of the heart) triggered by brief episodes of 
ischemia 71,72. 
1.1.8 Acute kidney injury associated with sepsis 
The kidney is another vital organ that is affected by sepsis. Acute kidney injury 
(AKI) occurs in almost 50% of ICU patients 73. Different aetiologies can lead to 
the development of AKI in hospitalized patients such as; major cardiac surgery, 
contrast-induced AKI, severe heart failure and sepsis. Among all causes, sepsis is 
the most common cause of AKI in critically ill patients with a prevalence of 45-
70% 74,75. The presence of AKI is associated with almost 50% in-hospital mortality 
73,76. After surviving AKI, patients become more susceptible to develop chronic 
kidneys disease 77.  
In 2004, Bellomo and co-workers proposed a classification system for acute 
kidney failure called RIFLE that depends on the change of serum creatinine from 




(AKIN) modified both the definition and the diagnostic criteria for acute kidney 
failure. In the new definition, a 48-hour time frame was proposed for the serum 
creatinine to increase a minimum of 0.3 mg/dl or 1.5 times increase from baseline 
or a decrease in urine output of less than 0.5 ml/kg for at least 6 hours (Table 
1.6)78. 
Table 1.6 AKIN definition and staging of AKI 
This table provides the three stages of AKI. Table is adopted from Mehtha et al. 
2007 78. 
Stage Serum creatinine criteria Urine output criteria 
 
1 
Increase in serum creatinine of more than 
or equal to 0.3 mg/dl (≥ 26.4 µmol/l) or 
increase to more than or equal to 150% 
to 200% (1.5- to 2-fold) from baseline 
 
Less than 0.5 ml/kg per 





Increase in serum creatinine to more than 




Less than 0.5 ml/kg per 




Increase in serum creatinine to more than 
300% (> 3-fold) from baseline (or serum 
creatinine of more than or equal to 4.0 
mg/dl [≥ 354 µmol/l] with an acute 
increase of at least 0.5 mg/dl [44 
µmol/l]) 
 
Less than 0.3 ml/kg per 
hour for 24 hours or 
anuria for 12 hours 
The pathophysiology of AKI in sepsis is multi-factorial. Diverse overlapping 
mechanisms have synergistic effects and result in the development of AKI 77. In 
the past, global ischaemia was considered as the cause of AKI in sepsis 79. 
However, studies showed that AKI could develop in patients even without a 
reduction in renal blood flow (RBF) 80,81. In 2009, Prowle and colleges reviewed 
the literature for studies that measured RBF in AKI patients. They showed that 
RBF was not reduced in all critically ill patients with AKI the thing that confirms 




The main mechanisms involved in the development of the AKI in septic patients 
are inflammation, alteration in the microcirculation and adaptive cell response. 
Inflammation is a key driver of AKI in sepsis. High cytokines levels (such as IL-6 
and IL-10) are associated with the development of AKI 83,84. Different receptors 
are activated in response to PAMPs and DAMPs resulting in activation of 
inflammatory cascades that result eventually in activating leucocytes, epithelial 
and endothelial cells 25. Cytokines, PAMPs and DAMPs are filtered in the 
glomerulus and come into close proximity to endothelial cells in the proximal 
tubule, where they bind to TLR4 and TLR2 85–88. Activated endothelial cells then 
increase the expression of adhesion molecules, increase the inflammatory 
cytokines levels and increase leucocytes recruitment to kidneys resulting in further 
damage to tubular cells. Inhibition of adhesion molecules resulted in complete 
elimination of AKI development in CLP model of sepsis 89.   
Alteration in the microcirculation is another key driver of AKI in sepsis. Both 
macro- and microcirculation are altered in septic patients as a consequence of a 
decrease in vascular resistance and a change of blood distribution into tissues and 
impairment in microcirculatory perfusion, and both result in heterogeneity of blood 
flow in the body and within organs and these alterations are more profound in 
severely ill patients with sepsis 90–92. Even though macro-vascular complication 
and haemodynamic alterations happen in sepsis, renal blood flow remains normal 
or even increases. In 2003, Giantomasso and co-workers measured the blood flow 
to some vital organs including kidneys during E-coli induced sepsis in sheep. They 
showed a significant increase in renal blood flow in this setting 93. Microcircular 




imbalance between vasodilation-vasoconstriction in the endothelial cells 94,95. All 
these result in regional ischaemia. This finding is confirmed by the patchy pattern 
of injury seen in tubular cells 69.   
After being exposed to the inflammatory insult and microcircular dysfunction, 
tubular cells try to adapt to the new environment to prevent apoptosis that may 
result from the oxidative stress results from sepsis in the kidney 95. Indeed, tubular 
cell necrosis is not reported in sepsis-related AKI 69. The adaptive response is 
shown as down-regulation of cell metabolism and enhanced cell cycle arrest. In 
sepsis setting, the tubular cell energy level is decreased because of mitochondrial 
injury. Tubular cell focuses the energy consumption on cell survival function 
rather than metabolic function the thing that stops further cell damage 59,96,97. The 
low ATP level in AKI stimulates cell-cycle arrest to prevent cell death and allow 
recovery 98,99. 
1.1.9 Liver injury associated with sepsis 
To date, the accurate prevalence of liver injury associated with sepsis has not been 
established. The prevalence ranges from 1-20% depends on the diagnostic criteria 
used to identify liver injury 100. For example, Angus and co-workers showed that 
only 1.3% of 192,980-sepsis cases developed liver failure. They used liver necrosis 
and liver infarction as the criteria for diagnosing liver failure 17. In their study, 
Bakker and colleagues used less restrictive diagnostic criteria for liver injury and 
reported that almost 20% of 312 patients with septic shock developed liver failure 
during the study period (72 hours) 101. Using SOFA scoring, among 541 patients 
with severe sepsis, 46.6% developed liver dysfunction and 6.3% developed liver 




The way of diagnosing liver failure is still controversial. Thus far, there is no 
single standardised diagnostic tool for diagnosing liver failure. However, most 
available diagnostic criteria require a bilirubin level of ≥ 2 mg/dl and at least 
duplication in alkaline phosphate or ALT levels for diagnosing liver injury 101. In 
the latest consensus definition of sepsis and septic shock (sepsis-3), the panel 
recommended using the SOFA score to assess organ failure in which bilirubin is 
used to identify the presence of acute liver injury 14. 
Different cell types in the liver are involved in the development of liver injury in 
septic patients. Kupffer cells (KCs) for example are responsible for scavenging 
bacteria and endotoxin in sepsis 103. After exposure to endotoxin, KCs are 
activated and produce inflammatory cytokines such as TNF-α 104. TNF-α, in turn, 
increases neutrophil recruitment leading to enhancement in the inflammatory 
response. TNF-α also enhances hepatocytes (HCs) to produce NO and IL-6 leading 







1.2 Diabetes Mellitus 
1.2.1 Definition and classification  
Diabetes is a group of metabolic disorders that manifests as a chronic elevation of 
blood glucose with abnormal metabolism of fat, carbohydrates and proteins. 
Elevation in blood glucose in patients with diabetes are due to an either an 
impairment in insulin secretion from the beta cells of the islets of Langerhans in 
the pancreas, ineffective use of the secreted insulin secondary to insulin resistance 
of tissues that use insulin or both 106,107. This results in sustained hyperglycaemia, 
which in turn can lead to organ damage, dysfunction and failure. Diabetic patients 
often do not have symptoms or present with very mild symptoms such as excessive 
thirst, urination, weight loss and hunger; and many patients usually suffer from 
prolonged pathological and functional changes in their systems before being 
diagnosed 108. However, many other patients may experience severe, acute and life 
threatening symptoms such as ketoacidosis or non-ketotic hyperosmolar syndrome 
or long-term complication of diabetes such as retinopathy, nephropathy, peripheral 
neuropathy and micro- and/or macro-vascular issues including cardiovascular 
dysfunction, sexual dysfunction, atherosclerosis and cerebrovascular 
diseases106,107. 
Before developing diabetes and/or its complications, patients usually suffer from 
an impairment in their oral glucose tolerance test (OGTT). Impairment in OGTT is 
considered as a transitional state (pre-diabetes) between ‘normal’ and diabetic 
patients, but is already associated with increased cardiovascular risk. However, not 




further divided into sub-groups including type-1 diabetes mellitus (T1DM) and 
type-2 diabetes mellitus (T2DM). T1DM, which is also called insulin-dependent 
diabetes, is an autoimmune disease characterised by a lack of insulin production. In 
T1DM, insulin is the cornerstone of treatment and patients cannot survive without 
it 106–108. In T2DM, on the other hand, the formation of insulin is normal or slightly 
impaired, but the effects of insulin (in causing glucose uptake) in tissues are 
impaired. Many effective ways have been identified to prevent type-two diabetes. 
Even after developing T1DM or T2DM, tight glycaemic control, exercise and 
weight loss can prevent both the complications and pre-mature death associated 
with diabetes 106–108. 
1.2.2 Diagnosis 
The diagnosis of diabetes and of patients with an impaired OGTT are made by 
measuring either A1C or plasma glucose (fasting plasma glucose or glucose 
tolerance test), (Table 1.7) 109,110.  
Table 1.7 Criteria for the diagnosis of diabetes. This table provides the tests and 
the thresholds for diagnosis diabetes mellitus. This table is adopted from the 
American Diabetes association report 2016 111. 
Criteria for the diagnosis of diabetes 
FPG >=126 mg/dL (7.0 mmol/L). Fasting is no caloric intake for at least 8 h. * 
OR 
2-h PG >=200 mg/dL (11.1 mmol/L) during an OGTT. The test should be 
performed as described by the WHO, using a glucose load containing the 
equivalent of 75 g anhydrous glucose dissolved in water. * 
OR 
A1C >=6.5% (48 mmol/mol). The test should be performed in a laboratory using a 
method that is NGSP certified and standardized to the DCCT assay. * 
OR 
In a patient with classic symptoms of hyperglycaemia or hyperglycaemic crisis, a 
random plasma glucose >=200 mg/dL (11.1 mmol/L). 
*In the absence of unequivocal hyperglycaemia, results should be confirmed by 




After doing the first diagnostic test and to confirm the diagnosis, a second test is 
required. It is recommended to repeat the same test directly using a new blood 
sample. If the two tests give above diagnostic threshold values, the diagnosis is 
confirmed. The same scenario is applied if different tests give above diagnostic 
threshold values. However, if a patient gives discordant data of two different tests, 
the above of diagnostic threshold test should be repeated and the diagnosis is made 
depending on the new result 110. 
The indications and the frequency of screening tests for diabetes depend on many 
factors such as: age, weight (BMI), risk factors and previous tests results 109.  
1.2.3 Epidemiology 
The number of patients living with diabetes has quadrupled since the 1980s. The 
estimated worldwide number of adult patients living with diabetes in 2014 was 422 
million. The prevalence of diabetes has recently increased in low and middle 
income counties more than the increase in the prevalence in high income countries 
107. 
In the past, T2DM was exclusively seen in adults. However, recently T2DM has 
also been diagnosed in children. This may be related to an increase in sedentary 
life style leading to obesity 106,107. Diabetes was responsible of 3.7 million deaths 
worldwide in 2012. Almost half of these deaths happen in patients before the age 
of 70. The hyperglycaemia in diabetic patients increases the risk of pre-mature 





1.2.4 Diabetic cardiomyopathy 
Rubler et al. were the first to introduce the concept of diabetic cardiomyopathy as 
the functional and structural changes in the heart that result from metabolic 
abnormalities that are associated with diabetes in the absence of other causes, such 
as hypertension or coronary artery diseases 112. However, the presence of these co-
morbidities can amplify the risk of developing left ventricular hypertrophy, 
ischaemic injury and heart failure, especially in patients with T2DM 113.  
The structural changes in the diabetic heart include: left ventricular hypertrophy 
114, increased storage of lipid within myocytes 115, increased oxidative stress 116, 
increased myocyte necrosis and apoptosis 117 and fibrosis and accumulation of 
collagen 118. Metabolic abnormalities include altered substrate utilization 119 and 
mitochondrial dysfunction 116. All these structural and metabolic changes lead 
eventually to functional changes including diastolic dysfunction followed by 
systolic dysfunction 120. 
1.2.4.1 Pathogenesis of diabetic cardiomyopathy 
Many hypotheses and mechanisms have been proposed to explain the pathogenesis 
of diabetic cardiomyopathy. The pathogenesis is clearly multifactorial and the 
most important mechanisms affecting the contractile dysfunction are: myocardial 
inflammation, impaired calcium homeostasis, a dysregulated renin-angiotensin 






1.2.4.1.1 Metabolic abnormalities 
Myocardial inflammation 
There is good evidence that chronic inflammation in the heart is related to diabetic 
cardiomyopathy 119,121,122. This inflammation is usually subclinical and leads to 
diabetic cardiomyopathy after prolonged periods of time 123. Different pathological 
agents and stimulus are able to initiate inflammation and induce secretion of 
different cytokines (IL-6), chemokines (MCP-1) and adhesion molecules (ICAM-
1) in the heart resulting in myocardial infiltration of lymphocytes and monocytes 
121,122,124. Different signalling mechanisms are involved in myocardial 
inflammation. These mechanisms eventually lead to the activation of the NF-ĸB 
pathway, which is considered to be strongly activated in diabetics hearts 123.  
Effect of high glucose and fatty acids 
High glucose levels in the blood drive increases in cytokine and chemokine 
expression via activating the Jun NH2-terminal kinase (JNK)/NF-ĸB pathway 125 
and glycogen synthase kinase 3 beta (GSK-3β) 126. Hyperglycaemia also increases 
the expression of high-mobility group box 1 (HMGB1) leading to the activation of 
MAPK and NF-ĸB pathways and induction of TNF-α and IL-6 secretion 127.  
Increased glucose levels dysregulate sirtuin-1 (SIRT1) activity and result in an 
increase in cardiac inflammation and decreases in SERCA2 expression128. Free 
fatty acids also contribute directly to cardiac inflammation by activating TLR4 and 
subsequently the NF-ĸB pathway 129. Free fatty acids also activate protein kinase C 





Effect of the Advanced glycation end products (AGEs) 
The receptor for advanced glycation end products (RAGE) is a pattern recognition 
receptor that is upregulated by NF-ĸB and activated by AGEs. Once activated, it 
forms a heterodimer with TLR4 leading to the activation of the inflammatory 
response and pro-inflammatory cytokines production 131. 
Effect of DAMPs 
Damage associated molecular patterns (DAMPs) are obtained from cells that 
underwent apoptosis, injured cells or tissues. TLRs can recognise DAMPs leading 
to its activation and subsequently activating different inflammatory pathways 132. 
Diabetes also enhances neutrophil NETosis by upregulating PAD-4 as a result of 
different stimulations that lead eventually to NF-ĸB activation. NETosis result in 
nuclear degradation and the release of digestion product to the extracellular space. 
These digestion products work as potent DAMPs that activate more leucocytes 133. 
Impaired calcium homeostasis 
Diabetes alters the homeostasis of calcium and other ions in the diabetic heart 134. 
This disturbed homeostasis results from reduced ATPases activity, decreased 
ability of the sarcoplasmic reticulum to take up Ca2+ and reduced activity of both 
Na+-Ca2+ exchangers and Ca2+ dependant sarcolemmal ATPases 135. 
Dysregulated renin-angiotensin system 
The renin-angiotensin system (RAS) is activated in diabetic patients leading to 
increased oxidative stress, increased apoptosis and necrosis of myocardial and 




with lisinopril results in protection of cardiac cells from the damage associated 
with impaired calcium homeostasis and inhibits reactive oxygen species (ROS) 
production 136. 
Increased oxidative stress 
In diabetic hearts, ROS production is increased from mitochondrial sources from 
cells exposed to hyperglycaemia 137 and non-mitochondrial sources as a result of 
reduced nNOS activity 138. This increase in ROS production leads to cell death via 
activating some kinase pathways such as JNK, p38 kinase and Akt 139. It may also 
activate protein kinase C isoform, increase production of advanced glycation end-
products (AGEs) and increase glucose flux 137,140.   
Altered substrate utilisation  
Diabetic hearts have enhanced fatty acid metabolism and reduced glucose and 
lactate metabolism 141. Even though the metabolism of fatty acids is increased in 
diabetic patients, lipids accumulate in the heart as a result of lower fatty acid 
oxidation compared to fatty acid uptake 142. This results in lipotoxicity and 
formation of toxic intermediate such as ceramide leading to myocyte apoptosis 143. 
Mitochondrial dysfunction  
Diabetes causes structural and functional abnormalities in the mitochondria 
inducing a reduction in oxidative phosphorylation capacity, lower ATP synthesis 
144, reduced creatine phosphate activity, lower creatine-stimulated respiration 145 





1.2.4.1.2 Structural changes 
Cardiac hypertrophy 
Diabetic cardiomyopathy manifests as dilated hypertrophic changes in the left 
ventricle. Although the left ventricle is more commonly affected, hypertrophy can 
be seen in both right and left ventricles. The increase in LV wall thickness is 
compensated by increasing in the LV volume 147. Left ventricle hypertrophy 
usually develops at late stages of T2DM and the exact mechanism is still not fully 
understood. However, many factors are known to increase LV mass. 
Hyperinsulinaemia, for example, showed to increase cardiac mass in rats as insulin 
is anabolic hormone that works as a growth factor 148,149. Another study linked the 
high levels of leptin in obese patients with diabetes and development of left 
ventricular hypertrophy 150. 
Cardiac fibrosis 
Biopsies from diabetic patients hearts have showed an increase in collagen 
deposition in the heart (both interstitial and perivascular fibrosis) 151. Many factors 
play role in the development of cardiac fibrosis. For example, collagen production 
is increased as a result of the activated renin angiotensin aldosterone system 152, 
collagen degradation is also impaired as a result of decreased degradation by the 
matrix metalloperoxidase and the decreased susceptibility of collagen to be 
degraded after cross linking with the AGE 151,153. This accumulation of collagen 
results in cardiac stiffness and eventually to development of diastolic dysfunction 





1.2.4.1.3 Functional changes 
Diastolic dysfunction 
Diastolic dysfunction develops early in diabetes and even with patients with 
impaired glucose tolerance 154,155. Diastolic function can be measured using 
Doppler echocardiography to measure mitral valve blood flow, flow velocity and 
the declaration and the isovolumetric times. Diastolic dysfunction is usually 
present before systolic dysfunction. In diastolic dysfunction there are impairments 
in ventricular filling and relaxation and this manifest as an increase in left ventricle 
end diastolic pressure and a decrease in left ventricle end diastolic volume 156,157.    
Systolic dysfunction 
Despite the inconsistency about the development of systolic dysfunction in 
diabetic hearts in the literature, many studies in animal models of diabetes and in 
diabetic patients showed development of systolic cardiac dysfunction 158,159. 
Systolic cardiac dysfunction manifests as decreases in ejection fraction, fractional 
shortening, fractional area change and cardiac output. Systolic dysfunction usually 
develops after diastolic dysfunction and is associated with poor prognosis and 




Figure 1.5 Cellular and metabolic factors that result in the development of 
diabetic cardiomyopathy. 
Different cellular and metabolic abnormalities associated with diabetes result in 
structural and ultimately functional changes in the diabetic hearts. Figure adapted 








1.2.5 Infection/sepsis in diabetes mellitus 
Patients with both T1DM and T2DM are more susceptible to, and at increased risk 
of, developing infections. This includes both common infections such as lower 
respiratory tract infections, urinary tract infections and skin and soft tissue 
infections 161 as well as rare infections, which are almost exclusive to diabetes 
patients such as invasive external otitis and rhinocerebral mucormycosis 162. 
Diabetes can also alter critical elements of the pathophysiology of sepsis and 
infection. It affects both innate (cellular and humoral) and adaptive immune 
systems, endothelial function and coagulation 163.  
To date, the effects of diabetes on outcome in patients with sepsis are largely 
controversial: Some studies show that pre-existing diabetes results in increased 
infection-related mortality, organ dysfunction (marker of bad prognosis) and 
hospitalization: a study reviewing all medical records of all diabetic patients in 
Ontario, Canada since 1999 concludes that patients with diabetes are more likely to 
develop and die from infectious diseases 164. Other studies show that the mortality 
among patients with community acquired pneumonia (CAP) and pneumonia in 
general is higher in the diabetic population and in patients with hyperglycaemia 
upon hospital admission 165,166. In the Danish population, diabetes is associated 
with increased hospitalisation due to pneumonia, urinary tract infection (UTI) and 
skin infections. In the same population, diabetes was associated with a worse UTI 
prognosis 167. Diabetes is also associated with worse prognosis in patients with 
bacteraemia 168. In animal models of obesity, diabetes and sepsis, obese mice were 




They also had increased incidence of liver injury, hepatic neutrophil infiltration 169, 
and hepatic microvasculature damage 171.  
Other studies show no influence of diabetes on outcome or mortality related to 
infection. For instance, hyperglycaemia upon admission to hospital was not 
associated with poor prognosis in over 2000 patients with CAP 172 and diabetes did 
not affect outcome in 164 patients with sepsis, who were admitted to the ICU and 
received standard critical care 173. The presence of diabetes did not affect the 30-
days mortality in patient with community acquired bacteraemia 174 nor the ICU 
related mortality in insulin-treated diabetics even though they were more ill and 
more likely to develop renal failure175. 
A protective effect of diabetes was observed in other studies: diabetes reduced the 
incidence of acute respiratory syndrome in septic patients 176 and lowered the risk 
of developing acute respiratory distress syndrome in septic shock patients177. This 
protective effect was also seen in animal models of obesity, diabetes and sepsis; 
obesity decreases airways inflammation in septic animals 171 and the 
hyperlipidaemia associated with type 1 obesity is thought to improve the innate 









1.3 Dipeptidyl Peptidase 4 
Dipeptidyl peptidase 4 (DPP-4), or also called cluster of differentiation 26 (CD26) 
or adenosine deaminase binding protein (ADBP), is a serine protease enzyme from 
the S9B family. More than 30% of all proteolytic enzymes known so far are serine 
proteases. All known proteolytic enzymes can be classified using MEROPS 
database that was founded by Barrett and colleagues in 1996 179. In this database 
enzymes are grouped according to their structure, the similarities in their amino 
acids sequence and their activities, according to this system, serine proteases are 
divided into 13 clans depending on their catalytic activity and 40 families 
depending on their common structure and ancestry 180. Serine proteases are also 
divided into endoproteases and exoproteases depending on the site of the peptide 
bond being hydrolysed in the polypeptide chain by the enzyme: endoproteases 
catalyse the hydrolysis of bonds located in the middle of proteins, while 
exoproteases catalyse the hydrolysis of bonds at the terminal part of the target 
protein. Serine proteases are distributed widely and found in both eukaryotic and 
prokaryotic cells 181. 
The serine protease S9 family is the most studied among all serine proteases 182 
and S9 proteases are responsible for peptide hormone degradation and processing, 
making it a target for drug design/development. For example, DPP-4 is involved in 
T2DM and also responsible for the processing of chemokines 183. DPP-4 is 
expressed in different tissues in humans. It is mostly found in the gastrointestinal 
(GI) track (in the small intestine and duodenum), but also highly expressed in the 




membrane bound form 184. A soluble isoform can also be found in the plasma, 
seminal fluid, cerebrospinal fluid and urine 185,186. 
1.3.1 The structure of DPP-4 
DPP-4 is a type II integral membrane glycoprotein. It is usually a dimer of 2 
identical monomers. Each monomer has a short cytoplasmic portion (N-terminal) 
consisting of 6 amino acids (AA 1-6), a 22 amino acid transmembrane part (AA 7-
29) followed by an extracellular domain consisting of two parts: an 8 blade β-
propeller domain and a large catalytic α/β-hydrolase domain 187,188. The catalytic 
activity of DPP-4 depends on nucleophilic attack of the substrate peptide bond 
(carbonyl atom) by the catalytic triad. The catalytic triad is a group of amino acids 
[serine (Ser), aspartate (Asp) and histidine (His)] in the catalytic site of DPP-4 
(Figure 1.6) 189. Although the homodimer is the most catalytically active form, 
DPP-4 is also found as monomer and homotetramer on the cell surface 190. 
Soluble form of DPP-4 is in the homodimer form and it lacks the cytoplasmic and 
transmembrane domains. However it still has the catalytic domain, therefore, the 






Figure 1.6 Structure of the extracellular part of the symmetric DPP-4 
homodimer 
Coloured in pink is the α/β hydrolase domain and the β-propeller domain (coloured 
in green) in each monomer. In the box is a close up of the DPP-4 active site 
catalytic triad (Ser630, His740 and Asp708). Figure adapted from Aertgeerts et al. 
2004 192. 
1.3.2 The function of DPP-4 
When it is in the active form, DPP-4 performs either catalytic or non-catalytic 
functions. Catalytic function is the most studied one and DPP-4 works as an 
exoprotease that cleaves the dipeptide from the N-terminal of the peptide chain if 
the second to last residue of the polypeptide is alanine, proline, hydroxyproline or 
dehydroproline 186. DPP-4 controls glucose metabolism and homeostasis through 
regulation of incretins 193. However, recently investigations into the potential 
importance of the non-catalytic effects of DPP-4 are on the rise. In the non-
catalytic pathway, many proteins such as adenosine deaminase, CD45, collagen 
and others activate DPP-4. Interaction with these molecules leads to co-stimulation 





1.3.2.1 Catalytic activity of DPP-4 
Ingestion of food stimulates the secretion of many gastrointestinal hormones. 
Some of these hormones are responsible for regulating gastric motility and gastric 
acid secretion. Other hormones such as glucagon like peptide-1 (GLP-1) and 
glucose-dependant insulinotropic peptide (GIP) help to lower glucose by 
increasing insulin secretion 194. GLP-1 is secreted from the L cells in the colon and 
the ilium and GIP is secreted from the K cells in the jejunum and duodenum. The 
plasma levels of GLP-1 and GIP elevate within minutes of food intake. However, 
their levels decrease rapidly due to the enzymatic inactivation by DPP-4 and 
excretion via the renal system 195. GLP-1 and GIP exert their effect after binding to 
G protein coupled receptors on the pancreatic β cells, adipocytes and the central 
nervous system for GIP and on the pancreatic α and β cells, heart, kidney, lung and 
gastrointestinal track for GLP-1194. Activation of the islet β cells by incretin leads 
to increase in cAMP level and intracellular calcium hence insulin secretion 196. 
Both incretins promote islet β cells proliferation and inhibit apoptosis. However, 
only GLP-1 is able to slow gastric emptying, decrease food intake and glucagon 
secretion (Figure 1.7) 197. 
Therefore, inhibition of DPP-4 results in an anti-hyperglycemic effect by 





Figure 1.7 Catalytic and non-catalytic function of DPP-4. Figure modified from 
Zhong, et al. 2015 198. 
1.3.2.2 Non-catalytic activity of DPP-4 
In addition to regulating the incretin system, DPP-4 has non-catalytic co-
stimulatory function. DPP-4 from T cells binds to adenosine deaminase (ADA) 
leading to the activation of intracellular inflammatory pathways 199. ADA is a 
polymorphic enzyme that regulates intracellular and extracellular adenosine levels 
by deaminating adenosine irreversibly to inosin 200. When ADA binds to DPP-4 it 
potentiates T cell activation, NF-ĸB translocation and increases pro-inflammatory 




Binding of the DPP-4 (from the T cells) with the exposed caveolin-1 (from the 
antigen presenting cells, APC) leads to IRAK-1/Tollip liberation from the caveolin 
complex in the APC. IRAK-1 is then phosphorylated leading to NF-ĸB activation 
and CD86 upregulation and subsequently T cell co-stimulation 202,203. Within the T 
cells, the interaction between caveolin-1 and DPP-4 results in the recruitment of a 
molecular complex of CARMA1-Bcl10MALT1-IKK in lipid rafts leading to 
strong NF-ĸB activation 202 (Figure 1.8). This mechanism is suggested to be the 
drive of some inflammatory diseases 204. 
 
Figure 1.8 Interaction between DPP-4 and caveolin-1 and co-stimulation of T 





1.3.3 DPP-4 activity and expression in diabetes mellitus  
The serum levels of DPP-4 are increased in diabetic patients with or without 
metabolic syndrome compared to healthy individuals. This results in decreased 
GLP-1 levels in diabetic patients 205. It has recently been suggested that DPP-4 is 
an adipokine 206 expressed in both subcutaneous and visceral adipocytes and this 
expression is positively correlated with body mass index. The levels of DPP-4 are 
also correlated with adipocytes size, HbA1c level and inflammatory status 207. For 
example, TNF-α increases DPP-4 release from the differentiated adipocytes. The 
released DPP-4 then exhibits paracrine activity on insulin sensitivity in skeletal 
muscle and adipocytes 206.  Peripheral T cell expression of DPP-4 increases in the 
blood of patients with diabetes and poor glycaemic control 208. Liver of patients 
suffering from non-alcoholic fatty liver disease shows increase in DPP-4 activity 
and this increase is correlated with the degree of insulin resistance and results in 
impaired glucose metabolism in the liver 209. 
1.3.4 DPP-4 inhibitors 
DPP-4 inhibitors [approved by the Food and Drug Administration (FDA) and the 
European Medicine Agency (EMA)] are divided into two groups depending on 
their structure: dipeptidomimitics (sitagliptin, vildagliptin and saxagliptin) and 







Table 1.8 Approved DPP-4 inhibitors classified according to their structure. 










Sitagliptin 2006 β-amino acid 
 
Vildagliptin 2007 Nitrile 
 












Linagliptin 2011 Xanthine 
 
Alogliptin 2013 Pyrimidinedione 
 
These drugs show moderate efficacy in lowering blood glucose and HbA1c 
compared to other classes of anti-hyperglycaemic drugs such as sulfonylureas, 
thiazolidinediones and insulin. However, they provide a good alternative or 
adjunct therapy to traditional anti-diabetic drugs such as metformin 210. Gliptins 
result in less than 1% reduction in HbA1c. This reduction depends on baseline 
HbA1c and concomitant drugs use 211. Common side effects related to gliptin use 
are headache, upper respiratory tract and urinary tract infections. Hypoglycaemia is 
not common with gliptins use alone. However, incidence of hypoglycaemia 
increases with the concomitant use of sulfonylurea or insulin 210. Unlike other 




1.3.4.1 Anti-inflammatory effect of DPP-4 inhibitors 
DPP-4 inhibitors have been used as anti-diabetic drugs. However, recent evidence 
indicates that DPP-4 inhibitors also have anti-inflammatory effects. 
1.3.4.1.1 DPP-4 effect on vascular inflammation 
Endothelial cell apoptosis and vascular dysfunction occur in many diseases 
including diabetes, atherosclerosis and sepsis. DPP-4 is expressed in endothelial 
cells and DPP-4 activity plays a role in vascular dysfunction related to these 
diseases, while inhibition of DPP-4 using different inhibitors results in improved 
vascular function. 
Pretreatment of animals with DPP-4 inhibitors prior to LPS challenge resulted in 
an increase in survival and an improvement in endothelial cell function. Mice and 
rats treated with linagliptin prophylactically prior to high dose of LPS showed an 
increase in survival rate. In contrast, pre-treatment with sitagliptin had no effect on 
survival in endotoxaemic animals 213,214. Both drugs attenuated the hypotension 214 
and vascular dysfunction 213,214 caused by LPS and corrected the inflammatory 
status by supressing mRNA expression of some pro-inflammatory cytokines, ROS 
formation and whole blood nitrosyl-iron haemoglobin 213,214. These beneficial 
effects were abolished in AMP-activated kinase (α1) knockout mice suggesting 
that AMPK mediated NF-ĸB activation may be the target of these drugs 214. This 
hypothesis was confirmed after measuring AMPK activity in diabetic rats aorta 
after treatment with sitagliptin215 and in isolated human umbilical vein endothelial 




Oral administration of linagliptin in rats for 7 days before LPS challenge reduced 
inflammatory cell filtration in the aorta and ROS formation in the heart, vesicles 
and blood 217. Linagliptin also suppressed the LPS-stimulated adhesion of isolated 
activated human neutrophils to HUVECs 217, increased the activity of both PKA 
and PKC, inhibited LPS induced AP-1 nuclear translocation and PKB 
phosphorylation 218, reduced IL-6 production, translocation of NF-ĸB to the 
nucleus and p38 MAPK phosphorylation 219. These results demonstrate that these 
beneficial effects of linagliptin are GLP-1 independent, as the effects of linaglipitin 
were studied in HUVECs which do not secrete GLP-1 219.  
1.3.4.1.2 DPP-4 effect on cardiac function 
Long-term linagliptin treatment of mice fed a high fat diet prevented structural 
(hypertrophy and fibrosis) and functional (contractile dysfunction) abnormalities in 
the heart by inhibiting TRAF3IP2 expression resulting in reduced NF-ĸB, AP-1 
and p38 MAPK activation 220. Sitagliptin treatment for 8 weeks in rats fed with 
high salt diet resulted in attenuation of diastolic dysfunction and improved survival 
by decreasing collagen deposition in the heart, reducing myocardial oxidative 
stress, pro-inflammatory cytokines levels and myocardial stiffness 221. Treatment 
of cardiac fibroblast incubated with aldosterone with linagliptin reduced 
TRAF3IP2 expression, inflammatory cytokines and collagen induction 220. 
Cardiomyoblast stimulated with LPS showed increase in TNF-α, IL-6, IL-1β, 
cyclooxygenase-2 and iNOS expression and NF-ĸB nuclear translocation. All of 





1.4 Hypotheses and Aims of the Thesis 
Sepsis is associated with a high mortality rate among ICU patients. The 
development of cardiac dysfunction results in further increase in the in-hospital 
mortality among patients with sepsis and septic shock. Both the incidence and the 
mortality rate of sepsis and septic shock increase with age mainly due to the 
presence of co-morbidities in this age group (e.g. diabetes). Further investigations 
are still needed to understand the pathophysiology of sepsis-associated cardiac 
dysfunction and the effect of pre-existing conditions such as diabetes in the 
pathophysiology and the severity of the cardiac dysfunction associated with sepsis. 
This thesis aims to investigate the following hypotheses: 
1. Feeding mice with a HFD results in a T2DM phenotype and diabetic 
cardiomyopathy. 
2. Pre-existing T2DM augments the cardiac dysfunction associated with 
endotoxaemia or CLP-sepsis in mice. 
3. Activation of the NF-κB pathway is the key driver of sepsis-associated 
cardiac dysfunction in mice with pre-existing T2DM, and 
4. Inhibition of the NF-κB pathway with a selective IKK inhibitor (IKK-16) 
or a DPP-4 inhibitor (linagliptin) attenuates the cardiac dysfunction in mice 








Based on the above hypotheses, this thesis had the overall aims to: 
1. Establish a mouse model of HFD-induced T2DM and diabetic 
cardiomyopathy, 
2. Investigate the effect of pre-existing T2DM on cardiac dysfunction 
associated with endotoxaemia or CLP-sepsis, 
3. Elucidate the signalling mechanism that resulted in the aggravation of 
cardiac dysfunction in mice with T2DM/sepsis, and 
4. Examine the effect of IKK-16 or linagliptin treatment on the cardiac 
dysfunction associated with sepsis in mice with pre-existing T2DM. 
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CHAPTER 2:  ESTABLISHING A MOUSE MODEL OF 
TYPE 2 DIABETES AND DIABETIC 
CARDIOMYOPATHY 
2.1 Introduction 
Diabetes mellitus is a complex metabolic disorder that develops secondary to 
impairment in insulin secretion as a result of pancreatic beta cell destruction, 
reduced sensitivity to insulin in different tissues or a combination of both. Diabetes 
results in an impairment in glucose homeostasis and manifests as a chronic 
elevation of blood glucose (hyperglycaemia) 106,223. The persistent hyperglycaemia 
can drive the development of different organs dysfunction, damage and failure 108.  
Hyperglycaemia is also linked to the increased incidence of premature death 
associated with different organs dysfunction 223. 
The most common types of diabetes are type 1 diabetes mellitus (T1DM), also 
called insulin-dependent diabetes and type 2 diabetes mellitus (T2DM), also called 
insulin-independent diabetes 106,108,223. In T1DM, hyperglycaemia develops 
secondary to insulin depletion as a result of β cells destruction in the pancreatic 
islets of Langerhans and it is believed to be a result of an autoimmune disorder that 
can be triggered by different environmental factors 224,225. In T2DM, on the other 
hand, hyperglycaemia develops secondary to insulin resistance or, in more severe 
cases of T2DM, beta cell failure. The cause of insulin resistance in T2DM is 




resistance is still unknown. However, studies suggest the involvement of complex 
genetic and environmental triggers 226. 
Around 422 million adults lived with diabetes in 2014, among them almost 90% 
suffered from T2DM 223. This number is expected to increase to 592 million by 
2035 227. The prevalence of T2DM has been increasing steadily for the past few 
decades and the incidence is increasing in all age groups including children 106. 
This makes T2DM a global issue with high economic cost in all countries. 
Therefore, If we can find effective ways to prevent this disease and manage its 
complications we can guarantee a better quality of life and reduce its economic 
burden 227. 
For a better understanding of this disease and its complications, different animal 
models have been introduced in the literature to study diabetes. This enables us to 
get a better insight of the pathophysiology of the disease, test the efficacy of 
potential therapies and insulin formulas, and study diabetes complications 228. 
Modelling T2DM in animals can be done either by genetic manipulation of single 
or multiple genes or environmental changes by introducing high fat diet (HFD) to 
animals to induce obesity and ultimately T2DM. Unfortunately, none of the 
existing models of T2DM can completely reflect the complex human disease. 
Different animal models provide different levels of severity of the disease 
measured as varying degrees of insulin resistance, beta cell dysfunction and 
diabetic complications.   
Genetically induced T2DM is subdivided into monogenic and polygenic models. 
The most common monogenic models of T2DM depend on the disturbance of 




(db/db mice) results in excessive food consumption and obesity 228. These two 
models are frequently used to study potential therapeutic interventions 229–231. 
Polygenic models of T2DM are also available. Although they are more clinically 
relevant than monogenic models, they still can’t exactly model the disease seen in 
man, because more than 50 genes have been identified to play a role in the 
pathophysiology of human diabetes, and the respective genes are not all affected in 
these polygenic models 232,233. Therefore, using gene-dependant models of T2DM 
to model diabetes may not be the most appropriate approach even though they are 
well standardised and characterised.  
As the increase in the sedentary lifestyle and western diet consumption are the 
main causes of type 2 diabetes to date 106,223, the administration of a HFD is 
considered to be the most appropriate strategy for inducing experimental T2DM 
especially when aiming to study cardiovascular alterations and diabetic 
cardiomyopathy 234. Thus far, no single standard protocol of HFD-induced diabetes 
has been established. Since its introduction in 1988 by Surwit and co-workers 235, 
different protocols (and compositions) of HFD have been reported in the literature. 
Protocols described in the recent publications used different i) mouse strains, ii) 
formulation of HFD (with fat fractions ranging from 20% to more than 60%) 236, 
iii) duration of feeding (ranging from few weeks up to more than a year) and iv) 
age of mice at the introduction of the HFD 237. Even with a similar percentage of 
fat, various compositions lead to very different biological responses. For example, 
with increasing amounts of saturated fatty acids and with the introduction of longer 
fatty acid chains, the diet becomes more obesogenic 238. Different origins of the fat 
in the HFD also affect outcome with animal-derived fat (such as lard) being more 




Like human T2DM, animal models of HFD-induced diabetes affect different 
tissues and organ systems and resulting in diabetes complications. In adipose 
tissues, for example, adipocytes change metabolism and morphology in mice fed 
with HFD. Both number and size of adipocytes increase after the introduction of 
HFD 240,241. Adipocytes also secrete adipocytokines as a result of HFD feeding 242. 
Visceral white fat is the most pathogenic, as it secretes large quantities of 
adiponectin, TNFα and IL-6 243. HFD also negatively affects the liver 244,245 by 
causing hepatic steatosis 246. Liver injury starts with fat accumulation in the liver 
(steatosis) that then results in inflammation and develops into non-alcoholic 
steatohepatitis (NASH), fibrosis, cirrhosis and untimely hepatocellular carcinoma 
with continuous HFD feeding 237. Unlike adipose tissue and the liver, the effects of 
HFD on cardiac tissue and function are less clear. Many studies show that HFD 
results in diabetic cardiomyopathy 247–250 while other studies show no cardiac 
dysfunction even after longer periods of HFD 234,251. Although the presence of 
variable protocols of HFD models of T2DM can be an advantage as it provides 
high flexibility, it makes finding the best protocol (diet composition and duration 
of feeding) quite challenging.       
In this chapter, I aimed to establish and standardise a mouse model of HFD-
induced T2DM with small degrees of diabetic complications (diabetic 
cardiomyopathy, liver injury and kidney injury) in order to use this model in later 
studies to investigate the effect of pre-existing T2DM on the cardiac and, indeed, 





2.2  Scientific Hypothesis and Aims  
This study is driven by the hypothesis that: 
§ Feeding mice with a HFD results in type 2 diabetes mellitus phenotype and 
diabetic cardiomyopathy. 
This study aims to: 
§ Establish a mouse model of HFD-induced type 2 diabetes mellitus and 
diabetic cardiomyopathy that can be used later as a first hit in the coming 
experiments to study the effect of diabetes on cardiac dysfunction in sepsis, 
§ Test an alternative HFD for developing diabetes and diabetic 
cardiomyopathy to be used instead of the first diet after having some issues 
with the supply of the first diet, 
§ Intensify the study about the new diet to make sure that is results in similar 





2.3  Methods and Materials   
The animal protocols followed in this study were approved by the local Animal 
Use and Care Committee in accordance with the derivatives of both, the Home 
Office Guidance in the Operation of Animals (Scientific Procedure Act 1986) 
published by Her Majesty’s Stationary Office, and the Guide for the Care and Use 
of Laboratory Animals of the National Research Council. 
2.3.1 Animals 
The studies in this chapter were conducted on 56 ten-week old male C57BL/6 mice 
(Charles River, Kent, UK) weighing 25-30 g, receiving a standard diet and water 
ad libitum (before starting the experiments). Mice were housed 5 per cage in a 
temperature-controlled room with a 12-hour light/dark cycle. Sixteen mice were 
used in the first study to establish the first mouse model of T2DM and diabetic 
cardiomyopathy and 40 mice were used to establish the second model of T2DM 
and diabetes complications and the follow-up study. 
2.3.2 Measuring body weight and feeding behaviour 
The body weight and food and calorie intake of mice were measured weekly to 
ensure good health and monitor their eating habits. The body weight of all animals 
was measured at the same time at the beginning of each week using the same 
balance for the whole experiment. New fresh food (150 gram/cage) was supplied 
to mice at the beginning of each week and observed every few days during the 




each week before being changed to measure food intake and calculate weekly 
calories intake for each cage using the following equations: 
Food intake
=
𝐷𝑖𝑒𝑡 𝑤𝑒𝑖𝑔ℎ𝑡 𝑏𝑒𝑔𝑖𝑛𝑖𝑛𝑔 𝑜𝑓 𝑡ℎ𝑒 𝑤𝑒𝑒𝑘 − 𝐷𝑖𝑒𝑡 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑒𝑛𝑑 𝑜𝑓 𝑡ℎ𝑒 𝑤𝑒𝑒𝑘)
(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑐𝑎𝑔𝑒×𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠)  
Equation 1: Food intake (grams/mouse/day) is calculated using 4 measurements 
a) diet wait at the start of the week (grams), b) diet weight at the end of the week 
(grams), c) number of mice in each cage and d) number of days. 
Calories intake
= Food intake×[  Protein,%×4 +  Fat,%×9 + Carb,%×4 ]  
Equation 2: Calories intake (Kcal/mouse/day) is calculated using 4 measurements 
a) food intake (grams/mouse/day), the percentage of b) protein, c) fat and d) 
carbohydrates.  
2.3.3 Oral Glucose Tolerance Test (OGTT)    
Mice were fasted for 6 h (8 am-2 pm) by being moved to clean cages with no food 
supply, but with free access to water. At the end of the 6 h fasting, the body weight 
was measured for each mouse, then a small cut to the side of the tail was made to 
obtain blood. Fasting blood glucose was measured and mice then received a bolus 
dose of glucose (2 g/kg, dissolved in drinking water) via oral gavage using an 18 G 
stainless steel feeding tube. Blood glucose levels were then measured at 15, 30, 45, 
60, 90 and 120 min post glucose administration using blood glucose meter Accu-





2.3.4 Insulin Tolerance Test (ITT) 
Mice were fasted for 4 h (10 am-2 pm) by being moved to clean cages with no 
food supply but with free access to water. At the end of the 4 h fasting, the body 
weight was measured for each mouse then a small cut to the side of the tail was 
made to obtain blood. Fasting blood glucose was measured and mice then received 
a dose of insulin aspart (NovoRapid®) (0.75 U/kg, i.p.). Blood glucose level was 
then measured at 15, 30, 45, 60, 90 and 120 min post insulin administration using 
blood glucose meter Accu-Chek® (Accu-Chek Compact System; Roche 
Diagnostics, Basel, Switzerland). 
2.3.5 Measuring fasting insulin level 
Mice were fasted for 6 h (8 am-2 pm) by being moved to clean cages with no food 
supply but with free access to water. Blood samples were obtained from the tail 
vein and serum samples were then obtained. Serum insulin was measured using a 
human insulin ELISA kit following manufacturer instructions (Abcam®, 
Cambridge, UK). 
2.3.6 Assessment of Cardiac Function in Vivo (Echocardiography) 
Echocardiography was conducted in vivo at baseline then at week 6 and 12 (and at 
week 16 in the first study) to measure cardiac function for the development of 
diabetic cardiomyopathy using a 30 MHz RMV707B scan head and a Vevo-770 
imaging system (VisualSonics, Toronto, Ontario, Canada).  
Animals were anaesthetized using 3% isoflurane delivered with 0.4 L/min oxygen 




echo table and taped from the limbs in a supine position onto the metal ECG leads 
on the Echo platform. Anaesthesia was maintained during the whole imaging 
process using 2% isoflurane delivered with 0.4 L/min oxygen via nosecone under 
spontaneous breathing. The handling platform was warmed to 40 °C in order to 
keep the core body temperature of the mice. After being placed on the platform, 
the fur on the chest was then removed carefully using Veet® hair removing cream. 
A pre-warmed echo gel is then applied to the chest to start the measurement. At 
least 10 min were left for the animals to stabilise before any measurement was 
taken. The body temperature was monitored using a rectal probe and the heart rate 
was obtained from ECG tracing during the whole procedure. 
Measurements from both two-dimensional (brightness mode, B-mode) (Figure 2.1) 
and one-dimensional (motion mode, M-mode) were obtained (Figure 2.2). 
Measurements of the left ventricle internal dimension (LVID) in both systole 
(LVID; s) and diastole (LVID; d) from the M-mode at the level of the papillary 
muscles were used to calculate the percentage ejection fraction (% EF), fractional 
shortening (% FS) and the measurements of LV end-systolic and end-diastolic 
areas from the B-mode were used to calculate the percentage functional area 
change (% FAC) using the following equations: 
% EF =  
(LVID;d! − LVID; s!)
LVID;d! ×100 
Equation 3: Ejection fraction (%) is calculated using 2 measurements a) left 
ventricle internal dimension during diastole (mm) and b) left ventricle internal 





% FS =  
(LVID;d− LVID; s)
LVID;d  ×100 
Equation 4: Fractional shortening (%) is calculated using 2 measurements a) left 
ventricle internal dimension during diastole (mm) and b) left ventricle internal 
dimension during systole (mm).  
% FAC =  
(LV area;d− LV area; s)
LV area;d  ×100 
Equation 5: Fractional area change (%) is calculated using 2 measurements a) left 
ventricle end-diastolic area (mm2) and b) left ventricle end-systolic area (mm2).  
  
Figure 2.1 Two dimensional (B-mode) murine echocardiography 
Representative brightness mode echocardiogram image of (A) a mouse heart in a 
parasternal short axis view at the papillary muscles level and (B) a measurement of the left 
ventricular endocardial area during systole to calculate the percentage fractional area 
change (FAC %). 
Figure 2.2 One dimensional (M-mode) murine echocardiography 
Motion mode is used to measure the left ventricle internal dimensions (LVID) during 
systole and diastole in order to calculate the percentage ejection fraction (EF %) and 
fractional shortening (FS %). 




2.3.7 Assessment of kidney function 
During the last week of the experiment, mice were housed in the metabolic cages 
to collect urine. They were housed (one mouse per cage) for 24 h with free access 
to food and water. Urine biochemistry (creatinine and sodium levels) was assessed 
blindly by IDEXX the commercial veterinary testing laboratory (IDEXX Ltd; West 
Sussex, UK). Urine albumin was measured using a mouse albumin ELISA kit 
following manufacturer instructions (Cambridge Bioscience®, Cambridge, UK). 
Then creatinine clearance (CrCl) and urine albumin to creatinine ratio (ACR) were 






Time   
Equation 6: Creatinine clearance (ml/min) is calculated using 4 measurements a) 
urine creatinine (µmol/L), b) serum creatinine (µmol/L), c) urine volume (ml) and 
d) time (minutes). 
ACR =  
Urine Albumin
Urine Creatinine 
Equation 7: Urine albumin to creatinine ratio is calculated using 2 measurements 
a) urine albumin (µg/L) and b) urine creatinine (mg/L). 
2.3.8 Blood and organ collection 
At the end of the last cardiac function assessment, mice were anesthetised with 
high dose isoflurane then blood samples were collected by cardiac puncture and 
then mice were sacrificed to terminate the experiment. Blood samples were 




and/or gel tubes (for serum separation).  Serum samples were obtained by 
centrifugation of the blood at 9000 RPM for 3 min and then snap frozen in liquid 
nitrogen and then kept in -80 °C freezer. Vital organs were collected and snap 
frozen in liquid nitrogen or frozen in cold 2-methyl butane and kept later in -80°C 
freezer for long-term storage or fixed in 10% neutral buffered formaldehyde for 48 
h then transferred into 70% ethanol for long-term storage and further analysis. 
2.3.9 Blood Analysis 
Serum biochemical markers (creatinine, urea, ALT, total cholesterol, triglycerides, 
LDL, HDL, glucose and sodium) were measured blindly by the commercial 
veterinary testing laboratories IDEXX (West Sussex, UK) and MRC Harwell 
institute (Oxford, UK). 
Whole blood analysis (complete blood count and WBC differential count) was 
conducted using IDEXX ProCyte Dx® haematology analyser (IDEXX 
BioResearch, Ludwigsburg, Germany)  
2.3.10  Histological analysis 
For collagen visualization, formalin-fixed liver samples were embedded in paraffin 
and cut into 4 µm sections. For staining, sections were deparaffinised using two 
washes of xylene and rehydrated with decreasing concentrations of ethanol (100%, 
95%, 90%, 80% and finally 70%) and washed with distilled water. Hydrated 
sections were adequately covered with Picro-Sirius Red stain (Abcam ®, 
Cambridge, UK) and incubated in the dark for 1 hour then rinsed twice with 0.5% 




ethanol), cleared with d-limonene (national diagnostic®, Nottingham, UK) and 
coverslipped using distyrene, plasticizer and xylene (DPX) mountant. 
For fat visualization, frozen liver samples (using 2-methyl butane) were embedded 
in optimal cutting temperature compound (OCT compound) and cut into 10 µm 
sections. Frozen sections were left at room temperature for 10 min and fixed in 
10% neutral buffered formaldehyde for 5 min then rinsed thoroughly with running 
tap water. Sections then were adequately covered with Oil Red-O stain (1% Oil 
Red-O in 60% isopropyl alcohol) and incubated for 15 min, differentiated twice 
with 60% isopropyl alcohol solution and rinsed with water. Sections were 
counterstained with Mayer’s haematoxylin for 2 min, blue in running tap water and 
coverslipped using aqueous Dako glycergel mounting medium (Dako, Cambridge, 
UK). 
Slides from both protocols were then scanned using a NanoZoomer Digital 
Pathology Scanner (Hamamatsu Photonics K.K. Japan) and high-resolution images 
were obtained for analysis. Form each image, 10 fields were selected randomly at 
magnification (40x) to quantify collagen or lipid. Percentages of Oil Red-O or 
Sirius Red positive staining were calculated using ImageJ software. 
2.3.11 Statistical analysis 
Data was analysed using GraphPad Prism 7.0 (GraphPad Software, San Diego, 
California, USA). Values stated in the text and figures are presented as a mean ± 
standard error of the mean (SEM) of n observations, where n is the number of 
animals used. Data was tested for normality using D’Agostino-Pearon normality 




Bonferroni’s post hoc test or unpaired Student t-test where appropriate. P values of 
less than 0.05 were considered to be statically significant. 
2.3.12 Materials 
Unless otherwise stated, all materials, reagents and solutions were purchased from 





2.4  Experimental Designs and Studies Groups 
2.4.1 First Model of T2DM Using HFD (58R3: Red diet): 
10 weeks old mice were randomised to receive HFD or chow diet as following 
Table 2.1 Experimental groups used to establish a mouse model of high fat diet 
induced T2DM and diabetic cardiomyopathy. 
Group name Diet Intervention Number 
Chow Normal chow diet None 8 
HFD* High fat diet None 8 
* Diet compositions and nutritional profile are provided in Table 2.4. Chow diet was purchased 
from TestDiet® (St. Louis, Missouri, USA) and the high fat diet (58R3: red diet) was purchased 
from LabDiet® (St. Louis, Missouri, USA). 
 
 
Figure 2.3 Summary of the experimental procedures and the follow-up plan used to 
study the first mouse model of high fat diet induced T2DM and diabetic 
cardiomyopathy. 
Mice were randomised to receive chow or high fat diet for 16 weeks. Body weight, food 
and calorie intakes were measured weekly. At 0, 6, 12 and 16 weeks, cardiac function was 
measured using in vivo echocardiography. At 12 and 16 weeks blood samples were 
collected to measure kidney and liver function. Mice were also challenged with bolus oral 
glucose to measure the degree of impaired glucose tolerance at 12 and 16 weeks.  
2.4.2 Second Model of T2DM Using HFD (58Y1: Blue diet): 
Table 2.2 Experimental groups used to establish a second mouse model of high fat 
diet induced T2DM and diabetic cardiomyopathy. 
Group name Diet Intervention Number 
Chow Normal chow diet None 10 
HFD* High fat diet None 10 
* Diet compositions and nutritional profile are provided in Table 2.4. Chow diet was purchased 
from TestDiet® (St. Louis, Missouri, USA) and the high-fat diets (58Y1: blue diet) was purchased 





Figure 2.4 Summary of the experimental procedures and the follow-up plan used to 
study the second mouse model of high fat diet induced T2DM and diabetic 
cardiomyopathy. 
Mice were randomised to receive chow or high fat diet for 12 weeks. Body weight, food 
and calorie intakes were measured weekly. At 0, 6 and 12 weeks, cardiac function was 
measured using in vivo echocardiography. At 6 and 12 weeks blood samples were 
collected to measure kidney and liver function. Mice were also challenged with bolus oral 
glucose to measure the degree of impaired glucose tolerance at 6 and 12 weeks.  
2.4.3 Follow up Study to Measure the Diabetes Complications that Result 
from the Second Model of T2DM Using HFD (58Y1: Blue diet): 
Table 2.3 Experimental groups used to study the diabetes complications in the second 
mouse model of high fat diet induced T2DM and diabetic cardiomyopathy. 
Group name Diet Intervention Number 
Chow Normal chow diet None 10 
HFD* High-fat diet None 10 
* Diet compositions and nutritional profile are provided in Table 2.4. Chow diet was purchased 
from TestDiet® (St. Louis, Missouri, USA) and the high-fat diets (58Y1: blue diet) was purchased 
from LabDiet® (St. Louis, Missouri, USA). 
Figure 2.5 Summary of the experimental procedure used to study the diabetes 
complications in the second mouse model of HFD induced T2DM and diabetic 
cardiomyopathy. 
Mice were randomised to receive chow or high-fat diet for 12 weeks. Body weight, food 
and calorie intakes were measured weekly. At weeks, mice were challenged with insulin to 
measure insulin resistance, blood samples were collected to measure serum insulin, 
glucose, lipids’ profile and haematology markers. Urine samples were collected to 










     Diet 










Protein, % 24.5 14.9 18.1 
Fat, % 13.1 59.4 61.6 
Carbohydrate, % 62.4 25.7 20.3 
Fat 
composition 
Cholesterol, ppm 142 0.0 301 
Linoleic Acid, % 2.14 1.28 4.7 
Linolenic Acid, % 0.27 0.19 0.39 
Arachidonic Acid, % <0.01 0.0 0.06 
Omega-3 Fatty Acids, % 0.44 0.19 0.39 
Total Saturated Fatty 
Acids, % 0.78 31.55 13.68 
Total Monounsaturated 
Fatty Acids, % 0.97 0.62 14.0 
Polyunsaturated Fatty 
Acids, % 0.0 1.47 0.0 
Fat Origin Animal (Lard) vs. plant 
(Coconut oil) Plant Plant Animal 
 





2.5.1 First Model of T2DM Using the HFD (58R3: Red Diet)  
1.  Effect of high-fat diet on eating habits and body weight in a 
model of HFD-induced T2DM 
When compared to chow-fed mice, food intake in mice fed the HFD was 
significantly lower during the whole experiment (P<0.05, Figure 2.6 A). However, 
there was no significant difference in calorie intake between the two groups 
(P>0.05, Figure 2.6 B). When compared to mice on a chow diet, mice fed the HFD 
showed a significant increase in body weight starting from week 3 (after the 
commencement of the diet) until the end of the experiment (P<0.05, Figure 2.6 C). 
At the end of week 16, HFD-fed mice showed a significant net weight gain 






Figure 2.6 Food intakes, calories intake and weight data. 
Summary of weekly change in (A) food intake, (B) calories intake and (C) body 
weight for 16 weeks in both chow and HFD fed groups and the (D) net weight gain 
at the end of the experiment in both groups. Data was analysed using unpaired t-
test and presented as mean ± SEM, *P< 0.05 when compared to chow mice (n=8 
per group). 
2. Effect of high-fat diet on diabetic parameters in a model of 
HFD-induced T2DM 
When compared to age-matched mice on a chow diet, mice fed the HFD for 12 or 
16 weeks and challenged with an oral dose of glucose showed significant 
impairment of glucose tolerance (P<0.05, Figure 2.7). When compared to mice on 
HFD for 12 weeks, mice on HFD for 16 weeks showed no significant changes in 
glucose tolerance after being challenged with an oral dose of glucose (P>0.05, 
Figure 2.7). 
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Figure 2.7 Comparison of oral glucose tolerance test (OGTT) between chow 
and HFD fed mice at different time points. 
After 6 hours of fasting, mice were given bolus oral dose of glucose (2 g/kg). We 
measured (A) blood glucose level at 0, 15, 30, 45, 60, 90 and 120 min and (B) area 
under the curve. Data was analysed using two-way ANOVA followed by 
Bonferroni’s post hoc test and expressed as mean ± SEM. *P<0.05 compared to 

























































3. Effect of high-fat diet on cardiac function in a model of HFD-
induced T2DM  
When compared to baseline (time 0), mice fed chow for 6, 12 and 16 weeks 
showed no significant change in systolic cardiac function (%EF, %FS or %FAC) 
(P>0.05, Figure 2.8 B-D). When compared to baseline (time 0), mice fed a HFD 
for 6 weeks showed no significant change in the systolic function (P>0.05, Figure 
2.8 A-D). However, mice fed a HFD for 12 weeks showed a small, but significant, 
reduction in %EF, %FS and %FAC when compared to baseline and mice fed a 
HFD for 6 weeks (P<0.05, Figure 2.8 A-D). In mice fed a HFD for 16 weeks, there 
was no further significant reduction in %EF, %FS and %FAC compared to mice 







Figure 2.8 Effect of prolonged administration of HFD on cardiac function in 
C57BL/6 mice 
Cardiac function was assessed at baseline, 6, 12 and 16 weeks. (A) Representative 
M-mode echocardiograms of HFD mice at different time points; percentage % (B) 
EF, (C) FS and (D) FAC.  Data was analysed using two-way ANOVA followed by 
Bonferroni’s post hoc test and expressed as mean ± SEM. *P<0.05 compared to 
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4. Effect of high-fat diet on kidney and liver function in a model of 
HFD-induced T2DM  
In mice fed either a chow or a HFD, there were no significant changes in serum 
urea, creatinine, and ALT at 16 weeks when compared to 12 weeks data (P>0.05, 
Figure 2.9 A). When compared to chow-fed mice at week 12, HFD fed mice for 12 
weeks showed no significant differences in serum urea or ALT levels (P>0.05, 
Figure 2.9 A, C). However, when compared to age-matched mice fed a chow diet, 
feeding mice a HFD for 12 weeks resulted in a significant reduction in serum 




Figure 2.9 Effect of prolonged administration of HFD on kidney and liver 
function inC57BL/6 mice. 
Kidney and liver dysfunction parameters were measured at 12 and 16 weeks. 
Serum (A) urea, (B) creatinine and (C) ALT.  Data was analysed using two-way 
ANOVA followed by Bonferroni’s post hoc test and expressed as mean ± SEM. 





































































2.5.2 Second Model of T2DM Using the HFD (58Y1: Blue Diet)  
1. Effect of high-fat diet on eating habits and body weight in a 
model of HFD-induced T2DM 
When compared to chow-fed mice, food intake in mice fed the HFD was 
significantly lower during the whole experiment (P<0.05, Figure 2.10 A). 
However, calorie intake was significantly higher in the HFD group compared to 
the chow group (P<0.05, Figure 2.10 B). When compared to mice on a chow diet, 
mice fed the HFD showed a significant increase in body weight starting from the 
first week of commencement of the diet until the end of the experiment (P<0.05, 
Figure 2.10 C). At the end of week 12, mice on HFD showed a significant gain in 




Figure 2.10 Food intakes, calories intake and weight data. 
Summary of weekly change in (A) food intake, (B) calories intake and (C) body 
weight for 12 weeks in both chow and HFD fed groups and the (D) net weight gain 
at the end of the experiment in both groups. Data was analysed using unpaired t-
test and presented as mean ± SEM, *P<0.05 when compared to chow group (n=10 
per group). 
2. Effect of high-fat diet on diabetic parameters in a model of 
HFD-induced T2DM 
When compared to age-matched mice on a chow diet, mice fed the HFD for 6 or 
12 weeks and challenged with an oral dose of glucose showed significant 
impairment of glucose tolerance (P<0.05, Figure 2.11). When compared to mice 
on HFD for 6 weeks, mice on HFD for 12 weeks showed a further significant 
increase in the degree of glucose intolerance after being challenged with an oral 
dose of glucose (P<0.05, Figure 2.11). 
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Figure 2.11 Comparison of oral glucose tolerance test (OGTT) between chow 
and HFD fed mice at different time points. 
After 6 hours of fasting, mice were given bolus oral dose of glucose (2 g/kg). We 
measured (A) blood glucose level at 0, 15, 30, 45, 60, 90 and 120 minutes and (B) 
area under the curve. Data was analysed using two-way ANOVA followed by 
Bonferroni’s post hoc test and expressed as mean ± SEM. *P<0.05 compared to 
age-matched mice on chow diet, $ P<0.05 (n=10 per group). 
 
 






















































3. Effect of high-fat diet on cardiac function in a model of HFD-
induced T2DM  
When compared to baseline (time 0), mice fed chow for 6 and 12 weeks showed no 
significant change in systolic cardiac function (%EF, %FS or %FAC) (P>0.05, 
Figure 2.12 B-D). When compared to baseline (time 0), mice fed a HFD for 6 
showed a small, but significant, reduction in %EF, %FS and %FAC (P<0.05, 
Figure 2.12 A-D). In mice fed a HFD for 12 weeks, there was no further 
significant reduction in %EF, %FS and %FAC compared to mice fed a HFD for 6 





Figure 2.12 Effect of prolonged administration of HFD on cardiac function in 
C57BL/6 mice 
Cardiac function was assessed at baseline, 6 and 12 weeks. (A) Representatives M-
mode echocardiograms of HFD mice at baseline and at 12 weeks. Percentage % 
(B) EF, (C) FS and (D) FAC.  Data was analysed using two-way ANOVA 
followed by Bonferroni’s post hoc test and expressed as mean ± SEM. *P<0.05 
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4. Effect of high-fat diet on kidney function and liver injury in a 
model of HFD-induced T2DM  
When compared to age-matched mice on a chow diet, feeding mice a HFD for 6 
weeks showed no significant changes in serum urea, creatinine or ALT levels 
(P>0.05, Figure 2.13 A-C). In mice fed either chow or a HFD, there were no 
significant changes in serum urea or creatinine at 12 weeks when compared to 6 
weeks data (P>0.05, Figure 2.13 A-B). When compared to mice fed a chow diet 
for 12 weeks, feeding mice HFD for 12 weeks resulted in significant increase in 
serum ALT (P<0.05, Figure 2.13 C).  
 
Figure 2.13 Effect of prolonged administration of HFD on kidney and liver 
function in C57BL/6 mice. Kidney and liver dysfunction parameters were 
measured at 6 and 12 weeks. Serum (A) urea, (B) creatinine and (C) ALT.  Data 
was analysed using two-way ANOVA followed by Bonferroni’s post hoc test and 
expressed as mean ± SEM. *P<0.05 compared to age-matched mice on chow diet, 































































2.5.3 Follow up Study to Measure Diabetes Complications that 
Result from Modeling T2DM Using the HFD (58Y1: Blue diet) 
1. Effect of HFD on insulin resistance  
When compared to chow-fed mice, mice fed with HFD for 12 weeks showed 
significantly higher levels of glucose when challenged with insulin. There was a 
significant increase in AUC after the HFD (P<0.05, Figure 2.14 A-B). Mice fed 
with HFD showed significant increases in fasting blood glucose and fasting serum 
insulin when compared to chow-fed mice (P<0.05, Table 2.14 C-D). 
 
Figure 2.14 Effect of HFD administrations on insulin resistance markers. 
After 6 hours of fasting, mice were given a dose of insulin (0.75U/kg, i.p.). We 
measured (A) blood glucose level at 0, 15, 30, 45, 60, 90 and 120 minutes, (B) area 
under the curve (C) fasting blood glucose and (D) fasting insulin level. Data was 
analysed using unpaired t-test and expressed as mean ± SEM. *P<0.05 when 
compared to chow group (n=10 per group). 
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2. Effect of HFD on kidney function  
When compared to mice fed with chow diet, mice on HFD showed a significant 
reduction in creatinine clearance (P<0.05, Figure 2.15 A). They also showed a 
significant increase in urine albumin to creatinine ratio (P<0.05, Figure 2.15 B). 
 
Figure 2.15 Effect of HFD on kidney function  
Mice were housed in metabolic cages for 24 hours. (A) Creatinine clearance and 
(B) albumin to creatinine ratio were calculated.  Data was analysed using unpaired 
t-test and expressed as mean ± SEM. *P<0.05 when compared to chow group 
(n=10 per group). 
3. Effect of HFD on liver histology  
Histological analysis of liver biopsies showed that when compared to mice fed 
with chow diet for 12 weeks, feeding mice a HFD resulted in a significant 
perivascular accumulation of collagen in the liver (P<0.05, Figure 2.16 A-B). 
Feeding mice with HFD for 12 weeks also resulted in a significant increase in fat 
in the liver when compared to mice fed with chow diet (P<0.05, Figure 2.16 C-D). 
Livers obtained from mice fed with HFD looked significantly enlarged when 
compared to livers obtained from mice on chow diet (Figure 2.16 E) and they were 






























Figure 2.16 Effect of HFD on liver histology after 12 weeks 
Liver sections were stained with (A) Picro-Sirius Red and (B) % collagen was 
calculated. Liver sections also stained with (C) Oil red-O and (D) % fat was 
calculated. (E) Liver appearance and (F) liver weight were compared.  Data was 
analysed using unpaired t-test and expressed as mean ± SEM. *P<0.05 when 
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4. Effect of HFD on lipids’ profile and blood haematology markers  
When compared to mice on chow diet, feeding the mice a HFD for 12 weeks 
resulted in significant impairment in the lipid profile with detection of significant 
increases in total cholesterol, LDL and HDL (P<0.05, Table 2.5).   
Table 2.5 Effect of HFD on serum lipid profile and blood haematology after 12 
weeks. 








 Total cholesterol (TC) 100.20±13.79 200.10±4.2* 
Low-density lipoprotein (LDL) 25.23±3.34 57.84±1.12* 
Triglyceride (TG) 114.50±9.17 116.70±10.11 








Red blood cells count (RBC) 10.25±0.29 10.32±0.57 
Haemoglobin (HGB) 14.37±0.39 14.59±0.78 
Haematocrit (HCT) 47.40±1.34 49.59±2.7 
Mean cell volume (MCV) 46.24±0.09 48.11±0.46* 
Mean cell haemoglobin (MCH) 14.02±0.06 14.15±0.09 
Mean cell haemoglobin concentration (MCHC) 30.30±0.1 29.43±0.29* 
RBC distribution width (RDW-SD) 31.92±0.52 35.38±1.29* 
Reticulocytes (RET) count  465.7±19.76 528.80±61.17 
Reticulocytes % 4.58±0.25 5.46±1.04 
Platelet (PLT) count 651.7±33.57 684±59.18 
PLT distribution width (PDW) 7.16±0.08 7.61±0.07* 
Mean platelet volume (MPV) 5.52±0.07 5.96±0.05* 
White blood cells (WBC) 5.42±0.75 9.91±1.39* 
Neutrophils count 0.51±0.07 0.65±0.13 
Lymphocytes count 4.60±0.70 7.90±1.03* 
Monocytes count 0.15±0.02 0.28±0.03* 
Eosinophils count 0.15±0.03 0.34±0.14 
Basophils count 0.00±0.001 0.02±0.01 
Neutrophils % 9.77±1.22 8.07±1.54 
Lymphocytes % 84.42±1.68 81.67±4.76 
Monocytes % 2.86±0.27 3.16±0.58 
Eosinophils % 2.93±0.51 2.07±0.19 
Basophils % 0.02±0.02 0.13±0.18* 
Mice fed a HFD were compared to age-matched mice fed a chow diet. Data is 
presented as mean ± SEM for n number of observations. Data was analysed using 





In this chapter, I have developed a clinically relevant model of T2DM with 
diabetic cardiomyopathy by feeding mice with a HFD (58R3: Red diet) for 12 
weeks. Exposure to HFD for 12 weeks resulted in a progressive increase in body 
weight. This continuous increase in body weight is consistent with a previous 
study that showed a continuous increase in the body weight after the introduction 
of HFD for 52 weeks (as two phases of rapid and slow weight gain before and after 
12 weeks of the HFD intervention) in C57BL/6 mice 252.  
I also report a significant impairment in oral glucose tolerance at week 12 in mice 
fed with the HFD and this impairment was stable until week 16. Similarly, others 
have reported that introduction of HFD results in an impairment in glucose 
tolerance as early as 1 week after dietary manipulation 253, while previous studies 
of our group show that feeding the same HFD (58R3: Red diet) to C57BL/6 mice 
resulted in an impairment in glucose tolerance after 10 or 14 weeks of dietary 
manipulation 254,255. 
Exposure to HFD (58R3: Red diet) for 10-14 weeks has been used by our group 
to study diabetes, diabetic nephropathy and liver steatosis in C57BL/6 mice 254,255. 
However, diabetic cardiomyopathy has not been investigated in this model. Here, I 
report for the first time a reduction in systolic cardiac function (as a small drop in 
%EF) after 12 weeks of dietary manipulation with the HFD (58R3: Red diet). 
This small degree of cardiac dysfunction was stable with no further increase in 
cardiac dysfunction (reduction in %EF) seen after 16 weeks of HFD. This result is 




dysfunction (as reduction in %FS) after 22 weeks on HFD (47% energy from fat) 
256, a decrease in %EF after 10 weeks on high sucrose diet 257 and the development 
of both systolic and diastolic dysfunction after 16 weeks on high-fat high-sucrose 
diet (45% energy from fat and 17% energy from sucrose) in C57BL/6 mice 258. 
I concluded that giving the HFD (58R3: Red diet) for 12 weeks to C57BL/6 mice 
can be used to model diabetes and diabetic cardiomyopathy as a first hit to study 
the effect of diabetes on the cardiac (organ) dysfunction associated with sepsis in 
mice in subsequent studies. However, this protocol was only used in the first study 
to investigate the effect of pre-existing T2DM on cardiac dysfunction caused by 
endotoxaemia. After facing a problem with the supply of the HFD (58R3: Red 
diet), I had to establish and test a new HFD-model of diabetes and diabetes 
complications using the most similar diet available HFD (58Y1: Blue diet) and 
compare it to first model to be used later in the subsequent study to investigate the 
effect of pre-existing T2DM on cardiac dysfunction associated with CLP induced 
sepsis. 
Using the second HFD (58Y1: Blue diet), I report a decrease in systolic cardiac 
function as early as week 6 after initiation of HFD. This decrease in cardiac 
function was maintained (stable) throughout the remaining experimental period. I 
also discovered an impaired glucose tolerance at week 6, and this impairment in 
glucose tolerance worsened after 12 weeks on HFD. This result is consistent with a 
previous study showing that mice fed with HFD develop glucose intolerance early 
after initiation of the HFD and then develop more severe alterations in glucose 
homeostasis after prolonged exposure to this diet 253. Although mice developed 




manipulation, they only showed a 26% increase in body weight from the baseline 
at this point. It has been suggested that models of obesity and diabetes should show 
at least a 33% increase in body weight from baseline 259 which was achieved at 
week 12 on HFD using the HFD (58Y1: Blue diet). This makes 12 weeks is the 
optimal duration of HFD in this protocol too. 
Using the HFD (58Y1: Blue diet) for 12 weeks, I also confirmed the development 
of insulin resistance. I reported an impairment in insulin tolerance and increases in 
fasting glucose and insulin levels. Previous studies also showed similar effects of 
HFD on insulin resistance criteria 260.  
Diabetic nephropathy has been reported in mice and patients with T2DM. An 
increase in ACR is a reliable indicator of the development of microalbuminurea in 
HFD-induced models of diabetes 261,262 and in patients with T2DM and pre-
diabetes 263,264. A reduction in CrCl has also been reported in diabetic patients 265.  
In this chapter, I demonstrate that the HFD (58Y1: Blue diet) also resulted in the 
development of renal dysfunction (higher ACR and lower CrCl) secondary to 
insulin resistance and hyperglycaemia. Using the first protocol with the HFD 
(58R3: Red diet) for 12 weeks resulted in similar kidney dysfunction as reported 
in previous studies by our group using the red diet for 10 or 14 weeks 254,255.       
The effect of HFD and diabetes on liver injury and steatosis is well characterised 
in the literature. Studies have shown an increase in lipid accumulation in the liver 
secondary to insulin resistance 266–268.  Indeed, in this model, liver obtained from 
mice treated with the HFD (58Y1: Blue diet) showed significant lipid 
accumulation and subsequent increase in serum ALT. Similarly, mice expose to 




Dyslipidaemia is well identified in both patients with T2DM 269 and in animal 
models of HFD diabetes (by us and others)  254,255,270,271. Mice fed the HFD (58Y1: 
Blue diet) also showed significant dyslipidaemia compared to chow-fed mice.  
2.7 Conclusion  
In this chapter, I concluded that using the HFD (58R3: Red diet) for 12 weeks to 
C57BL/6 male mice resulted in T2DM phenotype and diabetic cardiomyopathy, I 
also discovered that using the HFD (58Y1: Blue diet) for 12 weeks in C57BL/6 
mice can be used as an alternative model to the first model after knowing that the 
long-term supply of the HFD (58R3: Red diet) was no longer guaranteed.  
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CHAPTER 3: THE EFFECT OF PRE-EXISTING TYPE 
TWO DIABETES MELLITUS ON CARDIAC 
DYSFUNCTION ASSOCIATED WITH SEPSIS 
3.1 Introduction 
The cardiovascular system is one of the important systems affected by sepsis. Most 
septic patients, and all patients with septic shock develop sepsis-related 
cardiovascular dysfunction 272, which is a key driver of in-hospital mortality in 
these patients 273. Both the incidence of sepsis and sepsis-related mortality increase 
with age due to the presence of significant comorbidities including diabetes and 
chronic kidney disease in the elderly 17. The prevalence of diabetes is increasing 
worldwide 223. Patients with diabetes are at high risk of developing diabetic 
cardiomyopathy, left ventricular (LV) hypertrophy, ischaemic cardiac injury and 
heart failure 112,114,223,274. Diabetic patients are more susceptible to both common 
and rare infections and have a higher incidence of sepsis than patients that do not 
suffer from the disease 162,275. Activation of NF-ĸB plays a crucial role in both 
sepsis-related cardiac dysfunction 276–278  and in diabetic cardiomyopathy 279. In 
sepsis, activation of NF-κB is secondary to activation of TLR 2 and 4 by e.g. wall 
fragments of Gram-negative (e.g. LPS) or Gram-positive bacteria (e.g. PepG) 
and/or pro-inflammatory cytokines including TNF-α or IL-1. In addition to pro-
inflammatory cytokines, the activation of NF-κB in diabetes is also driven by free 




The effect of diabetes on outcome in patients with infections is controversial with 
some studies showing increased hospitalization, organ dysfunction/injury and 
mortality in diabetic patients with e.g. pneumonia 166,168,280, while other studies 
report either no effect 175,176,281 or even protective effects of diabetes 172,177–179.  
Some of the protective effects of diabetes can be explained by a phenomenon 
called “obesity paradox”. The prevalence of obesity among diabetic patients is 
high. Almost 90% of patients with T2DM are overweight or obese 282 . While the 
role of T2DM and obesity in developing chronic cardiovascular diseases is well 
known 283, the effect these conditions in acute illness (e.g. sepsis-associated cardiac 
dysfunction) is still not fully established 284. In 2007, the “obesity paradox” was 
first described in patients with decompensated heart failure by Fonarow and co-
workers 285. They showed that among 108,927 patients with decompensated heart 
failure, patients with higher BMI and diabetes had a better prognosis (higher %EF) 
and lower in-hospital mortality rate 285. Similar results were reported in two more 
recent studies showing that patients with higher BMI had better outcomes (than 
patients with normal BMI) after either an acute coronary event 286 or acute 
respiratory distress syndrome 287 although they had higher incidence of T2DM. 
In two recent meta-analyses, Pepper et al. and Wang et al. studied the obesity 
paradox in septic patients. They showed that obese and overweight patients have 
lower adjusted mortality in adult septic patients admitted to the ICU 288 and that 
overweight septic patients, but not obese septic patients, have lower sepsis-related 
mortality compared to patients with normal body weight 289. However, the authors 




effect of BMI on all-cause mortality with no information about the cardiac 
performance and cardiac related mortality.  
Therefore, the effect of T2DM (and obesity related to T2DM) on cardiac 
dysfunction associated with sepsis is still not clear and warrants further 
investigation. In this chapter, I have investigated i) the effects of pre-existing type 
2 diabetes mellitus (T2DM) caused by high fat diet (HFD) on cardiac dysfunction 
in mice with sepsis and ii) the role of NF-ĸB activation in the cardiac dysfunction 





3.2  Scientific Hypothesis and Aims  
This study is driven by the hypothesis that: 
§ Pre-existing T2DM augments the cardiac dysfunction associated with LPS 
induced endotoxaemia and CLP-induced polymicrobial sepsis in mice. 
This study aims to: 
• Investigate the effect of pre-existing T2DM on cardiac dysfunction 
associated with low dose LPS induced endotoxaemia or CLP-induced 
polymicrobial sepsis, 
• Understand the signalling mechanism that resulted in the aggravation of 











3.3  Methods and Materials   
3.3.1 Animals 
Studies in this chapter were conducted on 76 ten-week-old male C57BL/6 mice 
(Charles River, Kent, UK) weighing 25-30g, receiving a standard diet and water ad 
libitum (before starting the experiments). Mice were housed 5 per cage in a 
temperature-controlled room with a 12-hour light/dark cycle. Forty mice were used 
in the first experiment to study the effect of T2DM on cardiac dysfunction after 
LPS challenge and 36 mice were used in the second experiment to study the effect 
of T2DM on cardiac dysfunction after CLP surgery. The ethical statement is 
provided in section 2.3. 
3.3.2  Model of HFD induced T2DM and diabetic cardiomyopathy 
In this model of HFD-induced T2DM and diabetic cardiomyopathy, ten-week-old 
male C57BL/6 mice were randomised to receive HFD (≈ 60% energy from fat) or 
normal chow diet with free access to water for 12 weeks. 
3.3.3 Baseline Measurements for development of T2DM 
During the whole 12-week period, body weight and feeding behaviour were 
measured weekly to ensure healthy feeding behaviour as described in section 2.3.2. 
During week 12, OGTT was measured in all mice to ensure the development of 
impairment in glucose tolerance as described in section 2.3.3, baseline 
echocardiography was conducted in all mice to test the development of diabetic 




all mice to measure CrCl as described in section 2.3.7 and blood were collected 
from all mice from the tail vein to measure baseline urea, creatinine and ALT as 
described in section 2.3.9.    
3.3.4 Model of lipopolysaccharide (LPS) induced endotoxaemia 
Mice are considered to be more resistant and tolerant to LPS than other species 
(e.g. humans or rabbits) 290. To model sepsis and to cause systemic inflammation 
which leds to cardiac and organ dysfunction, a high dose LPS is be used (e.g. 9 
mg/kg) in young mice without co-morbidities 291. However, in mice with CKD, a 
much lower dose of LPS (2 mg/kg) was used to induce the same degree of 
systemic inflammation and cardiac (organ) dysfunction 292.  
In this study, a low dose of LPS was used to induce endotoxaemia in mice after 12 
weeks of HFD; mice fed either chow or HFD were randomised to receive LPS (2 
mg/kg, i.p.) or vehicle (PBS 5 ml/kg, i.p). At 18 h after the onset of endotoxaemia, 
mice were anaesthetised for cardiac function assessment in vivo using 
echocardiography. Then, as a terminal procedure, mice were anaesthetised using 
high dose isoflurane (3 % delivered in 0.9 L/min O2) before being sacrificed. 
Blood samples were collected by cardiac puncture and vital organs were collected 








3.3.5 Model of caecal ligation and puncture (CLP) induced 
polymicrobial sepsis 
At 12 weeks after starting the HFD, mice fed either chow or HFD were 
randomised to undergo either sham operation or CLP surgery. Before surgery, 
mice were anaesthetised using (1.5 ml/kg, i.p.) of 2:1 ketamine (100 mg/ml): 
xylazine (20 mg/ml) solution. To obtain adequate analgesia, buprenorphine (0.05 
mg/kg, i.p.) was administered just before starting the surgery. The fur of the 
abdomen was removed using Veet® hair removing cream and the area cleaned 
with 70% ethanol. A 1.5 cm midline incision of the abdomen was made and the 
caecum was exposed. The caecum then was ligated below the ileocaecal valve and 
two punctures were made one at each end using an 18-G needle. A small amount 
of faecal matter was then squeezed from both punctures before the caecum was 
returned to its anatomical position and the cut in the abdomen was then sutured. 
Each mouse then received a resuscitation fluid (1 ml 0.9 % NaCl, s.c.). Mice were 
left on a homeothermic blanket to recover then placed back into fresh clean cages. 
At 6 and 18 h after surgery, antibiotic (imipenem/cilastatin, 20 mg/kg) dissolved in 
resuscitation fluid (15 ml/kg 0.9% NaCl, s.c.) was administered along with 
analgesia (buprenorphine, 0.05 mg/kg, i.p.). At 24 h, mice were anaesthetised for 
assessment of cardiac function in vivo. Then, as a terminal procedure, mice were 
anaesthetised using high dose isoflurane (3 % delivered in 0.9 L/min O2) before 
being sacrificed. Blood samples were collected by cardiac puncture and vital 
organs were collected and snap frozen using liquid nitrogen then stored for further 
analysis at -80°C freezer. Mice underwent sham surgery were not subjected to 




3.3.6 Measuring physical activity and vital signs 
At 18 h after LPS challenge or 24 h after CLP surgery, mice were observed in their 
cages to assess the reduction in their physical activity. A scale of 0 to -5 was used 
to quantify the reduction in physical activity with 0 representing the most 
physically active (e.g. no reduction in physical activity compared to baseline) 
before starting the experiment (before starting the HFD). 
Body temperature and heart rate were documented directly after the induction of 
anaesthesia and before starting echocardiography measurements using rectal probe 
and ECG trace on the Echo platform. Then, they were monitored during the 
stabilisation phase and during the whole experiment. All the measurements of the 
cardiac function were conducted after stabilizing the mice to get a heart rate in the 
range of 450-500 beat/min and a body temperature of 35 °C or higher.    
3.3.7 Quantification of organs dysfunction 
Cardiac functions was assessed at 18 h after LPS challenge or at 24 h after CLP 
surgery using a 30 MHz RMV707B scan head and a Vevo-770 imaging system 
(VisualSonics, Toronto, Ontario, Canada) as described in section 2.3.6. Blood 
samples and vital organs were collected to measure organs dysfunction as 
described in section 2.3.8.   
3.3.8 Western blot analysis 
Immunoblot analyses of the hearts were carried out using a semi-quantitative 
western blotting. I measured the degree of phosphorylation of IKK, IĸBα and Akt, 




For samples preparation, a piece weighing 20-30 mg of the heart was taken from 
the apical site of the samples. A 10-time dilution with homogenisation buffer (HB) 
was used to homogenize the sample at 4 °C (composition of HB is detailed in 
Appendix 2, Table A.2.). For cytosolic protein extraction, the homogenate was 
centrifuged (at 4000 RPM, 5 min, 4 °C). The resulted supernatant contained 
cytosolic protein and the pellet contained nuclear protein (this pellet was used for 
nuclear protein extraction later). The supernatant was centrifuged again (at 14000 
RPM, 40 min, 4 °C). This time the pellet was discarded and supernatant kept at -
80°C freezer for cytosolic protein analysis later. The first pellet was re-suspended 
in extraction buffer (EB) and kept in ice for 30 min (composition of EB is detailed 
in Appendix 2, Table A.2.) before being centrifuged (at 14000 RPM, 20 min, 4 
°C). The pellet resulted was discarded and supernatant kept at -80°C freezer for 
nuclear protein analysis later. Both cytosolic and nuclear protein concentrations 
were measured using bicinchoninic acid (BCA) protein assay following 
manufacturer’s directions (Therma Fisher Scientific, Rockford, IL). Proteins were 
separated by gel electrophoresis using 8% sodium dodecyl sulphate 
polyacrylamide (SDS-PAGE) then transferred into a Polyvinylidene difluoride 
(PVDF) membrane. The membrane then was blocked using 10% milk solution in 
TBS-tween. Incubation of the membrane was conducted overnight at 4 °C with 
primary antibody in 5% blocking solution then incubated the next day with the 
secondary antibody at room temperature for 30 min and then developed using ECL 
detection system. Bands analysis was performed using densitometry Gel pro 
analyser 4.5, 2000 software (Media Cybernetics, Silver Spring, MD, USA). 





3.3.9  Cytokines measurements using multiplex method 
Serum cytokines levels (TNF-α, IL-6, KC and IL-10) were measured using a bead-
based immunoassay method. Serum samples were prepared and handled following 
manufacturer instructions (Biolegend®, San Diego, USA). Data was obtained using 
a LSR Fortessa (Biociences®, Berkshire, UK) and analysed using the 
LegendplexTM 7.1.0.0 software. 
Serum samples were diluted with assay buffer and incubated with the selected set 
of captures beads for 2 h in the dark under continuous shaking. The samples then 
centrifuged (at 2500 RPM, 5 min, at room temperature). Supernatants were 
discarded and the pallet washed and re-suspended with the biotinylated detection 
antibodies and incubated for 1 h in the dark under continuous shaking to form 
capture bead-analyte-detection antibody sandwiches. Then the Streptavidin-
phycoerythrin (SA-PE) was added and incubated for 30 min in the dark under 
continuous shaking to bind with the antibodies and form fluorescent signals.  The 
samples then centrifuged (at 2500 RPM, 5 min, at room temperature). Supernatants 
were discarded and the pallet washed and re-suspended with washing buffer.  The 
intensity of PE signal fluorescence was then quantified using flow cytometry. The 
concentrations of TNF-α, IL-6, KC and IL-10 were then calculated based on 
known standards concentrations.    
3.3.10 Measuring MPO activity in the lung 
MPO was extracted from the tissues according to the methods described by Barone 





For samples preparation, a piece of lung weighing 30-40 mg was used. A 20-time 
dilution with 5 mM potassium phosphate buffer was used to homogenize the 
sample (at 4 °C). For measurements of MPO activity, the homogenate was 
centrifuged (at 13000 RPM, 30 min, 4 °C). The resulted supernatant was 
discarded.  A 5-time dilution with 0.5% hexadecyltrimethylammonium bromide in 
50 mM potassium phosphate buffer was used to re-suspend and homogenize the 
pellet. The resulted solution was then frozen and thawed 3 times followed by 10 
sec sonication at room temperature and then incubated at 4 °C for 30 min then 
centrifuged (at 12500 RPM, 15 min, 4 °C).  MPO activity was measured in the 
supernatant by mixing 100 µl of the supernatant with 0.167 mg/ml o-dianiside 
dihydrochloride and 0.0005% hydrogen peroxide in 2.9 ml 50 mM potassium 
phosphate buffer. UV-visible spectrophotometer was used to measure the change 
in absorbance at 460 nm for 1.5 min. MPO activity was presented as the quantity 
of the enzyme degraded 1 µmol of peroxide/min at 25 °C and expressed as 
µU/gram of the lung tissue.  
3.3.11 Measuring N-Acetyl-Beta-D-Glucosaminidase (NAG) 
activity in the lung  
NAG activity was analysed to measure macrophage accumulation in the lung. For 
samples preparation, a piece of lung weighing 30-40 mg was used. Samples were 
then diluted with 0.01 M phosphate buffer saline and homogenised (at 4 °C). The 
resulted solutions were then frozen and thawed 3 times followed by 10 sec 
sonication at room temperature to break the cells. For measurements of NAG 
activity, the homogenate was centrifuged (at 5000 RPM, 30 min, 4 °C). The 




ELISA kit following manufacturer instructions (Elabscience®, Houston, Texas, 
USA). 
3.3.12 Statistical analysis 
Data were analysed using GraphPad Prism 7.0 (GraphPad Software, San Diego, 
California, USA). Values stated in the text and figures are presented as a mean ± 
standard error of the mean (SEM) of n observations, where n is the number of 
animals used. Data was tested for normality using D’Agostino-Pearon normality 
test and then assessed using Two-way or One-way ANOVA test followed by 
Bonferroni’s post hoc test or unpaired Student t-test where appropriate. P values of 
less than 0.05 were considered to be statically significant. 
3.3.13 Materials 
Unless otherwise stated, all materials, reagents and solutions were purchased from 





3.4  Experimental Designs and Studies Groups 
3.4.1 Effect of T2DM on the cardiac dysfunction associated with 
endotoxaemia 
Ten-week old mice were randomised to revive chow diet or HFD. At 12 weeks 
mice from both groups were challenged with LPS or vehicle as following. 
Table 3.1 Experimental groups used to study the effect of low dose LPS on 
cardiac dysfunction in animals with pre-existing T2DM.  
Group name Diet Intervention Number 
Chow Chow PBS 5ml/kg i.p. 10 
Chow+LPS Chow LPS 2mg/kg i.p. 10 
HFD High fat diet PBS 5ml/kg i.p. 10 
HFD+LPS High fat diet LPS 2mg/kg i.p. 10 
	
 
Figure 3.1 Timeline and summary of the protocol used to study the effect of 
low dose LPS on cardiac dysfunction in animals with pre-existing T2DM. 
Mice were randomised to either chow diet or high fat diet (HFD). At 12 weeks, 
HFD fed mice were tested for development of diabetes phenotype and compared to 
chow-fed mice. Mice were then challenged with either low dose LPS (2 mg/kg, 
i.p.) or vehicle (5 ml/kg PBS, i.p.). At 18 h after LPS, cardiac function was 






3.4.2 Effect of T2DM on cardiac dysfunction associated with CLP-
induced polymicrobial sepsis 
Ten-week old mice were randomised to revive chow diet or HFD. At 12 weeks 
mice from both groups were subjected to sham or CLP surgery as following. 
Table 3.2 Experimental groups used to study the effect of CLP on cardiac 
dysfunctions in animals with pre-existing T2DM.  
Group name Diet Intervention Number 
Chow+sham Chow Sham surgery 8 
Chow+CLP Chow CLP surgery 10 
HFD+sham High fat diet Sham surgery 8 
HFD+CLP High fat diet CLP surgery 10 
	
Figure 3.2 Timeline and summary of the protocol used to study the effect of 
CLP surgery on cardiac dysfunction in animals with pre-existing T2DM. 
Mice were randomised to either chow diet or high fat diet (HFD). At 12 weeks, 
animals on HFD were tested for development of diabetes phenotype and compared 
to chow-fed mice. Mice were then subjected to either CLP or sham surgery. At 24 






3.5.1 Endotoxaemia in mice with pre-existing T2DM  
1. Effect of HFD on organ function before LPS challenge 
After 12 weeks of dietary manipulation and before sepsis challenge, mice on HFD 
showed signs of the development of T2DM including a significant increase in 
body weight and a significant impairment in OGTT when compared to mice on 
chow diet. When compared to age-matched mice on chow diet, HFD-fed mice also 
showed significant reduction in systolic cardiac function (%EF) (P<0.05, Table 
3.3).  
Table 3.3 Baseline data for both chow and HFD groups before interventions 
(LPS or PBS challenge). 
Parameter Chow HFD 
Net weight gain (grams) 5.7 ± 0.39 14.69 ± 1.41* 
Food intake$ (grams/mouse/week) 3.71 ± 0.07 2.29 ± 0.39* 
Calories intake$ (Kcal/mouse/week) 18.81 ± 0.27 15.86 ± 0.8* 
AUC for OGTT (mg.min/dl) 25244 ± 1776 40343 ± 3253* 
Fasting blood glucose (mg/dl) 186.4 ± 12.1 188.5 ± 7.91 
Ejection fraction (%) 70.96 ± 1.28 61.88 ± 1.59* 
Fractional shortening (%) 33.84 ± 1.08 31.98 ± 1.02* 
Fractional area change (%) 45.35 ± 1.27 41.44 ± 1.28* 
Left ventricle mass (mg) 119.8 ± 9.55 132.0 ± 7.09  
Urea (mmol/L) 10.19 ± 0.42 10.2 ± 0.22 
Creatinine (µmol/L) 34.52 ± 1.05 21.16 ± 2.59* 
Alanine aminotransferase (U/L) 43.69 ± 11.32 45.8 ± 3.67 
Mice fed a HFD were compared to age-matched mice fed a chow diet. Data are presented 
as mean ± SEM for n number of observations. Data were analysed by unpaired t-test. 
*P<0.05 versus the chow-fed group (n=8-10 in each group). $: Mean food intake of 10 




2. Effect of pre-existing T2DM on physical activity and vital signs 
after LPS challenge  
When compared to mice fed a chow diet, mice fed with HFD showed no 
significant change in physical activity, heart rate or body temperature (P>0.05; 
Figure 3.3 A-C). When compared to animals on regular chow diet challenged with 
vehicle, mice on chow diet challenged with low dose LPS (2 mg/kg i.p.) showed 
no significant decrease in physical activity, heart rate or body temperature 
(P>0.05; Figure 3.3 B-C).  However, mice on HFD challenged with low dose LPS 
exhibited large and significant reductions in physical activity, heart rate and body 
temperature when compared to mice on HFD challenged with vehicle (P<0.05; 
Figure 3.3 A-C) and exhibited large and significant reduction in physical activity 
and heart rate when compred to mice on chow diet and challenged with the same 
dose of LPS (2 mg/kg i.p.) (P<0.05; Figure 3.3 A-B). It should be noted that at the 
beginning of measurements, and after stabilising the animals, there were no 
significant difference in the core body temperature or the heart rate between the 





Figure 3.3 Effect of low dose LPS challenge on vital signs and physical activity 
in mice with T2DM. 
Vital signs and physical activity were assessed at 18 h after LPS or vehicle 
challenge in mice fed a chow diet or a HFD. (A) Physical activity change (B) heart 
rate and (C) body temperature. Data was analysed using two-way ANOVA 
followed by Bonferroni’s post hoc test and expressed as mean ± SEM.	 *P<0.05 





















































3. Pre-existing T2DM augments the cardiac dysfunction caused by 
low dose of LPS.  
When compared to mice fed with chow diet, mice fed with HFD showed a small, 
but  significant attenuation in cardiac function (P<0.05; Figure 3.4 B-D). When 
compared to animals on regular chow diet challenged with vehicle, mice on chow 
diet challenged with low dose LPS (2 mg/kg i.p.) showed a small, but significant, 
reduction in systolic cardiac function (measured as %EF, %FS and %FAC; 
P<0.05; Figure 3.4 B-D). However, animals on HFD challenged with low dose 
LPS exhibited a large and significant reduction in systolic cardiac function when 
compared to mice on HFD challenged with vehicle. The reductions in %EF, %FS 
and %FAC caused by LPS in mice fed a HFD were significantly greater than those 







Figure 3.4 Effect of low dose LPS challenge on cardiac function in mice with 
T2DM. 
Cardiac function was assessed at 18 h after LPS or vehicle challenge in mice fed a 
chow diet or a HFD. (A) Representative M-mode echocardiograms; percentage % 
(B) EF, (C) FS and (D) FAC.  Data were analysed using two-way ANOVA 
followed by Bonferroni’s post hoc test and expressed as mean ± SEM. *P<0.05 
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4. Effect of low dose LPS on NF-ĸB signalling pathway in mice 
with pre-existing T2DM 
In a separate set of experiments, I investigated the effects of HFD/diabetes on the 
activation of key signalling pathways including pathways leading to the activation 
of NF-ĸB. When compared to cardiac biopsies obtained from chow-fed mice, 
cardiac tissue obtained from mice fed a HFD exhibited a significant increase in a) 
the phosphorylation of IKKα/β on Ser178/180, b) the phosphorylation of IĸBα on 
Ser32/36, c) the translocation of p65 NF-ĸB to the nucleus, and d) increased 
expression of iNOS (P<0.05; Figure 3.5 A-D). When compared to cardiac tissue 
obtained from mice fed on a chow diet challenged with vehicle, cardiac tissue 
obtained from chow fed diet challenged with LPS showed a significant increase in 
a) the phosphorylation of IKKα/β on Ser178/180, b) the phosphorylation of IĸBα on 
Ser32/36, c) the translocation of p65 NF-ĸB into the nucleus, and d) an increased 
expression of iNOS (P<0.05; Figure 3.5 A-D). When compared to mice fed a HFD 
and challenged with vehicle, mice on HFD challenged with LPS did not have a 
significant effect on the phosphorylation of IKKα/β or IĸBα (P>0.05; Figure 3.5 
A-B). When compared to mice fed a HFD and subjected to vehicle, challenging 
mice on HFD with LPS did, however, result in significant increases in a) the 
translocation of p65 NF-ĸB to the nucleus and b) iNOS expression (P<0.05; Figure 
3.5 C-D). It should be noted that the degree of phosphorylation of IKKα/β and 
IĸBα in cardiac tissue obtained from mice fed a HFD challenged with vehicle was 
a) significantly greater than that in cardiac tissue of mice fed a chow diet 
challenged with vehicle (P<0.05; Figure 3.5 A-B), and b) not significantly 




with LPS (P>0.05; Figure 3.5 A-B).	
	
Figure 3.5 Effect of pre-existing T2DM in NF-ĸB signalling pathway in the heart of 
mice challenged with low dose LPS (2mg/kg). 
Mice on chow and high fat diet were subjected to low dose LPS (2 mg/kg i.p.) or PBS (5 
ml/kg i.p.). At 18 h, heart samples were collected and signalling events were assessed. 
Densitometry analysis of the bands is expressed as relative optical density (O.D.) of (A) 
IKKα/β phosphorylation on Ser178/180 corrected to the corresponding total IKKα/β content 
and normalized using the related sham band; (B) IĸBα phosphorylation on Ser32/36 
corrected to the corresponding total IĸBα content and normalized using the related sham 
band; (C) NF-κB p65 subunit levels in both, cytosolic and nuclear fractions expressed as a 
nucleus/cytosol ratio normalized using the related sham bands; (D) Inducible nitric oxide 
synthase (iNOS) expression corrected for the corresponding tubulin band. Data were 
analysed using two-way ANOVA followed by Bonferroni’s post hoc test and expressed as 
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5. Effect of low dose LPS on the phosphorylation of Akt in mice 
with pre-existing T2DM 
When compared to cardiac biopsies obtained from chow-fed mice, cardiac tissue 
obtained from mice fed a HFD exhibited a significant decrease in Akt 
phosphorylation on Ser473. When compared to mice fed a chow diet and challenged 
with vehicle, challenge with mice on chow diet with LPS did result in a significant 
reduction in Akt phosphorylation (P<0.05; Figure 3.6). When compared to mice 
fed a HFD and challenged with vehicle, challenge with mice on HFD with LPS did 
not, however, result in a significant change in Akt phosphorylation (P>0.05; 
Figure 3.6).  
Figure 3.6 Effect of pre-existing T2DM in Akt phosphorylation in the heart of mice 
challenged with low dose LPS (2mg/kg). 
Mice on chow and high fat diet were subjected to low dose LPS (2 mg/kg i.p.) or PBS (5 
ml/kg i.p.). At 18 h, heart samples were collected and signalling events were assessed. 
Densitometry analysis of the bands is expressed as relative optical density (O.D.) of 
phosphorylated Akt on Ser473 corrected for the corresponding total Akt content and 
normalized using the related sham band. Data were analysed using two-way ANOVA 
followed by Bonferroni’s post hoc test and expressed as mean ± SEM for n number of 





































6. Effect of low dose LPS on the severity of renal dysfunction and 
hepatocellular injury in mice with pre-existing T2DM 
When compared to mice on chow diet, mice on HFD showed no significant 
changes in serum urea, creatinine or ALT (P>0.05; Figure 3.7 A-C). When 
compared to mice on regular chow diet challenged with the vehicle, mice on chow 
diet challenged with low dose LPS (2 mg/kg i.p.) did not show significant changes 
in the serum levels of creatinine or ALT (P>0.05; Figure 3.7 B, C). When 
compared to animals on regular chow diet challenged with the vehicle, mice on 
chow diet challenged with low dose LPS did, however, show an increase in serum 
urea (P<0.05; Figure 3.7 A). Animals on HFD challenged with low dose LPS 
exhibited a large and significant increase in serum urea, creatinine, and ALT when 
compared to mice on HFD challenged with the vehicle. The increase in serum 
urea, creatinine, and ALT caused by LPS in mice fed a HFD were significantly 








Figure 3.7 Effect of low dose LPS challenge on kidney function and liver injury in 
mice with T2DM. 
Kidney function and liver injury were assessed at 18 h after LPS or vehicle challenge in 
mice fed a chow diet or a HFD. Serum (A) urea, (B) creatinine and (C) ALT levels were 
measured. Data were analysed using two-way ANOVA followed by Bonferroni’s post hoc 
test and expressed as mean ± SEM. *P<0.05 compared respective PBS group, $P<0.05 























































7. Pre-existing T2DM increases neutrophil and macrophage 
accumulation in the lung after LPS challenge  
When compared to mice on chow diet, mice on HFD showed no significant 
changes in MPO or NAG activities in the lung (P>0.05; Figure 3.8 A-B). When 
compared to mice on regular chow diet challenged with vehicle, mice on chow diet 
challenged with low dose LPS (2 mg/kg i.p.) showed significant increases in MPO 
and NAG activities in the lung (P<0.05; Figure 3.8 A-B). Challenge of mice on 
HFD with LPS resulted in big increases in both MPO and NAG activities when 
compred to mice on HFD challenged with vehicle and mice on chow diet 
challenged with the same dose of LPS (P<0.05; Figure 3.8 A-B).	
	
Figure 3.8 Effect of pre-existing T2DM on neutrophil/macrophage infiltration (lung) 
in mice challenged with low dose LPS (2mg/kg). 
Mice on chow and high fat diet were subjected to low dose LPS (2 mg/kg i.p.) or PBS (5 
ml/kg i.p.). At 18 h, lung samples were collected and neutrophil and macrophages 
infiltration were measured as (A) MPO and (B) NAGase activities. Data were analysed 
using two-way ANOVA followed by Bonferroni’s post hoc test and expressed as mean ± 
SEM for n number of observations. *P<0.05 compared to respective PBS group. $P<0.05 













































 A  B 




8. Effect of pre-existing T2DM on serum cytokine levels after LPS 
challenge  
When compared to mice on chow diet, mice on HFD showed no significant 
changes in cytokines levels (P>0.05; Figure 3.9 A-D). When compared to mice on 
regular chow diet challenged with vehicle, mice on chow diet challenged with low 
dose LPS (2 mg/kg i.p.) showed significant increases in IL-6 and KC 
concentrations in the serum (P<0.05; Figure 3.9 B-C). However, they did not show 
any significant changes in TNF-α or IL-10 when compred to mice on chow diet 
and challenged with vehicle (P<0.05; Figure 3.9 A, D). Challengin mice on HFD 
with LPS resulted in huge increases in all cytokines levels when compred to mice 
on HFD challenged with vehicle and mice on chow diet challenged with the same 






Figure 3.9 Effect of pre-existing T2DM on serum cytokines in mice challenged with 
low dose LPS (2 mg/kg). 
Mice on chow and high fat diet were subjected to low dose LPS (2 mg/kg i.p.) or PBS (5 
ml/kg i.p.). At 18 h, blood samples were collected and inflammatory cytokines 
concentrations were measured in the serum. (A) TNF-α, (B) IL-6, (C) KC and (D) IL-10. 
Data were analysed using two-way ANOVA followed by Bonferroni’s post hoc test and 
expressed as mean ± SEM for n number of observations. *P<0.05 compared to respective 
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3.5.2 CLP model of polymicrobial sepsis in mice with pre-existing 
T2DM  
1. Effect of HFD on organ function before CLP/sham surgeries 
After 12 weeks of dietary manipulation and before sepsis challenge, mice on HFD 
showed signs of development of T2DM including significant increases in body 
weight, fasting blood glucose and a significant impairment in OGTT when 
compared to mice on chow diet. When compared to age matched mice on chow 
diet, HFD-fed mice showed significant reduction in systolic cardiac function 
(%EF) and creatinine clearance and significant increases in ALT and total 
cholesterol levels (P<0.05, Table 3.4).  
Table 3.4 Baseline data for both chow and HFD groups before interventions (CLP or 
sham surgeries). 
Parameter Chow HFD 
Net weight gain (grams) 5.34 ± 0.47 15.92 ± 1.19* 
Food intake$ (grams/mouse/week) 3.38 ± 0.02 2.82 ± 0.03* 
Calories intake$ (Kcal/mouse/week) 17.29 ± 0.12 20.0 ± 0.24* 
AUC for OGTT (mg.min/dl) 29646 ± 547.5 47727 ± 2958* 
Fasting blood glucose (mg/dl) 183.9 ± 4.68 294.9 ± 13.9* 
Ejection fraction (%) 71.92 ± 0.81 64.26 ± 0.95* 
Fractional shortening (%) 40.73 ± 0.67 34.73 ± 0.68* 
Fractional area change (%) 51.37 ± 0.41 45.8 ± 1.14* 
Left ventricle mass (mg) 127.2 ± 2.92 131.6 ± 4.04 
Urea (mmol/L) 9.47 ± 0.32 9.45 ± 0.24 
Creatinine (µmol/L) 28.49 ± 1.71 32 ± 1.25 
Alanine aminotransferase (U/L) 32.9 ± 4.05 68.26 ± 9.54* 
Creatinine Clearance£ (ml/min) 154.1 ± 17.56 96.55 ± 8.79* 
Triglyceride (mg/dl) 183.6 ± 9.65 175.4 ± 8.53 





Mice fed a HFD were compared to age-matched mice fed a chow diet. Data are presented 
as mean ± SEM for n number of observations. Data were analysed by unpaired t-test. 
*P<0.05 versus the chow-fed group (n=18 per group). $: mean food intake of 18 mice in 
each group during the study period 12 weeks (n=12). £: Creatinine clearance was 
calculated using (urine creatinine/serum creatinine) x (urine output/time in min). 
 
2. Effect of pre-existing T2DM on vital signs and physical activity 
after CLP-sepsis   
When compared to mice fed with chow diet, mice fed with HFD for 12 weeks 
showed no significant change in physical activity, heart rate or body temperature 
(P>0.05; Figure 3.10 A-C). When compared to animals on regular chow diet 
subjected to sham surgery, mice on chow diet subjected to CLP surgery showed no 
significant decrease in physical activity, heart rate or body temperature (P>0.05; 
Figure 3.10 B-C).  However, mice on HFD subjected to CLP surgery exhibited 
large and significant reduction in physical activity, heart rate and body temperature 
when compared to mice on HFD subjected to sham surgery (P<0.05; Figure 3.10 
A-C) and exhibited large and significant reduction in physical activity and heart 
rate when compred to mice on chow diet and subjected to the same CLP surgery 
(P<0.05; Figure 3.10 A-B). It should be noted that at the beginning of 
measurements, and after stabilising the animals, there were no significant 





Figure 3.10 Effect of CLP-sepsis on vital signs and physical activity in mice with 
T2DM. 
Physical activity and vital signs were assessed at 24 h after CLP or sham surgeries in mice 
fed a chow diet or a HFD. (A) Physical activity change (B) heart rate and (C) body 
temperature. Data were analysed using two-way ANOVA followed by Bonferroni’s post 
hoc test and expressed as mean ± SEM. *P< 0.05 compared to respective PBS group, $P< 

























































3. Pre-existing T2DM augments the cardiac dysfunction associated 
with poly-microbial sepsis caused by CLP.  
When compared to mice fed with chow diet and subjected to sham surgery, mice 
fed with HFD and subjected to sham surgery showed no significant change in 
cardiac function (P>0.05; Figure 3.11 B-D). When compared to animals on regular 
chow diet subjected to sham surgery, mice on chow diet subjected to CLP surgery 
showed no significant reduction in systolic cardiac function (measured as EF, FS 
and FAC; P>0.05; Figure 3.11 B-D). However, animals on HFD subjected to CLP 
surgery exhibited a large and significant reduction in systolic cardiac function 
when compared to mice on HFD subjected to sham surgery. The reductions in EF, 
FS and FAC caused by CLP surgery in mice fed a HFD were significantly greater 
than those caused by CLP surgery in mice fed a normal chow diet (P<0.05; Figure 






Figure 3.11 Effect of CLP-induced poly-microbial sepsis on cardiac function in mice 
with pre-existing T2DM. 
Cardiac function was assessed at 24 h after CLP or sham surgery in mice fed a chow diet 
or a HFD. (A) Representative M-mode echocardiograms, percentage % (B) EF, (C) FS 
and (D) FAC.  Data were analysed using two-way ANOVA followed by Bonferroni’s post 
hoc test and expressed as mean ± SEM. *P<0.05 compared respective sham surgery 
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4. Effect of CLP-sepsis on NF-ĸB signalling in mice with pre-
existing T2DM 
In a separate set of experiments, I investigated the effects of HFD/diabetes on the 
activation of key signalling pathways of inflammation and cell survival including 
pathways leading to the activation of NF-ĸB. When compared to cardiac biopsies 
obtained from chow-fed mice, cardiac tissue obtained from mice fed a HFD 
exhibited a significant increase in a) the phosphorylation of IKKα/β on Ser178/180, 
b) the phosphorylation of IĸBα on Ser32/36, c) the translocation of p65 NF-ĸB to the 
nucleus, and d) increased expression of iNOS (P<0.05; Figure 3.12 A-D). When 
compared to cardiac tissue obtained from mice fed on a chow diet subjected to 
sham surgery, cardiac tissue obtained from chow-fed mice subjected to CLP/sepsis 
showed a significant increase in a) the phosphorylation of IKKα/β on Ser178/180, b) 
the phosphorylation of IĸBα on Ser32/36, c) the translocation of p65 NF-ĸB to the 
nucleus, and d) increased expression of iNOS. When compared to mice fed a HFD 
and subjected to sham surgery, induction of polymicrobial sepsis in mice on HFD 
after CLP/sepsis resulted in a further significant increase in a) the phosphorylation 
of IKKα/β on Ser178/180, b) the phosphorylation of IĸBα on Ser32/36, c) the 
translocation of p65 NF-ĸB into the nucleus, and expression of iNOS (P<0.05; 
Figure 3.12 A-D) The changes in IKKα/β and IĸBα phosphorylations, p65 NF-ĸB 
translocation, and iNOS expression caused by CLP/sepsis in mice fed a HFD were 
significantly greater than those caused by CLP/sepsis in mice fed a normal chow 






Figure 3.12 Effect of pre-existing T2DM on NF-ĸB signalling pathway in the heart of 
mice with CLP/sepsis. 
Mice on chow and high fat diet were subjected to CLP or sham surgery. At 24 h, heart 
samples were collected and signalling events were assessed. Densitometry analysis of the 
bands is expressed as relative optical density (O.D.) of (A) IKKα/β phosphorylation on 
Ser178/180 corrected to the corresponding total IKKα/β content and normalized using the 
related sham band; (B) IĸBα phosphorylation on Ser32/36 corrected to the corresponding 
total IĸBα content and normalized using the related sham band; (C) NF-κB p65 subunit 
levels in both, cytosolic and nuclear fractions expressed as a nucleus/cytosol ratio 
normalized using the related sham bands; (D) Inducible nitric oxide synthase (iNOS) 
expression corrected for the corresponding tubulin band. Data were analysed using two-
way ANOVA followed by Bonferroni’s post hoc test and expressed as mean ± SEM. 
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5. Effect of CLP-sepsis on the phosphorylation of Akt in mice with 
pre-existing T2DM 
When compared to cardiac biopsies obtained from chow-fed mice, cardiac tissue 
obtained from mice fed a HFD exhibited a significant decrease in Akt 
phosphorylation on Ser473. When compared to mice fed a chow diet and subjected 
to sham surgery, induction of poly-microbial sepsis by CLP-sepsis in mice on 
chow diet resulted in a significant reduction in Akt phosphorylation (P<0.05; 
Figure 3.13). When compared to mice fed a HFD and subjected to sham surgery, 
induction of poly-microbial sepsis by CLP in mice on HFD did not, however, 
result in a significant change in Akt phosphorylation (P>0.05; Figure 3.13). The 
reductions in Akt phosphorylation caused by CLP in mice fed a HFD was 
significantly greater than that caused by CLP in mice fed a normal chow diet 
(P<0.05; Figure 3.13 B-D).	
	
Figure 3.13 Effect of pre-existing T2DM on Akt phosphorylation in the heart of mice 
subjected to CLP. 
Mice on chow and HFD were subjected to CLP or sham surgery. At 24 h, heart samples 
were collected and signalling events were assessed. Densitometry analysis of the bands is 
expressed as relative optical density (O.D.) of phosphorylated Akt on Ser473 corrected for 
the corresponding total Akt content and normalized using the related sham band. Data 
were analysed using two-way ANOVA followed by Bonferroni’s post hoc test and 
expressed as mean ± SEM. *P<0.05 compared to respective sham surgery group, $P<0.05. 
































6. Effect of CLP-sepsis on the severity of renal dysfunction and 
hepatocellular injury in mice with pre-existing T2DM 
When compared to mice on chow diet subjected to sham surgery, mice on HFD 
subjected to sham surgery showed no significant changes in serum urea, creatinine 
or ALT (P>0.05; Figure 3.14 A-C). When compared to mice on regular chow diet 
subjected to sham surgery, mice on chow diet subjected to CLP did not have 
significant changes in serum urea, creatinine, or ALT levels (P>0.05; Figure 3.14 
A-C). Animals on HFD subjected to CLP exhibited large and significant increases 
in serum urea, creatinine, and ALT when compared to mice on HFD subjected to 
sham surgery. The increases in serum urea, creatinine, and ALT caused by CLP in 
mice fed a HFD were significantly greater than those caused by CLP in mice fed a 






Figure 3.14 Effect of CLP induced poly-microbial sepsis on the severity of renal 
dysfunction and hepatocellular injury in mice with pre-existing T2DM. 
Kidney function and liver injury were assessed at 24 h after CLP or sham surgery in mice 
fed a chow diet or a HFD. Serum (A) urea, (B) creatinine and (C) ALT levels were 
measured. Data were analysed using two-way ANOVA followed by Bonferroni’s post hoc 
test and expressed as mean ± SEM. *P<0.05 compared respective PBS group, $P<0.05 



















































7. Pre-existing T2DM increases neutrophil and macrophage 
accumulation infiltration in the lung after CLP-sepsis  
When compared to mice on chow diet, mice on HFD showed no significant 
changes in MPO or NAG activities in the lungs after sham surgery (P>0.05; Figure 
3.15 A-B). When compared to mice on regular chow diet subjected to sham 
surgery, mice on chow diet subjected to CLP showed a significant increase in 
NAG activity in the lung (P<0.05; Figure 3.15 B) with no change in MPO activity 
(P>0.05; Figure 3.8 A). Subjecting mice on HFD to CLP surgery resulted in big 
increases in both MPO and NAG activities when compred to mice on HFD 
subjected to sham surgery and mice on chow diet subjected to the same CLP 
(P<0.05; Figure 3.15 A-B).	
	
Figure 3.15 Effect of pre-existing T2DM on neutrophil/macrophage infiltration in the 
lung in mice after CLP-sepsis. 
Mice on chow and high fat diet were subjected to sham or CLP surgeries. At 24 h, lung 
samples were collected and neutrophil and macrophages infiltration were measured as the 
(A) MPO and (B) NAG activities. Data were analysed using two-way ANOVA followed 
by Bonferroni’s post hoc test and expressed as mean ± SEM for n number of observations. 













































8. Effect of pre-existing T2DM on serum inflammatory cytokines 
after CLP sepsis.  
When compared to mice on chow diet, mice on HFD for 12 weeks showed no 
significant changes in cytokines levels (P>0.05; Figure 3.16 A-D). When 
compared to mice on regular chow diet subjected to sham surgery, mice on chow 
diet subjected to CLP surgery showed no significant changes in cytokines levels in 
the serum (P>0.05; Figure 3.16 A-D). Subjecting mice on HFD to CLP resulted in 
large increases in the serum levels of TNF-α, IL-6, KC and IL-10 when compred to 
mice on HFD subjected to sham surgery and mice on chow diet subjected to CLP 






Figure 3.16 Effect of pre-existing T2DM on serum cytokines in mice subjected to 
CLP-sepsis. 
Mice on chow and high fat diet were subjected to sham or CLP. At 24 h, blood samples 
were collected and inflammatory cytokines concentrations were measured in the serum. 
(A) TNF-α, (B) IL-6, (C) KC and (D) IL-10. Data were analysed using two-way ANOVA 
followed by Bonferroni’s post hoc test and expressed as mean ± SEM for n number of 
observations. *P<0.05 compared to respective sham group. $P<0.05 (n=4 per sham 






































































 A  B 






Among patients with sepsis and septic shock, there is a strong association between 
the development of cardiac dysfunction and the increased mortality rate 273. The 
exact aetiology and pathophysiology of the cardiac dysfunction associated with 
sepsis (in previously healthy patients or patients with pre-existing conditions) is 
not fully understood and stills warrants further investigation in order to develop 
new therapeutic interventions that may reduce the high mortality rate among those 
patients. Patients with diabetes have a higher risk of developing infections and 
subsequently sepsis 161. However, the effect of pre-existing T2DM on outcomes in 
patients with infections and sepsis is still highly controversial. In this chapter, I 
designed a two-hit model to investigate (i) the effect of T2DM on cardiac 
dysfunction, renal dysfunction, liver injury and lung inflammation in sepsis and (ii) 
to understand the signalling mechanism underlying the cardiac dysfunction in 
T2DM/sepsis.     
In this study, I induced T2DM by feeding mice with a HFD for 12 weeks as the 
first hit, then expose the mice to a moderate endotoxemia (by injection of low dose 
LPS) or CLP-sepsis that (in the absence of diabetes) would result only in a 
moderate degree of systemic inflammation and cardiac dysfunction in young and, 
previously, healthy mice.  
In mice fed with a HFD for 12 weeks, I detected a development of T2DM 
phenotype as mice showed increased body weight, fasting blood glucose and 
impaired glucose tolerance. They also developed some diabetes complications such 




significant, reduction in ejection fraction (%EF)), hepatocellular injury (measured 
as an increase in serum ALT) and a mild reduction in renal function (measured as a 
decrease in creatinine clearance). These results are consistent with results from 
previous studies showing a reduction in ejection fraction, development of liver 
injury and kidney disease in patients with T2DM 265,294,295 and in mouse model of 
HFD-induced type 2 diabetes 296–298. The baseline cardiac dysfunction developed 
in this model after 12 weeks on HFD is likely to be a result of the increased NF-ĸB 
pathway activation and the subsequent increase in iNOS expression in the heart, as 
an enhanced formation of NO by iNOS results in a reduction in cardiac 
myofilament response to calcium, changes both the preload and the afterload and 
down regulates the β-adrenergic receptors 49,299. 
The elevation of ALT is likely to be a result of the fat accumulation in the liver 
(steatosis) as it is well known that steatosis leads to excessive local inflammation 
that is associated with liver injury and, hence, high serum ALT levels 300.  
I report, here, for the first time that the cardiac dysfunction associated 
endotoxaemia (caused by low dose LPS) is augmented in mice with T2DM. I also 
showed that the cardiac dysfunction associated with CLP-sepsis is significantly 
greater in mice with pre-existing T2DM.  The model of CLP-sepsis used here is 
more clinically relevant than LPS-model as it is a model of local infection and 
sepsis (rather than hyperinflammation) and the animals are treated with both 
antibiotics and fluids. Studies have shown that iNOS expression and high IL-6 
levels are responsible for the late cardiac dysfunction in sepsis 45. In my study, 
mice with diabetes and sepsis (LPS or CLP) showed an augmentation in NF-ĸB 




increase in the serum levels of the proinflammatory cytokines TNF-α, IL-6 and 
KC, both of which may importantly contribute to the development of a significant 
systolic cardiac dysfunction in T2DM/sepsis. Although there was also a small 
activation of the NF-ĸB pathway after low dose LPS and CLP in mice fed with 
chow diet, it did not result in a large decrease in systolic cardiac function (as the 
one seen in mice on HFD) suggesting that there is an association between the 
degree of iNOS expression and cytokines levels and the severity of cardiac 
dysfunction in sepsis.  
I also studied the Akt pro-survival pathway in the heart. In the cardiomyocytes, 
insulin receptor substrate-1 (IRS-1) is phosphorylated as a result of insulin binding 
to the insulin receptors on the cell surface. IRS-1 transmits insulin signalling by 
activating the phosphatidylinositol 3 kinase (PI3K). PI3K activation ultimately 
leads to Akt phosphorylation and activation 301. Activated Akt modulates cell 
survival by regulating apoptosis, chemotaxis and inflammatory responses. It is 
known that diabetes results in impaired insulin signalling 302. Indeed, in my study 
Akt phosphorylation was attenuated in mice after HFD and the subsequent 
development of insulin resistance. Previous studies have shown that the cardiac 
dysfunction associated with sepsis was attenuated by Akt activation 277,278,302,303. In 
my study, both LPS and CLP models of hyperinflammation/sepsis resulted in a 
reduction in Akt phosphorylation in chow-fed mice. However, no further decline in 
Akt phosphorylation in HFD-fed mice after sepsis challenge was observed.  
In addition to cardiac dysfunction, both endotoxaemia and sepsis resulted in an 
augmentation of both liver injury and acute kidney injury in diabetic mice. The 




TNF-α and IL-6 levels 104,105. Indeed, the acute kidney injury associated with 
sepsis also develops as a result of the high IL-6 and IL-10 levels 83,84. In my study, 
the development of acute liver and kidney injury may be, at least partially, the 
result of the high serum cytokines levels (TNF-α, IL-6, IL-10 and KC) after sepsis 
challenge in diabetic mice. The incidence of liver injury is increased in mouse 
model of sepsis and T2DM 169, and the PROWESS trial showed that the presence 
of baseline liver injury is associated with worse outcome in patients with sepsis 304. 
In addition, a recent meta-analysis also suggests that the incidence of acute kidney 
injury associated with sepsis is higher in diabetic patients 305. 
In this study, I also reported a development of a small degree of lung inflammation 
(measured as an increase in neutrophil and macrophage accumulation) in the lung 
in response to sepsis in previously healthy mice. However, sepsis challenge in 
diabetic mice resulted in further increase in lung inflammation with recruitment of 
both neutrophils (increase in MPO activity) and macrophages (increases in NAG 
activity). This further increase in leukocytes infiltration may be a result of the high 
inflammatory cytokines levels and the development of AKI, both of which have 









In this chapter, I have detected an augmentation of cardiac dysfunction associated 
with sepsis in mice with pre-existing T2DM. After the first hit (T2DM) there was 
moderate activation of NF-ĸB (and subsequent iNOS expression) in the heart 
tissues. However, sepsis as a second hit resulted in dramatic increase in the pro-
inflammatory cytokines (in the serum) and further increase in NF-ĸB activation 
(and subsequent iNOS expression) in the heart.  
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CHAPTER 4: INHIBITION OF NF-ĸB ATTENUATES 
THE CARDIAC DYSFUNCTION ASSOCIATED WITH 
SEPSIS IN MICE WITH PRE-EXISTING T2DM 
4.1 Introduction 
Many potential therapeutic agents showed beneficial effects in different animal 
models of sepsis. However, a lot of these agents failed to improve outcomes in 
clinical studies. Both experimental design and animal model limitations contribute 
to this lack of translation of these agents from pre-clinical to clinical settings 307. 
Many elements are usually tightly controlled in order to get consistent results in 
animal models. For example, young and healthy [with no pre-existing diseases; 
hypertension, diabetes or chronic kidney disease (CKD)] animals that are from the 
same gender, genetic background and strain that are housed in a clean environment 
are used to conduct experiments and to test these potential therapeutic agents, the 
thing that may decrease its clinical relevance 307,308.  
Activation of NF-ĸB plays a crucial role in both sepsis related cardiac dysfunction 
276–278 and in diabetic cardiomyopathy 279. Different stimuli such as inflammatory 
cytokines, LPS, PepG, AngII, AGE and FFA activate receptors such as TLR 2, 
TLR 4 and RAGE leading to NF-ĸB pathway activation. Under physiological 
conditions, NF-ĸB is sequestered in the cytoplasm as inactive complex with IĸB-α. 
For NF-ĸB to be activated, IKK phosphorylates IĸB-α. This phosphorylation 
results in IĸB-α degradation and NF-ĸB release from the complex.  NF-ĸB then 




DPP-4 receptors are also involved in the activation of NF-κB 201–204. In sepsis, 
microbial components activate different antigen presenting cells (APCs) after 
binding to TLR 4 and 2. Exposed caveolin-1 from the activated APC interacts with 
the DDP-4 receptors in T cells which results in strong NF-κB activation in both the 
APCs and the T cells 204. Adenosine deaminase (ADA) is another activator of 
DPP-4. The activity of ADA in the serum is increased during inflammatory 
diseases (e.g sepsis) as a results of increased macrophages activity 310 the 
interaction of ADA with DPP-4 receptors leads to NF-κB activation in T cells 201 
(Figure 4.1).  
Figure 4.1 An overview of the NF-κB pathway. 
Different stimuli such as pro-inflammatory cytokines, bacterial cell wall 
components, FFAs, AngII result in TLR 4 activation. ADA and exposed caveolin-
1 activate DPP-4 receptors. TLR 4 and DPP-4 activations lead to downstream 











Recent studies of our group showed that inhibition of NF-κB with a selective IKK 
inhibitor (IKK-16) attenuates the multiple organ dysfunction associated with sepsis 
in mice without co-morbidities 291, and also attenuates the cardiac dysfunction 
caused by sepsis in mice with pre-existing chronic kidney disease 292. Other studies 
suggest that inhibition of DPP-4 receptors by different gliptins (DPP-4 receptor 
inhibitors) results in less cardiac dysfunction in mice model of HFD-induced 
fibrosis and inflammation 220 and rat model of heart failure 221 by inhibiting the 
NF-κB pathway and by reducing the formation of pro-inflammatory cytokines. 
However, the effect of DPP-4 inhibitors on the cardiac (organ) dysfunction 
associated with sepsis has not yet been investigated. 
Having found that HFD exacerbates the degree of cardiac dysfunction caused by 
sepsis in mice and augments NF-ĸB activation, iNOS expression and inflammatory 
cytokines concentrations, I have investigated the effect of NF-ĸB inhibition using 
IKK-16 or linagliptin on cardiac performance in a two-hit model of sepsis/T2DM.  
 
Figure 4.2 The chemical structure of IKK-16. 
IKK-16 is a selective IKK inhibitor. The compound name is [N-(4-Pyrrolidin-1-
ylpiperidin-1-yl-)-[4-(4-benzo[b]thiophen-2-yl-pyrimidin-2-ylamino)-phenyl]-




4.2  Scientific Hypothesis and Aims  
This study is driven by the hypothesis that: 
§ Inhibition of the NF-B pathway attenuates the cardiac dysfunction 
associated with endotoxaemia and CLP sepsis in mice with pre-existing 
T2DM 
This study aims to: 
§ Examine the effect of IKK-16 treatment after LPS challenge and CLP 
surgery on cardiac dysfunction in mice with pre-existing T2DM using in 
vivo echocardiography, and  
§ Investigate whether pharmacological treatment with Linagliptin (Anti-
diabetic and anti-inflammatory drug) is able to reduce CLP-associated 





4.3  Methods and Materials   
4.3.1 Animals 
Studies in this chapter were conducted on 68 ten-week-old male C57BL/6 mice 
(Charles River, Kent, UK) weighing 25-30g, receiving a standard diet and water ad 
libitum (before starting the experiments). Mice were housed 5 per cage in a 
temperature-controlled room with a 12-hour light/dark cycle. Thirty mice were 
used in the first experiment to study the effect of IKK-16 treatment on cardiac 
dysfunction after LPS challenge and 38 mice were used in the second experiment 
to study the effect of IKK-16 or linagliptin treatments on cardiac dysfunction after 
CLP surgery. The ethical statement is provided in section 2.3. 
4.3.2  Model of HFD induced T2DM and diabetic cardiomyopathy 
In this model of HFD induced T2DM and diabetic cardiomyopathy, ten-week-old 
male C57BL/6 mice were randomised to receive HFD (≈ 60% energy from fat) or 
normal chow diet with free access to water for 12 weeks. 
4.3.3 Baseline Measurements for development of T2DM 
During the whole 12-week period, body weight and feeding behaviour were 
measured weekly to ensure healthy feeding behaviour as described in section 2.3.2. 
During week 12, OGTT was measured in all mice to ensure the development of 
impairment in glucose tolerance as described in section 2.3.3, baseline 
echocardiography was conducted in all mice to test the development of diabetic 




all mice to measure CrCl as described in section 2.3.7 and blood were collected 
from all mice from the tail vein to measure baseline urea, creatinine and ALT as 
described in section 2.3.9.    
4.3.4 Model of lipopolysaccharide (LPS) induced endotoxaemia 
At 12 weeks after starting the HFD, mice were randomised to receive low dose 
LPS (2 mg/kg, i.p.) or vehicle (PBS 5 ml/kg, i.p.). At 1 h after LPS, mice were 
randomised to receive IKK-16 (1 mg/kg, i.v.) or vehicle (2% DMSO, 3 ml/kg, 
i.v.). At 18 h after the onset of endotoxaemia, mice were anaesthetised for cardiac 
function assessment using in vivo echocardiography. As a terminal procedure, mice 
were anaesthetised using high dose isoflurane (3 % delivered in 0.9 L/min O2) 
before being sacrificed. Blood samples were collected by cardiac puncture and 
vital organs were collected and snap frozen using liquid nitrogen then stored for 
further analysis at -80°C freezer.  
4.3.5 Model of caecal ligation and puncture (CLP) induced 
polymicrobial sepsis 
At 12 weeks after starting the HFD, mice were randomised to undergo either sham 
or CLP surgery. Polymicrobial sepsis was induced by caecal ligation and double 
puncture using 18 G needle. Mice received analgesia (buprenorphine, 0.05 mg/kg 
i.p.) and antibiotic (imipenem/cilastatin, 20 mg/kg s.c.) dissolved in the 
resuscitation fluid (0.09% NaCl, 15 ml/kg s.c.). Detailed surgery is described in 
section 3.3.5. At 1 h after CLP surgery, mice randomised to receive IKK-16 (1 
mg/kg, i.v.), linagliptin (10 mg/kg, i.v.) or vehicle (2% DMSO, 3 ml/kg, i.v.). At 




terminal procedure, mice were anaesthetised using high dose isoflurane (3 % 
delivered in 0.9 L/min O2) before being sacrificed. Blood samples were collected 
by cardiac puncture and vital organs were collected and snap frozen using liquid 
nitrogen then stored for further analysis at -80°C freezer. Mice underwent sham 
surgery were not subjected to perforation of the cecum, but otherwise treated the 
same. 
4.3.6 Measuring physical activity and vital signs 
At 18 h after LPS challenge and 24 h after CLP surgery, physical activity and vital 
signs were measured as described in section 3.3.6.  
4.3.7 Quantification of organs dysfunction 
Cardiac functions was assessed at 18 h after LPS challenge and at 24 h after CLP 
surgery using a 30 MHz RMV707B scan head and a Vevo-770 imaging system 
(VisualSonics, Toronto, Ontario, Canada) as described in section 2.3.6. Blood 
samples and vital organs were collected to measure organs dysfunction as 
described in sections 2.3.8.   
4.3.8 Western blot analysis 
Immunoblot analyses of heart tissues were carried out using a semi-quantitative 
western blotting. I measured the degree of phosphorylation of IKK, IĸBα and Akt, 
nuclear translocation of p65 NF-ĸB subunit to the nucleus and iNOS expression. 





4.3.9  Cytokines measurements using multiplex method 
Serum cytokines levels (TNF-α, IL-6, KC and IL-10) were measured using a bead-
based immunoassay method. Serum samples were prepared and handled following 
manufacturer instructions (Biolegend®, San Diego, USA). Data was obtained 
using a LSR Fortessa (Biociences®, Berkshire, UK) and analysed using the 
LegendplexTM 7.1.0.0 software. Detailed procedure is described in section 3.3.9. 
4.3.10 Measuring MPO activity in the lung 
MPO was extracted from the lung tissues according to the methods described by 
Barone et al. in 1991 293 with slight modifications to measure neutrophil 
accumulation in the lungs. MPO activity was presented as the quantity of the 
enzyme that degrades 1 µmol of peroxide/min at 25 °C and expressed as micro-
unit/gram of the lung tissue.  The detailed protocol is described in section 3.3.10. 
4.3.11 Measuring NAG activity in the lung  
NAG activity was analysed to measure macrophages accumulation in the lungs 
using a NAGase ELISA kit following manufacturer instructions (Elabscience®, 
Houston, Texas, USA). The detailed procedure is descriped in section 3.3.11. 
4.3.12 Statistical analysis 
Data was analysed using GraphPad Prism 7.0 (GraphPad Software, San Diego, 
California, USA). Values stated in the text and figures are presented as a mean ± 
standard error of the mean (SEM) of n observations, where n is the number of 




test and then assessed using using One-way ANOVA test followed by Bonferroni’s 
post hoc test. P values of less than 0.05 were considered to be statically significant. 
4.3.13 Materials 
Unless otherwise stated, all materials, reagents and solutions were purchased from 





4.4  Experimental Designs and Studies Groups 
4.4.1 Effect of IKK-16 treatment on cardiac dysfunction 
associated with endotoxaemia in mice with T2DM 
At 12 weeks after dietary manipulation, mice were randomised into 3 groups 
(Table 4.1) to study the effect of IKK inhibition on the cardiac (organ) dysfunction 
associated with endotoxaemia. 
Table 4.1 Experimental groups used to study the effect of IKK-16 treatment 
on cardiac dysfunction after a low dose LPS challenge in mice with pre-
existing T2DM.  
Group name Diet Intervention Treatment Number 
HFD High fat 
diet 
PBS 5ml/kg i.p. 2 % DMSO 10 
HFD+LPS High fat 
diet 
LPS 2mg/kg i.p. 2 % DMSO 10 
HFD+LPS+IKK-16 High fat 
diet 
LPS 2mg/kg i.p. 1 mg/kg IKK-16 10 
 
 
Figure 4.3 Timeline and summary of the protocol used to study the effect of 
IKK-16 treatment on the cardiac dysfunction after low dose LPS challenge in 
mice with pre-existing T2DM. 
At 12 weeks after dietary manipulation, mice were tested for development of 
diabetes phenotype. Mice were then challenged with either low dose LPS (2 
mg/kg, i.p.) or vehicle (5 ml/kg PBS, i.p.). At 1 h, mice were treated with IKK-16 





4.4.2 Effect of IKK-16 or linagliptin treatments on cardiac 
dysfunction associated with CLP induced polymicrobial sepsis in 
mice with pre-existing T2DM 
At 12 weeks after dietary manipulation, mice were randomised into 4 groups 
(Table 4.2) to study the effect of NF-κB inhibition on the cardiac (organ) 
dysfunction associated with CLP-sepsis. 
Table 4.2 Experimental groups used to study the effect of IKK-16 or 
linagliptin treatments on cardiac dysfunction after CLP sepsis in mice with 
pre-existing T2DM.  
Group name Diet Intervention Treatment Number 
HFD+sham HFD Sham  2 % DMSO 8 
HFD+CLP HFD CLP  2 % DMSO 10 
HFD+CLP+IKK-16 HFD CLP  1 mg/kg IKK-16 10 
HFD+CLP+linagliptin HFD CLP  10 mg/kg linagliptin 10 
 
 
Figure 4.4 Timeline and summary of the protocol used to study the effect of 
IKK-16 or linagliptin treatment on cardiac dysfunction after CLP surgery in 
animals with pre-existing T2DM. 
At 12 weeks after dietary manipulation, mice were tested for development of 
diabetes phenotype. Mice were then subjected to either CLP or sham surgery. At 1 
h, mice were treated with IKK-16, linagliptin or vehicle. At 6 and 18 h, mice 
received analgesia, antibiotic and fluid resuscitation. At 24 h after CLP surgery, 





4.5.1 LPS model of endotoxaemia in mice with pre-existing T2DM  
1. IKK-16 improves the physical activity and stabilise heart rate 
after LPS challenge 
When compared to mice on HFD challenged with vehicle, HFD fed mice 
challenged with LPS showed significant reduction in the core body tempreture, 
baseline heart rate and physical activity at 18 h after the LPS challenge (P<0.05, 
Figure 4.5). When compred to HFD fed mice challenged with LPS and treated with 
vehicle, treatment with IKK-16 (at 1 h) significantly increased the physical activity 
and baseline heart rate at 18 h after the LPS challenge (P<0.05, Figure 4.5). 
However, Treatment with IKK-16 after LPS challenge did not improve the core 
body temperature when compred to mice challenged with LPS and treated with 
vehicle (P>0.05, Figure 4.5). It should be noted that at the beginning of the 
measurements, and after stabilising the animals, there was no significant difference 






Figure 4.5 Effect of IKK-16 treatment on physical activity and vital signs after low 
dose LPS challenge in mice with T2DM. 
Physical activity and vital signs were assessed at 18 h after LPS challenge. (A) Physical 
activity change (B) heart rate and (C) body temperature. Data were analysed using one-
way ANOVA followed by Bonferroni’s post hoc test and expressed as mean ± SEM. *P< 
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2. IKK-16 attenuates cardiac dysfunction associated with 
endotoxaemia cause by a low dose of LPS in mice with pre-existing 
T2DM 
When compared to mice on HFD challenged with vehicle, mice on HFD 
challenged with low dose LPS (2 mg/kg i.p.) showed significant reduction in 
systolic cardiac contractility (P<0.05, Figure 4.6 B-D). The degree of cardiac 
dysfunction was significantly attenuated by treatment of HFD/LPS-mice with 







Figure 4.6 Effect of IKK-16 treatment at 1 hour after LPS challenge on cardiac 
function in mice with pre-existing T2DM. 
Mice fed a HFD were challenged with low dose LPS (2 mg/kg i.p.) or PBS (5 ml/kg i.p.). 
At 1 h, mice challenged with LPS were treated with IKK-16 (1 mg/kg i.v.) or vehicle (2 % 
DMSO i.v.). Cardiac function was assessed at 18 h. (A) Representative M-mode 
echocardiograms, percentage % (B) EF, (C) FS and (D) FAC.  Data was analysed using 
one-way ANOVA followed by Bonferroni’s post hoc test and expressed as mean ± SEM. 
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3. Effect of IKK-16 post treatment on NF-ĸB signalling pathway in 
mice with pre-existing T2DM challenged with low dose LPS. 
In a separate set of experiments, I investigated the effects of IKK-16 on the activity 
of key signalling pathways including pathways leading to the activation of NF-ĸB. 
When compared to cardiac biopsies obtained from mice fed a HFD and challenged 
with vehicle, challenging the mice on HFD with LPS did not have a significant 
effect on the phosphorylation of IKKα/β or IĸBα (P>0.05; Figure 4.7 A-B). When 
compared to mice fed a HFD and challenged with vehicle, challenge of mice on 
HFD with LPS did, however, result in significant increases in a) the translocation 
of p65 NF-ĸB to the nucleus and b) iNOS expression (P<0.05; Figure 4.7 C-D). 
The degree of a) the IKKα/β phosphorylation, b) IĸBα phosphorylation, c) the 
translocation of p65 NF-ĸB to the nucleus and d) iNOS expression was 
significantly attenuated by treatment of HFD/LPS-mice with IKK-16 (1 h after 









Figure 4.7 Effect of IKK-16 post-treatment on NF-ĸB signalling pathway in the heart 
of mice with pre-existing T2DM and challenged with low dose LPS. 
Mice fed a HFD were challenged with low dose LPS (2 mg/kg i.p.) or PBS (5 ml/kg i.p.). 
At 1h, mice challenged with LPS were treated with IKK-16 (1 mg/kg i.v.) or vehicle (2 % 
DMSO i.v.). At 18 h, heart samples were collected and signalling events were assessed. 
Densitometry analysis of the bands is expressed as relative optical density (O.D.) of (A) 
IKKα/β phosphorylation on Ser178/180 corrected to the corresponding total IKKα/β content; 
(B) IĸBα phosphorylation on Ser32/36 corrected to the corresponding total IĸBα content; 
(C) NF-κB p65 subunit levels in both, cytosolic and nuclear fractions expressed as a 
nucleus/cytosol ratio; (D) Inducible nitric oxide synthase (iNOS) expression corrected for 
the corresponding tubulin band. All bands were normalised using the related HFD band. 
Data was analysed using one-way ANOVA followed by Bonferroni’s post hoc test and 
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4. Effect of IKK-16 post treatment on Akt phosphorylation in mice 
with pre-existing T2DM challenged with low dose LPS. 
When compared to cardiac biopsies obtained from HFD-fed mice challenged with 
vehicle, cardiac tissue obtained from mice fed a HFD and challenge with LPS did 
not result in a significant change in Akt phosphorylation on Ser473 (P>0.05; Figure 
4.8). In contrast, the degree of Akt phosphorylation on Ser473 was significantly 
higher (and therefore restored) by treatment of HFD/LPS-mice with IKK-16 (1 h 
after LPS challenge) (P<0.05; Figure 4.8). 
 
Figure 4.8 Effect of IKK-16 post-treatment on Akt phosphorylation in the heart of 
mice with pre-existing T2DM and challenged with low dose LPS (2mg/kg). 
Mice fed a HFD were challenged with low dose LPS (2 mg/kg i.p.) or PBS (5 ml/kg i.p.). 
At 1h, mice challenged with LPS were treated with IKK-16 (1 mg/kg i.v.) or vehicle (2 % 
DMSO i.v.). At 18 h, heart samples were collected and signalling events were assessed. 
Densitometry analysis of the bands is expressed as relative optical density (O.D.) of 
phosphorylated Akt on Ser473 corrected for the corresponding total Akt content and 
normalized using the related HFD band. Data was analysed using one-way ANOVA 
followed by Bonferroni’s post hoc test and expressed as mean ± SEM. *P<0.05 compared 
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5. Effect of IKK-16 post tretment on the severity of kidney 
dysfunction and hepatocelleular injury in mice with pre-existing 
T2DM challenged with low dose LPS 
When compared to mice fed a HFD and challenged with vehicle, mice fed a HFD 
and challenged with low dose LPS exhibited a large and significant increase in 
serum urea, creatinine, and ALT (P<0.05, Figure 4.9 A-C). Post treatment with 
IKK-16, however, did not result in significant changes in urea, creatinine or ALT 
levels in the serum compared to mice on HFD challenged with low dose LPS and 





Figure 4.9 Effect of IKK-16 treatment on the severity of renal dysfunction and 
hepatocelleular injury in mice with pre-existing T2DM challenged with LPS. 
Mice fed a HFD were challenged with low dose LPS (2 mg/kg i.p.) or PBS (5 ml/kg i.p.). 
At 1h, mice challenged with LPS were treated with IKK-16 (1 mg/kg i.v.) or vehicle (2 % 
DMSO i.v.). At 18 h, blood samples were collected and serum (A) urea, (B) creatinine and 
(C) ALT levels were measured. Data was analysed using one-way ANOVA followed by 
Bonferroni’s post hoc test and expressed as mean ± SEM. *P<0.05 compared to 
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6. Effect of IKK-16 post tretment on neutrophils and macrophages 
infiltration to the lungs in mice with pre-existing T2DM challenged 
with low dose. 
When compared to mice fed a HFD and challenged with vehicle, mice fed a HFD 
and challenged with low dose LPS exhibited large and significant increases in 
MPO and NAG activities in the lung (P<0.05, Figure 4.10 A-B). Post treatment 
with IKK-16, resulted in significant reduction in the MPO and NAG avtivities in 
the lungs compared to mice on HFD challenged with low dose LPS and treated 
with vehicle (P<0.05, Figure 4.10 A-B). 
 
 
Figure 4.10 Effect of IKK-16 treatment on neutrophil/macrophage infiltration (lung) 
in mice with pre-existing T2DM challenged with LPS. 
Mice fed a HFD were challenged with low dose LPS (2 mg/kg i.p.) or PBS (5 ml/kg i.p.). 
At 1h, mice challenged with LPS were treated with IKK-16 (1 mg/kg i.v.) or vehicle (2 % 
DMSO i.v.). At 18 h, lungs were collected and (A) MPO and (B) NAG activities were 
measured. Data was analysed using one-way ANOVA followed by Bonferroni’s post hoc 





















-     +      +





















-     +      +
-   -     +
*
*




7. Effect of IKK-16 post tretment on serum inflammatory 
cytokines in mice with pre-existing T2DM challenged with low dose 
LPS.  
When compared to mice fed a HFD and challenged with vehicle, mice fed a HFD 
and challenged with low dose LPS exhibited large and significant increases in 
TNF-α, IL-6, KC and IL-10 concentrations in the serum (P<0.05, Figure 4.11 A-
D). Post treatment with IKK-16, resulted in significant reduction in the TNF-α, IL-
6, KC levels when compared to mice on HFD challenged with low dose LPS and 
treated with vehicle (P<0.05, Figure 4.11 A-C). However, Treatment with IKK-16 
did not result in reduction in IL-10 concentration in the serum when compared to 






Figure 4.11 Effect of IKK-16 treatment on serum inflammatory cytokines in mice 
with pre-existing T2DM challenged with LPS. 
Mice fed a HFD were challenged with low dose LPS (2 mg/kg i.p.) or PBS (5 ml/kg i.p.). 
At 1 h, mice challenged with LPS were treated with IKK-16 (1 mg/kg i.v.) or vehicle (2 % 
DMSO i.v.). At 18 h, blood samples were collected and inflammatory cytokines 
concentrations were measured in the serum. (A) TNF-α, (B) IL-6, (C) KC and (D) IL-10. 
Data was analysed using one-way ANOVA followed by Bonferroni’s post hoc test and 
expressed as mean ± SEM. *P<0.05 compared to HFD+LPS. (n=4 per vehicle group and 
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4.5.2 CLP model of polymicrobial sepsis in mice with pre-existing 
T2DM  
1. Effect of IKK-16 or linagliptin treatments on the physical 
activity, heart rate and body temperature after CLP sepsis 
When compared to mice on HFD subjected to sham surgery, HFD-fed mice 
subjected to CLP surgery showed significant reduction in the core body 
tempreture, baseline heart rate and physical activity at 24 h after the surgery 
(P<0.05, Figure 4.12). When compred to HFD fed mice subjected to CLP and 
treated with vehicle, treatment with IKK-16 or linagliptin (at 1 h) significantly 
increased body tempreture, baseline heart rate and physical activity at 24 h after 
the CLP surgery (P<0.05, Figure 4.12). It should be noted that at the beginning of 
the measurements, and after stabilising the animals, there was no significant 






Figure 4.12 Effect of IKK-16 or linagliptin treatments on the physical activity and 
the vital signs after CLP surgery in mice with T2DM. 
Physical activity and vital signs were assessed at 24 h after CLP surgery. (A) Physical 
activity change (B) heart rate and (C) body temperature. Data were analysed using one-
way ANOVA followed by Bonferroni’s post hoc test and expressed as mean ± SEM. 
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2. Treatments with IKK-16 or linagliptin attenuate cardiac 
dysfunction associated with the polymicrobial sepsis in mice with pre-
existing T2DM 
When compared to mice on HFD subjected to sham surgery, mice on HFD 
subjected to CLP surgery showed significant depression in systolic cardiac 
function (P<0.05, Figure 4.13 B-D). The degree of cardiac dysfunction was 
significantly attenuated by treatment of HFD/CLP-mice with IKK-16 or linagliptin 






Figure 4.13 Effect of IKK-16 or linagliptin treatments 1 hour after CLP surgery on 
cardiac function in mice with pre-existing T2DM. 
Mice on HFD were subjected to CLP or sham surgery. At 1 h, mice subjected to CLP 
surgery were treated with IKK-16 (1mg/kg i.v.), linagliptin (10 mg/kg i.v.) or vehicle (2% 
DMSO i.v.). Cardiac function was assessed at 24 h. (A) Representative M-mode 
echocardiograms, percentage % (B) EF, (C) FS and (D) FAC.  Data was analysed using 
one-way ANOVA followed by Bonferroni’s post hoc test and expressed as mean ± SEM. 
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3. Effect of IKK-16 or linagliptin post treatment on the NF-ĸB 
signalling pathway in mice with pre-existing T2DM underwent CLP 
surgery. 
In a separate set of experiments, I investigated the effects of IKK-16 and 
linagliptin on the activity of key signalling pathways including pathways leading to 
the activation of NF-ĸB. When compared to cardiac biopsies obtained from mice 
fed a HFD and subjected to sham surgery, subjecting the mice on HFD to CLP 
surgery resulted in significant increase in a) the phosphorylation of IKKα/β on 
Ser178/180, b) the phosphorylation of IĸBα on Ser32/36, c) the translocation of p65 
NF-ĸB to the nucleus, and d) increased expression of iNOS (P<0.05; Figure 4.14 
A-D). The degree of a) the IKKα/β phosphorylation, b) IĸBα phosphorylation, c) 
the translocation of p65 NF-ĸB to the nucleus and d) iNOS expression were 
significantly attenuated by treatment of HFD/CLP-mice with IKK-16 or linagliptin 




Figure 4.14 Effect of IKK-16 or linagliptin post-treatment on NF-ĸB signalling 
pathway in the heart of mice with pre-existing T2DM that were subjected to CLP 
surgery. 
Mice on HFD were subjected to CLP or sham surgery. At 1 h, mice subjected to CLP 
surgery were treated with IKK-16 (1 mg/kg i.v.), linagliptin (10 mg/kg i.v.) or vehicle (2 
% DMSO i.v.). At 24 h, heart samples were collected and signalling events were assessed. 
Densitometry analysis of the bands is expressed as relative optical density (O.D.) of (A) 
IKKα/β phosphorylation on Ser178/180 corrected to the corresponding total IKKα/β content; 
(B) IĸBα phosphorylation on Ser32/36 corrected to the corresponding total IĸBα content 
and; (C) NF-κB p65 subunit levels in both, cytosolic and nuclear fractions expressed as a 
nucleus/cytosol ratio; (D) Inducible nitric oxide synthase (iNOS) expression corrected for 
the corresponding tubulin band. Bands were normalized using the HFD band. Data was 
analysed using one-way ANOVA followed by Bonferroni’s post hoc test and expressed as 
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4. Effect of IKK-16 or linagliptin post treatment on Akt 
phosphorylation in mice with pre-existing T2DM subjected to CLP 
surgery. 
When compared to cardiac biopsies obtained from HFD-fed mice subjected to 
sham surgery, cardiac tissue obtained from mice fed a HFD and subjected to CLP 
surgery did not result in a significant change in Akt phosphorylation on Ser473 
(P>0.05; Figure 4.15). In contrast, the degree of Akt phosphorylation on Ser473 was 
significantly higher (and therefore restored) by treatment of HFD/CLP-mice with 
IKK-16 or linagliptin (1 h after CLP surgery) (P<0.05; Figure 4.15). 
 
Figure 4.15 Effect of IKK-16 or linagliptin post-treatment on Akt phosphorylation in 
the heart of mice with pre-existing T2DM subjected to CLP surgery. 
Mice on HFD were subjected to CLP or sham surgery. At 1 h, mice subjected to CLP 
surgery were treated with IKK-16 (1 mg/kg i.v.), linagliptin (10 mg/kg i.v.) or vehicle (2 
% DMSO i.v.). At 24 h, heart samples were collected and signalling events were assessed. 
Densitometry analysis of the bands is expressed as relative optical density (O.D.) of 
phosphorylated Akt on Ser473 corrected for the corresponding total Akt content and 
normalized using the HFD band. Data was analysed using one-way ANOVA followed by 
Bonferroni’s post hoc test and expressed as mean ± SEM. *P< 0.05 compared HFD+CLP 
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5. Effect of IKK-16 or linagliptin post treatment on the severity of 
kidney dysfunction and hepatocellular injury in mice with pre-existing 
T2DM subjected to CLP surgery  
When compared to mice fed with a HFD and subjected to sham surgery, mice fed a 
HFD and subjected to CLP surgery exhibited a large and significant increases in 
serum urea, creatinine, and ALT (P<0.05, Figure 4.16 A-C). Post-treatment with 
IKK-16 or linagliptin in mice on HFD subjected to CLP surgery attenauted the 
CLP-induced rise in serum urea, creatinine and ALT compared to mice on HFD 





Figure 4.16 Effect of IKK-16 or linagliptin treatments on the severity of renal 
dysfunction and hepatocelleular injury in mice with pre-existing T2DM underwent 
CLP surgery. 
Mice on HFD were subjected to CLP or sham surgery. At 1 h, mice subjected to CLP 
surgery were treated with IKK-16 (1 mg/kg i.v.), linagliptin (10 mg/kg i.v.) or vehicle (2 
% DMSO i.v.). At 24 h, blood samples were collected and serum (A) urea, (B) creatinine 
and (C) ALT levels were measured. Data was analysed using one-way ANOVA followed 
by Bonferroni’s post hoc test and expressed as mean ± SEM. *P<0.05 compared to 
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6. Effect of IKK-16 or linagliptin post treatment on neutrophils and 
macrophages infiltration to the lungs after CLP sepsis in mice with 
pre-existing T2DM  
When compared to mice fed a HFD and subjected to sham surgery, induction of 
polymicrobial sepsis by CLP in mice on HFD resulted in large and significant 
increases in the MPO and NAG activities in the lung (P<0.05, Figure 4.17 A-B). 
Post treatment with IKK-16 or linagliptin, resulted in significant reduction in the 
MPO and NAG avtivities in the lungs compared to mice on HFD subjected to CLP 
and treated with vehicle (P<0.05, Figure 4.17 A-B). 
 
Figure 4.17 Effect of IKK-16 or linagliptin treatments on nuetrophil/macrophage 
infiltration (lung) in mice with pre-existing T2DM underwent CLP surgery. 
Mice on HFD were subjected to CLP or sham surgery. At 1 h, mice subjected to CLP 
surgery were treated with IKK-16 (1 mg/kg i.v.), linagliptin (10 mg/kg i.v.) or vehicle (2 
% DMSO i.v.). At 24 h, lungs were collected and tissue (A) MPO and (B) NAG activities 
were measured. Data was analysed using one-way ANOVA followed by Bonferroni’s post 
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7. Effect of IKK-16 post tretment on serum inflammatory 
cytokines in mice with pre-existing T2DM after CLP sepsis.  
When compared to mice fed a HFD and subjected to sham surgery, induction of 
polymicrobial sepsis by CLP in mice on HFD resulted in a large and significant 
increase in TNF-α, IL-6, KC and IL-10 concentrations in the serum (P<0.05, 
Figure 4.18 A-D). Post-treatment with IKK-16, resulted in significant reduction in 
the TNF-α, IL-6, KC and IL-10 levels when compared to mice on HFD subjected 
to CLP sepsis and treated with vehicle (P<0.05, Figure 4.18 B-D). Treatment with 
linagliptin resulted in significant reduction in the IL-6, KC and IL-10 levels 
(P<0.05, Figure 4.18 B-D) and in a reduction in TNF-α that did not, however, 
reached statistical significancy when compared to mice treated with vehicle 






Figure 4.18 Effect of IKK-16 or linagliptin treatments on serum inflammatory 
cytokines in mice with pre-existing T2DM subjected to CLP surgery. 
Mice on HFD were subjected to CLP or sham surgery. At 1 h, mice subjected to CLP 
surgery were treated with IKK-16 (1 mg/kg i.v.), linagliptin (10 mg/kg i.v.) or vehicle (2 
% DMSO i.v.). At 24 h, blood samples were collected and inflammatory cytokines 
concentrations were measured in the serum. (A) TNF-α, (B) IL-6, (C) IL-1β, (D) IL-10 
and (E) KC. Data was analysed using one-way ANOVA followed by Bonferroni’s post 
hoc test and expressed as mean ± SEM. *P<0.05 compared to HFD+CLP group. (n=4 per 
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Activation of NF-ĸB is a key driver of the cardiac dysfunction in sepsis 291.  NF-
ĸB activation results in increases in the inflammatory cytokines synthesis and the 
iNOS expression. By working as myocardial depressant factors, the inflammatory 
cytokines and the NO contribute to the development of cardiac dysfunction in 
sepsis 35. Studies have shown that pharmacological inhibition of NF-ĸB activation 
enhanced the cardiac performance and attenuated the cardiac (organ) dysfunction 
associated with sepsis in previously healthy mice and in mice with CKD 
277,291,292,302. 
Having found that the cardiac dysfunction and the NF-ĸB activity are augmented 
after sepsis challenge in diabetic mice (chapter 3), I have investigated (this 
chapter) the effect of NF-ĸB inhibition on the degree of cardiac dysfunction 
associated with sepsis in mice with T2DM.  
I have studied the effect of the selective inhibition of IKK (using IKK-16) on the 
cardiac (organ) dysfunction in mice with T2DM/sepsis. I demonstrated for the first 
time that a single dose of IKK-16 (at 1 h after LPS or CLP) preserves the systolic 
cardiac function after 18 or 24 h of endotoxaemia or polymicrobial sepsis in mice 
with T2DM respectively. I also reported that treatment with IKK-16 increases the 
physical activity and stabilises the core body temperature and/or the heart rate in 
the mice after LPS or CLP. Previous studies of our group showed similar effect of 
IKK-16 treatment in septic mice 291,292. 
Mechanistically, IKK-16 inhibits NF-ĸB activity by preventing IKKα/β (an 




study treating mice with IKK-16 after LPS or CLP significantly attenuates the IKK 
phosphorylation and the subsequent IĸB-α phosphorylation, NF-ĸB translocation 
to the nucleus and iNOS expression in the heart. Furthermore, my results show that 
treatment with IKK-16 activates the Akt pro-survival pathway in the heart. It is 
known that Akt phosphorylation and activation enhances cell survival by 
regulating different biological responses in the cells such as apoptosis and 
chemotaxis 302. Similar to the results reported in this chapter, Akt phosphorylation 
was also restored after IKK-16, erythropoietin or peptide 19-2.5 treatment in 
murine models of sepsis and this increase in Akt phosphorylation was associated 
with attenuated cardiac dysfunction 277,291,302. Thus, the cardioprotective effect of 
IKK-16 in T2DM/sepsis is, at least partially, a result of NF-ĸB pathway inhibition 
and Akt pathway activation. 
In addition to reducing the cardiac dysfunction, treatment with IKK-16 in 
T2DM/sepsis mice reduces the serum inflammatory cytokines levels. This 
reduction in inflammatory cytokines levels is most likely a result of NF-ĸB 
inhibition and the subsequent inhibition of the acute cytokines release after sepsis 
challenge 312. 
After investigating the effect of IKK-16 on cardiac dysfunction, I studied its effect 
on the dysfunction of other organs. In this chapter, I showed for the first time that 
(when compared with vehicle) treatment with IKK-16 results in attenuation of the 
kidney dysfunction and the liver injury associated with CLP-sepsis in mice with 
T2DM. It is known that high levels of TNF-α, IL-6 and IL-10 contribute to the 
development of the acute kidney dysfunction and the liver injury in sepsis 




least partially, a result of the lower inflammatory cytokine levels after NF-ĸB 
inhibition by IKK-16 treatment in mice with T2DM and CLP-sepsis. These results 
are consistent with a study by Coldeway and co-workers who showed attenuation 
in kidney dysfunction and liver injury after IKK-16 treatment in mice with sepsis 
291. Although inhibition of NF-ĸB with IKK-16 in T2DM/CLP-sepsis resulted in 
attenuation of kidney dysfunction and liver injury, IKK-16 treatment after 
endotoxaemia in mice with T2DM did not show similar beneficial effects. This 
could be a result of a lower degree of attenuation of the TNF-α and IL-6 and IL-10 
synthesis after IKK-16 treatment in the LPS model compared to the CLP model. 
This result is consistent with a previous study that showed no reduction in kidney 
dysfunction or liver injury after IKK-16 treatment in mice with CKD and sepsis 
292.  
In this study, I also reported less sepsis-induced lung inflammation in response to 
IKK-16 treatment (at 1 h after sepsis challenges) in mice with T2DM.  I detected 
lower MPO and NAG activities (markers of neutrophil/macrophage infiltration) in 
the lungs. This result is in line with previous studies that showed attenuated lung 
inflammation as a result of IKK-16 treatment after sepsis in previously healthy 
mice and in mice with CKD 291,292. 
In parallel with IKK-16 treatment in CLP model of sepsis, I studied the effect of 
inhibiting NF-ĸB using a DPP-4 inhibitor (linagliptin) on the cardiac (organ) 
dysfunction in mice with T2DM/sepsis. I showed here, for the first time, that a 
single dose of linagliptin (1 h after CLP surgery) ameliorates the cardiac 
dysfunction associated with CLP-sepsis in mice with T2DM. This attenuation of 




subsequent reduction in iNOS expression in the heart. My results also show that 
the improvement in cardiac function may be a result of the increased activation of 
the Akt pro-survival pathway in the heart and the reduced formation of 
proinflammatory cytokines (lower serum inflammatory cytokines levels) after the 
inhibition of NF-ĸB with linagliptin. A recent study by Suda and co-workers also 
reported a protective effect of DPP-4 inhibitors on cardiac function in a model of 
cardiac ischemia in obese mice 313. Moreover, Treatment with linagliptin improves 
the physical activity and stabilise the heart rate and body temperature after CLP in 
mice with T2DM.  
In this study, I reported for the first time that linagliptin attenuates the renal 
dysfunction and the liver injury in mice with T2DM/sepsis (reductions in serum 
urea, creatinine and ALT compared to untreated mice). The observed preservation 
of renal function and liver integrity by linagliptin in sepstic mice are likely to be, at 
least partially, secondary to the reduced serum TNF-α, IL-6 and IL-10 
concentrations after NF-ĸB inhibition by linagliptin administration. A previous 
study by Shinjo et al. showed that co-administration of anagliptin with LPS 
inhibited the NF-ĸB activation in the liver 313. Another study by Chen et al. 
showed that treatment with sitagliptin attenuated the inflammatory reaction in the 
kidney and preserved the kidney function after ischemia-reperfusion injury by 
inhibiting the NF-ĸB activation 314. In this chapter, I also reported for the first time 
a reduction in lung inflammation after linagliptin treatment (measured as less MPO 
and NAG activities in lung tissue) in mice with T2DM/sepsis. This result is in line 
with a study by Nader et al. showing that treatment with sitagliptin reduced the 




4.7 Conclusion     
In this chapter, I have discovered that activation of NF-κB is a key driver of the 
cardiac dysfunction in T2DM/sepsis. I also showed that inhibiting the NF-ĸB 
activation using a selective IKK inhibitor (IKK-16) or a DPP-4 inhibitor 
(linagliptin) after sepsis challenge revokes the systematic inflammation and the 
cardiac (organ) dysfunction associated with sepsis in mice with pre-existing 
T2DM. Therefore, targeting NF-ĸB activation may be a potential strategy to treat 
the excessive inflammation and the cardiac (organ) dysfunction in patients with 
T2DM and sepsis.   
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CHAPTER 5: GENERAL DISCUSSION, 
CONCLUSIONS AND RESEARCH 
LIMITATIONS 
Although the mortality rate among septic patients has declined recently due to the 
improved supportive care for patients in the ICU 20, 25% of patient with sepsis still 
die from the disease in the ICU. Furthermore, this percentage is almost doubled in 
patients with septic shock and it can reach 70% in patients with sepsis who 
develop cardiovascular dysfunction. This makes sepsis the leading cause of death 
in ICU patients 15.  
The incidence of sepsis has increased recently mainly as a result of the aging of the 
population 15 which is associated with the presence of significant comorbidities 
such as T2DM 17. Patients with T2DM are more liable to infections and 
subsequently sepsis 162,275. The cardiovascular system is one of the most important 
systems that are affected by sepsis and the development of cardiovascular 
dysfunction in sepsis has been linked to several factors including inflammatory 
cytokines and NO.  Many studies targeted these factors showed beneficial effects 
in pre-clinical models of sepsis. However, clinical studies that targeted these 
factors failed to improve survival in septic patients.  
A possible cause of this lack of translatability from pre-clinical animal studies to 
clinical setting is that animal models of sepsis do not completely mimic the 
complex human sepsis. Most of the animals used in the pre-clinical study are 




sepsis in the clinical setting develops in patients with different gender, genetic 
background, age (most frequently in older patients) that frequently have one or 
more comorbidities including hypertension, diabetes and CKD. Another cause of 
lack of translatability of animal studies is that treatments are often given before the 
induction of sepsis or very early in the disease course. However, in the clinical 
setting, treatment is given after the diagnosis of sepsis was made and this is often 
at a relatively late stage when complications (e.g. organ dysfunction) have already 
developed. Therefore, this thesis had the overall aims to a) study the effect of 
T2DM on the severity of cardiac dysfunction associated with sepsis b) to 
investigate the pathophysiology of cardiac dysfunction associated with sepsis (in 
the presence of T2DM) and c) to identify novel therapeutic interventions to 
attenuate the cardiac dysfunction associated with sepsis/T2DM using a more 
translatable approach. 
So far, there is no single animal model of sepsis or T2DM that reflects all the 
components of the complex human diseases, but rather a number of 
complementary models that epitomize individual aspects of the diseases while 
neglecting others.  During my PhD, I have developed two models of T2DM and 
two models of sepsis to be used to study the effect of T2DM on cardiac 
dysfunction in sepsis, the pathophysiology of cardiac dysfunction in T2DM/sepsis 
and to find novel therapeutic interventions for sepsis related cardiac dysfunction in 
mice with T2DM. 
In chapter 2, two clinically relevant models of T2DM caused by prolonged 
administration of HFD were established using C57BL/6 male mice. In these 




different source and compositions of fat, were administered for 12 weeks. As the 
consumption of the western diet is the main cause of T2DM, this model of 
prolonged feeding of a HFD recapitulates the main cause of T2DM in human and 
considered to be the most clinically relevant model of T2DM available. Both 
models (chapter 2) resulted in the development of a diabetic phenotype (significant 
weight gain and impaired glucose tolerance) and diabetic cardiomyopathy 
(reduction in %EF). The development of diabetic cardiomyopathy observed is 
most probably a result of NF-ĸB activation in the heart (chapter 3). Although both 
diets resulted in a similar degree of cardiac dysfunction, there was a difference in 
the development of liver injury (measured using ALT levels) that only developed 
after the HFD (58Y1: Blue diet).  
In chapter 3, I developed a “two-hit” model of pre-existing T2DM (secondary to 
HFD administration) followed by low dose LPS injection or mild CLP surgery, 
aiming to study the effect of pre-existing T2DM on the cardiac dysfunction 
associated with sepsis and to test novel therapies in order to attenuate cardiac 
dysfunction in T2DM/sepsis mice (chapter 4). I showed for the first time that pre-
existing T2DM augments the cardiac dysfunction associated with sepsis. T2DM 
alone resulted in a small degree of NF-ĸB activation and iNOS expression in the 
heart. However, sepsis (second hit) in diabetic mice resulted in a dramatic increase 
in the serum concentrations of proinflammatory cytokines and a further increase in 
both NF-ĸB activation and iNOS expression in the heart. Diabetes also resulted in 
reduction in the activation (phosphorylation) of the Akt pro-survival pathway, 
while sepsis resulted in further reduction Akt phosphorylation in the heart. These 
two findings suggest that the cardiac dysfunction associated with T2DM/sepsis is 




subsequent increase in iNOS expression and serum inflammatory cytokines levels) 
and Akt pro-survival pathway inhibition.  
In chapter 4, to confirm the assumptions that the activation of NF-ĸB pro-
inflammatory and the inhibition of Akt pro-survival pathway are the reasons for 
the cardiac dysfunction in T2DM/sepsis, I studied the effect of NF-ĸB inhibition 
and Akt activation on cardiac performance. In this chapter, I used a more 
translatable approach of treatment. The drug (IKK-16) was administered 
intravenously at one hour after the induction of sepsis. In my study, I showed for 
the first time that inhibition of IKK complex with IKK-16 (a selective inhibitor of 
IKK) at 1 h after sepsis challenge ameliorated the cardiac dysfunction in mice with 
T2DM/sepsis. This enhanced cardiac function was associated with, or a result of, 
the decreased NF-ĸB activation (and iNOS expression) and inflammatory 
cytokines synthesis and the restored Akt phosphorylation. NF-ĸB is rapidly 
activated in sepsis 291. Many studies showed that pharmacological interventions 
that inhibit NF-ĸB reduced the MOD associated with sepsis 291,292,302. Indeed, in 
my study a single dose of IKK-16 at 1 h after CLP resulted in attenuation of the 
multiple organ dysfunction associated with T2DM/sepsis. Although my study 
showed beneficial effects, further studies are still needed to answer the question 
how late after the induction of sepsis the IKK-16 can be given to attenuate cardiac 
(organ) dysfunction and improve survival in mice with T2DM/sepsis. Furthermore, 
more investigation is still needed to evaluate the efficacy and safety of IKK-16 in 
large animals before moving to human studies.    
To overcome some of the issues related to toxicity and safety that might be 




make my finding more translational, I repositioned one of the DPP-4 inhibitors that 
are already in the market from treatment of T2DM to treat the cardiac (organ) 
dysfunction associated with sepsis in diabetic mice. The non-catalytic effect of 
DPP-4 inhibitors has recently emerged in the literature as potential new treatment 
of some inflammatory diseases. Indeed, the results in chapter 4 highlighted, for the 
first time, that inhibition of DPP-4 using linagliptin attenuates the cardiac 
dysfunction associated with T2DM/CLP-sepsis. This effect is most likely due to 
inhibition of NF-ĸB activation and preservation of Akt pathway activation in the 
heart. Treatment with linagliptin also resulted in attenuation of the multiple organ 
dysfunction associated with T2DM/CLP-sepsis. Therefore, inhibiting NF-ĸB by 
linagliptin may be a useful and clinically translatable approach to treat cardiac 





1. Feeding mice with a HFD for 12 weeks results in a T2DM phenotype and 
small degree of cardiac dysfunction. 
2. A pre-existing diabetic phenotype worsens the organ injury/dysfunction 
associated with sepsis. 
3. Activation of the NF-κB pathway is a key, but not the only, driver of the 
cardiac dysfunction in sepsis. 
4. Inhibition of NF-κB with IKK-16 or linagliptin reduces the systemic 
inflammation and organ injury/dysfunction caused by sepsis in mice with 
pre-existing T2DM, and  
5. Targeting NF-κB activation may be a potential strategy to treat the 
excessive inflammation and the cardiac (organ) dysfunction in patients with 





Limitations of the study 
Many interventions which showed promising results in pre-clinical studies failed 
to improve outcome in clinical trials. This can be related to limitations in both 
animal models and experimental design. In this thesis, I have tried to overcome 
some of these limitations to make my findings more clinically relevant.  
To model T2DM, I used a dietary manipulation to induce insulin resistance and 
diabetes. Although this HFD-model of diabetes is the most clinically relevant, it 
only models the early stages of diabetes associated with a moderate degree of 
complications (e.g., cardiac dysfunction and proteinuria) without any impairment 
in beta-cell function. Therefore, more severe models of diabetes (genetic 
manipulation or HFD+streptozosin) should be used in future studies to confirm my 
findings.   
To model sepsis, I used two different models of ‘sepsis’ (administration of 
bacterial toxin; LPS and alternation of endogenous barrier; CLP). However, none 
of the established murine models of sepsis can reflect all aspects of the complex 
human disease.  Endotoxaemia is associated with a rapid and large increase in 
many cytokines, and similar cytokine kinetics are not seen in (all cases) of clinical 
sepsis. The CLP model on the other hand is a model of systemic infection which, if 
unchecked (by the use of antibiotics), will cause a high degree of mortality. In 
addition, the CLP-model is highly variable between animals, which makes it less 
reproducible.  
In my experiments, sepsis challenge was introduced to mice when they were 22-




sepsis (as the septic insult was not preceded by a period of HFD). This makes my 
finding more clinically relevant as sepsis is more prevalent in the elderly. To 
reproduce my data in ‘old’ mice, one should ideally repeat these studies in animals 
that are between 12 and 18 months of age.  
To study the effect of interventions, mice then were treated at 1 h after the onset of 
sepsis. Although I gave drugs after sepsis challenge, 1 h is still very early in the 
disease process and more studies are needed to see how late after the onset of 
sepsis the treatment with IKK-16 or linagliptin can be given to attenuate cardiac 
dysfunction in mice with T2DM/sepsis. This is of particular importance, as most 
cases of sepsis are diagnosed later in the disease when patients had already 
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Table A.1. The SSC guideline (2016) recommendations and best practice 
statements. Table adapted from Rhodes et al., 2017 21.  
A. INITIAL RESUSCITATION 
1. Sepsis and septic shock are medical emergencies, and we recommend that 
treatment and resuscitation begin immediately (BPS).  
2. We recommend that, in the resuscitation from sepsis-induced 
hypoperfusion, at least 30 mL/kg of IV crystalloid fluid be given within the 
first 3 hours (strong recommendation, low quality of evidence).  
3. We recommend that, following initial fluid resuscitation, additional fluids 
be guided by frequent reassessment of hemodynamic status (BPS). 
Remarks: Reassessment should include a thorough clinical examination 
and evaluation of available physiologic variables (heart rate, blood 
pressure, arterial oxygen saturation, respiratory rate, temperature, urine 
output, and others, as available) as well as other non-invasive or invasive 
monitoring, as available.  
4. We recommend further hemodynamic assessment (such as assessing 
cardiac function) to determine the type of shock if the clinical examination 
does not lead to a clear diagnosis (BPS).  
5. We suggest that dynamic over static variables be used to predict fluid 
responsiveness, where available (weak recommendation, low quality of 
evidence).  
6. We recommend an initial target mean arterial pressure of 65 mm Hg in pa-
tients with septic shock requiring vasopressors (strong recommendation, 
moderate quality of evidence).  
7. We suggest guiding resuscitation to normalize lactate in patients with 
elevated lactate levels as a marker of issue hypoperfusion (weak 
recommendation, low quality of evidence). 
B. SCREENING FOR SEPSIS AND PERFORMANCE IMPROVEMENT 
1. We recommend that hospitals and hospital systems have a performance 
improvement program for sepsis, including sepsis screening for acutely ill, 
high risk patients (BPS). 
C. DIAGNOSIS 
1. We recommend that appropriate routine microbiologic cultures (including 
blood) be obtained before starting antimicrobial therapy in patients with 
suspected sepsis or septic shock if doing so results in no substantial delay 
in the start of antimicrobials (BPS). Remarks: Appropriate routine 
microbiologic cultures always include at least two sets of blood cultures 
(aerobic and anaerobic). 
D. ANTIMICROBIAL THERAPY 
1. We recommend that administration of IV antimicrobials should be initiated 
as soon as possible after recognition and within one hour for both sepsis 
and septic shock (strong recommendation, moderate quality of evidence).  
2. We recommend empiric broad-spectrum therapy with one or more 




all likely pathogens (including bacterial and potentially fungal or viral 
coverage) (strong recommendation, moderate quality of evidence).  
3. We recommend that empiric antimicrobial therapy be narrowed once 
pathogen identification and sensitivity are established and/or adequate 
clinical improvement is noted (BPS).  
4. We recommend against sustained systemic antimicrobial prophylaxis in 
patients with severe inflammatory states of non-infectious origin (e.g., 
severe pancreas, burn injury) (BPS).  
5. We recommend that dosing strategies of antimicrobials be optimized based 
on accepted pharmacokinetic/pharmacodynamics principles and specific 
drug properties in patients with sepsis or septic shock (BPS). 
6. We suggest empiric combination therapy (using at least two antibiotics of 
different antimicrobial classes) aimed at the most likely bacterial 
pathogen(s) for the initial management of septic shock (weak 
recommendation, low quality of evidence). Remarks: Readers should 
review  
7. We suggest that combination therapy not be routinely used for ongoing 
treatment of most other serious infections, including bacteraemia and sepsis 
without shock (weak recommendation, low quality of evidence). Remarks: 
This does not preclude the use of multidrug therapy to broaden 
antimicrobial activity.  
8. We recommend against combination therapy for the routine treatment of 
neutropenic sepsis/bacteraemia (strong recommendation, moderate quality 
of evidence). Remarks: This does not preclude the use of multidrug therapy 
to broaden antimicrobial activity.  
9. If combination therapy is used for septic shock, we recommend de-escala-
tion with discontinuation of combination therapy within the first few days 
in response to clinical improvement and/or evidence of infection resolution. 
This applies to both targeted (for culture-positive infections) and empiric 
(for culture-negative infections) combination therapy (BPS).  
10. We suggest that antimicrobial treatment duration of 7 to 10 days is 
adequate for most serious infections associated with sepsis and septic shock 
(weak recommendation, low quality of evidence).  
11. We suggest that longer courses are appropriate in patients who have a slow 
clinical response, undrainable foci of infection, bacteraemia with 
Staphylococcus aureus, some fungal and viral infections, or immunologic 
deficiencies, including neutropenia (weak recommendation, low quality of 
evidence).  
12. We suggest that shorter courses are appropriate in some patients, parti-
cularly those with rapid clinical resolution following effective source 
control of intra-abdominal or urinary sepsis and those with anatomically 
uncomplicated pyelonephritis (weak recommendation, low quality of 
evidence).  
13. We recommend daily assessment for de-escalation of antimicrobial therapy 
in patients with sepsis and septic shock (BPS).  
14. We suggest that measurement of procalcitonin levels can be used to support 
shortening the duration of antimicrobial therapy in sepsis patients (weak 
recommendation, low quality of evidence).  
15. We suggest that procalcitonin levels can be used to support the 




have sepsis, but subsequently have limited clinical evidence of infection 
(weak recommendation, low quality of evidence). 
E. SOURSE CONTROL 
1. We recommend that a specific anatomic diagnosis of infection requiring 
emergent source control should be identified or excluded as rapidly as 
possible in patients with sepsis or septic shock, and that any required 
source control intervention should be implemented as soon as medically 
and logistically practical after the diagnosis is made (BPS).  
2. We recommend prompt removal of intravascular access devices that are a 
possible source of sepsis or septic shock after other vascular access has 
been established (BPS). 
F. FLUID THERAPY 
1. We recommend that a fluid challenge technique be applied where fluid 
administration is continued as long as hemodynamic factors continue to 
improve (BPS).  
2. We recommend crystalloids as the fluid of choice for initial resuscitation 
and subsequent intravascular volume replacement in patients with sepsis 
and septic shock (strong recommendation, moderate quality of evidence).  
3. We suggest using either balanced crystalloids or saline for fluid 
resuscitation of patients with sepsis or septic shock (weak recommendation, 
low quality of evidence).  
4. We suggest using albumin in addition to crystalloids for initial resuscitation 
and subsequent intravascular volume replacement in patients with sepsis 
and septic shock, when patients require substantial amounts of crystalloids 
(weak recommendation, low quality of evidence).  
5. We recommend against using hydroxyethyl starches for intravascular 
volume replacement in patients with sepsis or septic shock (strong 
recommendation, high quality of evidence).  
6. We suggest using crystalloids over gelatines when resuscitating patients 
with sepsis or septic shock (weak recommendation, low quality of 
evidence). 
G. VASOACTIVE MEDICATION 
1. We recommend norepinephrine as the first-choice vasopressor (strong 
recommendation, moderate quality of evidence).  
2. We suggest adding either vasopressin (up to 0.03 U/min) (weak 
recommendation, moderate quality of evidence) or epinephrine (weak 
recommendation, low quality of evidence) to norepinephrine with the intent 
of raising mean arterial pressure to target, or adding vasopressin (up to 0.03 
U/min) (weak recommendation, moderate quality of evidence) to decrease 
norepinephrine dosage.  
3. We suggest using dopamine as an alternative vasopressor agent to 
norepinephrine only in highly selected patients (e.g., patients with low risk 
of tachyarrhythmias and absolute or relative bradycardia) (weak 
recommendation, low quality of evidence).  
4. We recommend against using low-dose dopamine for renal protection 
(strong recommendation, high quality of evidence).  




hypoperfusion despite adequate fluid loading and the use of vasopressor 
agents (weak recommendation, low quality of evidence). Remarks: If 
initiated, dosing should be treated to an end point reflecting perfusion, and 
the agent reduced or discontinued in the face of worsening hypotension or 
arrhythmias.  
6. We suggest that all patients requiring vasopressors have an arterial catheter 
placed as soon as practical if resources are available (weak 
recommendation, very low quality of evidence). 
H. CORTICOSTEROIDS 
1. We suggest against using IV hydrocortisone to treat septic shock patients if 
adequate fluid resuscitation and vasopressor therapy are able to restore 
hemodynamic stability. If this is not achievable, we suggest IV 
hydrocortisone at a dose of 200 mg per day (weak recommendation, low 
quality of evidence). 
I. BLOOD PRODUCTS 
1. We recommend that RBC transfusion occur only when haemoglobin 
concentration decreases to < 7.0 g/dL in adults in the absence of 
extenuating circumstances, such as myocardial ischemia, severe 
hypoxemia, or acute haemorrhage (strong recommendation, high quality of 
evidence).  
2. We recommend against the use of erythropoietin for treatment of anaemia 
associated with sepsis (strong recommendation, moderate quality of 
evidence).  
3. We suggest against the use of fresh frozen plasma to correct clotting 
abnormalities in the absence of bleeding or planned invasive procedures 
(weak recommendation, very low quality of evidence).  
4. We suggest prophylactic platelet transfusion when counts are 
<10,000/mm3 (10 × 10 9 /L) in the absence of apparent bleeding and when 
counts are < 20,000/mm3 (20 × 109 /L) if the patient has a significant risk 
of bleeding. Higher platelet counts (≥ 50,000/mm3 [50 x 109 /L]) are 
advised for active bleeding, surgery, or invasive procedures (weak 
recommendation, very low quality of evidence). 
J. IMMUNOLOGY 
1. We suggest against the use of IV immunoglobulins in patients with sepsis 
or septic shock (weak recommendation, low quality of evidence). 
K. BLOOD PURIFICATION 
1. We make no recommendation regarding the use of blood purification 
techniques. 
L. ANTICOAGULANT 
1. We recommend against the use of antithrombin for the treatment of sepsis 
and septic shock (strong recommendation, moderate quality of evidence).  
2. We make no recommendation regarding the use of thrombomodulin or 
heparin for the treatment of sepsis or septic shock 




1. We recommend using a target dal volume of 6 mL/kg predicted body 
weight compared with 12 mL/kg in adult patients with sepsis-induced acute 
respiratory distress syndrome (ARDS) (strong recommendation, high 
quality of evidence).  
2. We recommend using an upper limit goal for plateau pressures of 30 cm 
H2O over higher plateau pressures in adult patients with sepsis-induced 
severe ARDS (strong recommendation, moderate quality of evidence).  
3. We suggest using higher positive end-expiratory pressure (PEEP) over 
lower PEEP in adult patients with sepsis-induced moderate to severe 
ARDS (weak recommendation, moderate quality of evidence).  
4. We suggest using recruitment manoeuvres in adult patients with sepsis-
induced, severe ARDS (weak recommendation, moderate quality of 
evidence).  
5. We recommend using prone over supine position in adult patients with 
sepsis-induced ARDS and a PaO2/FIO2 ratio <150 (strong 
recommendation, moderate quality of evidence).  
6. We recommend against using high-frequency oscillatory ventilation in 
adult patients with sepsis-induced ARDS (strong recommendation, 
moderate quality of evidence).  
7. We make no recommendation regarding the use of non-invasive ventilation 
for patients with sepsis-induced ARDS.  
8. We suggest using neuromuscular blocking agents for ≤ 48 hours in adult 
patients with sepsis-induced ARDS and a PaO2/FIO2 ratio < 150 mm Hg 
(weak recommendation, moderate quality of evidence).  
9. We recommend a conservative fluid strategy for patients with established 
sepsis-induced ARDS who do not have evidence of issue hypoperfusion 
(strong recommendation, moderate quality of evidence).  
10. We recommend against the use of ß-2 agonists for the treatment of patients 
with sepsis-induced ARDS without bronchospasm (strong 
recommendation, moderate quality of evidence).  
11. We recommend against the routine use of the pulmonary artery catheter for 
patients with sepsis-induced ARDS (strong recommendation, high quality 
of evidence). 
12. We suggest using lower dal volumes over higher dal volumes in adult 
patients with sepsis-induced respiratory failure without ARDS (weak 
recommendation, low quality of evidence).  
13. We recommend that mechanically ventilated sepsis patients be maintained 
with the head of the bed elevated between 30 and 45 degrees to limit 
aspiration risk and to prevent the development of ventilator-associated 
pneumonia (strong recommendation, low quality of evidence).  
14. We recommend using spontaneous breathing trials in mechanically 
ventilated patients with sepsis who are ready for weaning (strong 
recommendation, high quality of evidence).  
15. We recommend using a weaning protocol in mechanically ventilated 
patients with sepsis-induced respiratory failure who can tolerate weaning 
(strong recommendation, moderate quality of evidence). 
N. SEDATION AND ANALGESIA 
1. We recommend that continuous or intermittent sedation be minimized in 





O. GLUCOSE CONTROL 
1. We recommend a protocolized approach to blood glucose management in 
ICU patients with sepsis, commencing insulin dosing when two 
consecutive blood glucose levels are > 180 mg/dL. This approach should 
target an upper blood glucose level ≤ 180 mg/dL rather than an upper target 
blood glucose level ≤ 110 mg/dL (strong recommendation, high quality of 
evidence).  
2. We recommend that blood glucose values be monitored every 1 to 2 hours 
until glucose values and insulin infusion rates are stable, then every 4 hours 
thereafter in patients receiving insulin infusions (BPS).  
3. We recommend that glucose levels obtained with point-of-care testing of 
capillary blood be interpreted with caution because such measurements 
may not accurately estimate arterial blood or plasma glucose values (BPS).  
4. We suggest the use of arterial blood rather than capillary blood for point-
of-care testing using glucose meters if patients have arterial catheters (weak 
recommendation, low quality of evidence). 
P. RENAL REPLACEMENT THERAPY 
1. We suggest that either continuous or intermittent renal replacement therapy 
(RRT) be used in patients with sepsis and acute kidney injury (weak 
recommendation, moderate quality of evidence).  
2. We suggest using continuous therapies to facilitate management of fluid 
balance in hemodynamically unstable septic patients (weak 
recommendation, very low quality of evidence).  
3. We suggest against the use of RRT in patients with sepsis and acute kidney 
injury for increase in creatinine or oliguria without other definitive 
indications for dialysis (weak recommendation, low quality of evidence). 
Q. BICARBONATE THERAPY 
1. We suggest against the use of sodium bicarbonate therapy to improve 
haemodynamics or to reduce vasopressor requirements in patients with 
hypoperfusion-induced lactic acidemia with pH ≥ 7.15 (weak 
recommendation, moderate quality of evidence). 
R. VENOUS THROMBOEMBOLISM PROPHYLAXIS 
1. We recommend pharmacologic prophylaxis (unfractionated heparin [UFH] 
or low-molecular-weight heparin [LMWH]) against venous 
thromboembolism (VTE) in the absence of contraindications to the use of 
these agents (strong recommendation, moderate quality of evidence).  
2. We recommend LMWH rather than UFH for VTE prophylaxis in the 
absence of contraindications to the use of LMWH (strong recommendation, 
moderate quality of evidence).  
3. We suggest combination pharmacologic VTE prophylaxis and mechanical 
prophylaxis, whenever possible (weak recommendation, low quality of 
evidence).  
4. We suggest mechanical VTE prophylaxis when pharmacologic VTE is 




S. STRESS ULCER PROPHYLAXIS 
1. We recommend that stress ulcer prophylaxis be given to patients with 
sepsis or septic shock who have risk factors for gastrointestinal (GI) 
bleeding (strong recommendation, low quality of evidence).  
2. We suggest using either proton pump inhibitors or histamine-2 receptor 
antagonists when stress ulcer prophylaxis is indicated (weak 
recommendation, low quality of evidence).  
3. We recommend against stress ulcer prophylaxis in patients without risk 
factors for GI bleeding (BPS). 
T. NUTRITION 
1. We recommend against the administration of early parenteral nutrition 
alone or parenteral nutrition in combination with enteral feedings (but 
rather initiate early enteral nutrition) in critically ill patients with sepsis or 
septic shock who can be fed enterally (strong recommendation, moderate 
quality of evidence).  
2. We recommend against the administration of parenteral nutrition alone or 
in combination with enteral feeds (but rather to initiate IV glucose and 
advance enteral feeds as tolerated) over the first 7 days in critically ill 
patients with sepsis or septic shock for whom early enteral feeding is not 
feasible (strong recommendation, moderate quality of evidence).  
3. We suggest the early initiation of enteral feeding rather than a complete fast 
or only IV glucose in critically ill patients with sepsis or septic shock who 
can be fed enterally (weak recommendation, low quality of evidence).  
4. We suggest either early trophic/hypocaloric or early full enteral feeding in 
critically ill patients with sepsis or septic shock; if trophic/hypocaloric 
feeding is the initial strategy, then feeds should be advanced according to 
patient tolerance (weak recommendation, moderate quality of evidence).  
5. We recommend against the use of omega-3 fay acids as an immune 
supplement in critically ill patients with sepsis or septic shock (strong 
recommendation, low quality of evidence).  
6. We suggest against routinely monitoring gastric residual volumes in criti-
cally ill patients with sepsis or septic shock (weak recommendation, low 
quality of evidence). However, we suggest measurement of gastric 
residuals in patients with feeding intolerance or who are considered to be at 
high risk of aspiration (weak recommendation, very low quality of 
evidence). Remarks: This recommendation refers to nonsurgical critically 
ill patients with sepsis or septic shock.  
7. We suggest the use of prokinec agents in critically ill patients with sepsis or 
septic shock and feeding intolerance (weak recommendation, low quality of 
evidence).  
8. We suggest placement of post-pyloric feeding tubes in critically ill patients 
with sepsis or septic shock with feeding intolerance or who are considered 
to be at high risk of aspiration (weak recommendation, low quality of 
evidence).  
9. We recommend against the use of IV selenium to treat sepsis and septic 
shock (strong recommendation, moderate quality of evidence).  
10. We suggest against the use of arginine to treat sepsis and septic shock 
(weak recommendation, low quality of evidence).  




shock (strong recommendation, moderate quality of evidence).  
12. We make no recommendation about the use of carnitine for sepsis and 
septic shock 
U. SETTING GOALS OF CARE  
1. We recommend that goals of care and prognosis be discussed with patients 
and families (BPS).  
2. We recommend that goals of care be incorporated into treatment and end-
of-life care planning, utilizing palliative care principles where appropriate 
(strong recommendation, moderate quality of evidence).  
3. We suggest that goals of care be addressed as early as feasible, but no later 






Table A.2. Compositions of the solutions used for protein extraction from 
cytoplasm and nucleus for western blotting 
SOLUTION COMPONENTS 
Homogenisation buffer (HB) 20 mM hepes-KOH pH 7.9 
1 mM MgCl2 
0.5 mM EDTA 
1 mM EGTA 
0.1% Triton X-100 
100 ml Distilled H2O 
Protease Inhibitors 
0.1% Protease inhibitor cocktail (PIC) 
0.5 mM PMSF 
0.1 mM DL-Dithiethrectol (DTT) 
Extraction buffer (EB) 20 mM hepes-KOH pH 7.9 
1 mM MgCl2 
0.5 mM EDTA 
1 mM EGTA 
20% Glycerol 
420 mM NaCl 
50 ml Distilled H2O 
Protease Inhibitors 
0.1% Protease inhibitor cocktail (PIC) 
0.5 mM PMSF 
0.1 mM DL-Dithiethrectol (DTT) 
 
 
   
 
 
 
